Carboxyl derivative and pharmaceutical use thereof
By developing a compound with selective inhibitory activity of αvβ1 and αvβ6 and weak inhibition of αvβ5 adhesion off-target inhibition, the problem that existing drugs for treating idiopathic pulmonary fibrosis cannot effectively inhibit αvβ1 and αvβ6, and better treatment is achieved Effects and safety.
Patent Information
- Application Number
- PCT/CN2024/093821
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-01-26
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-21
AI Technical Summary
The existing drugs for the treatment of idiopathic pulmonary fibrosis (IPF) cannot effectively inhibit the dual targets of αvβ1 and αvβ6, resulting in poor treatment effects, and no dual target inhibitors have been approved for marketing.
A novel structure compound was developed with selective inhibitory activity on αvβ1 and αvβ6, and weak inhibition of adhesion off-target of αvβ5, with good pharmacopoeia and bioavailability, and can be taken orally and have good safety.
This compound can effectively inhibit αvβ1 and αvβ6, potentially improve the therapeutic effect of idiopathic pulmonary fibrosis, prolong patient survival and improve quality of life.
Smart Images

Figure CN2024093821_21112024_PF_FP_ABST
Abstract
Description
A carboxyl derivative and its application in medicine Technical Field
[0001] The present invention belongs to the field of medicine, and specifically relates to a compound of general formula (I) or its stereoisomers, tautomers, deuterated substances, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals, and intermediates thereof, as well as their use in αvβ1- and αvβ6-related diseases such as idiopathic pulmonary fibrosis. Background Art
[0002] Idiopathic pulmonary fibrosis (IPF) is a fatal disease with an average survival of less than 4 years. Existing standard therapies for IPF have only limited success in improving lung function and prolonging survival, and are unable to prevent the progression of the disease or provide sustained improvements in patients' lives. One of the characteristics of IPF is upregulated transforming growth factor-β (TGF-β) signaling, which promotes the transformation of fibroblasts to myofibroblasts, the expression of collagen genes, and the deposition of scar tissue, thereby impairing lung function. In pulmonary fibrosis, α v Integrins are considered key regulators of TGF-β activation. v Integrins are potential therapeutic targets for IPF. Studies in lung tissue explants from IPF patients have shown that dual inhibition of integrins αvβ1 and αvβ6 is effective in treating pulmonary fibrosis caused by integrin-mediated TGF-β activation. Currently, no dual-target inhibitors of αvβ1 and αvβ6 have been approved for marketing.
[0003] Therefore, it is necessary to develop dual-target inhibitors of αvβ1 and αvβ6 for the treatment of idiopathic pulmonary fibrosis.
[0004] Summary of the Invention
[0005] The purpose of the present invention is to provide a novel dual-target inhibitor capable of inhibiting αvβ1 and αvβ6.
[0006] The compound of the present invention has selective inhibitory activity on αvβ1 and αvβ6, weak off-target inhibition on the adhesion of αvβ5, good pharmacokinetic properties and bioavailability, oral performance and good safety.
[0007] The present invention provides a compound represented by general formula (I) or its stereoisomers, tautomers, deuterated substances, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals, wherein:
[0008] In some embodiments, the compound represented by general formula (I) is selected from the compound represented by general formula (II),
[0009] In some embodiments, the compound represented by general formula (I) or (II) is selected from the compounds represented by general formula (III-1) and general formula (III-2).
[0010] In some embodiments, B is selected from 3 to 15 membered carbocyclyl or 4 to 15 membered heterocyclyl, said carbocyclyl or heterocyclyl being optionally substituted with 1 to 4 R b substituted, or B is selected from H or C 1-6 Alkyl, the alkyl group is optionally substituted by 1 to 4 R b replace;
[0011] In some embodiments, B is selected from 3 to 15 membered carbocyclyl or 4 to 15 membered heterocyclyl, said carbocyclyl or heterocyclyl being optionally substituted with 1 to 4 R b replace;
[0012] In some embodiments, B is selected from a 3- to 12-membered carbocyclic ring or a 4- to 12-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted with 1 to 4 R b replace;
[0013] In some embodiments, B is selected from 3- to 7-membered cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, 4- to 6-membered heteroalkyl, 5- to 12-membered cyclocarbocyclyl, 5- to 12-membered spirocyclic carbocyclyl, 5- to 12-membered bridged carbocyclyl, 5- to 12-membered cycloheterocyclyl, 5- to 12-membered spirocyclic heterocyclyl, and 5- to 12-membered bridged heterocyclyl;
[0014] In some embodiments, A is selected from 3 to 15 membered carbocyclyl or 4 to 15 membered heterocyclyl, wherein the carbocyclyl or heterocyclyl is optionally substituted by 1 to 4 R a Substituted, or A is selected from C 1-6 Alkyl, the alkyl group is optionally substituted by 1 to 20 R a replace;
[0015] In some embodiments, A is selected from a 3- to 15-membered carbocyclic ring or a 4- to 15-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted with 1 to 20 R a replace;
[0016] In some embodiments, A is selected from a 3- to 12-membered carbocyclic ring or a 4- to 12-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted with 1 to 20 R a replace;
[0017] In some embodiments, A is selected from 3 to 7 membered cycloalkyl, 6 to 10 membered aryl, 5 to 10 membered heteroaryl, 4 to 6 membered heteroalkyl, 5 to 12 membered cyclic carbocyclyl, 5 to 12 membered spirocyclic carbocyclyl, 5 to 12 membered bridged carbocyclyl, 5 to 12 membered cyclic heterocyclyl, 5 to 12 membered spirocyclic heterocyclyl, 5 to 12 membered bridged heterocyclyl, and the ring A is optionally substituted by 1 to 20 Ra replace;
[0018] In some embodiments, A or B is selected from phenyl, naphthyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, thiazolyl, thienyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, oxetanyl, tetrahydrofuranyl, oxacyclohexyl, benzocyclobutenyl, benzocyclopentenyl, benzocyclohexenyl, benzopyrrolyl, benzopyrazolyl, benzimidazolyl , benzopyridinyl, benzopyrimidinyl, benzopyrazinyl, benzopyridazinyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, benzisoxazolyl, benzisothiazolyl, benzofuranyl, pyridopyrrolyl, pyridopyrazolyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridothiazolyl, pyridothiphenyl, pyridoxazolyl, pyridisoxazolyl, pyridisothiazolyl, pyridofuranyl, pyrazolopyrimidinyl, pyrrolopyrimidinyl, thienopyrimidinyl, imidazopyrimidinyl, thiazolopyrimidinyl, furopyrimidinyl, benzodihydrofuranyl, pyridonyl, The A is optionally replaced by 1 to 4 R a substituted, said B is optionally substituted with 1 to 4 R b replace;
[0019] In some embodiments, A is selected from phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, azetidinyl, pyrrolidinyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, piperidinyl, piperazinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, thienyl, oxazolyl, furanyl, oxetanyl, tetrahydrofuranyl, oxacyclohexyl, benzocyclopentenyl, phenyl pyridopyrrolyl, benzopyrazolyl, benzopyridinyl, benzopyrimidinyl, benzopyridazinyl, benzopyrazinyl, benzothiophenyl, benzofuranyl, pyridopyrrolyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrazinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, pyridopyrimidinyl, pyrazolopyrimidinyl, pyrrolopyrimidinyl, thienopyrimidinyl, benzodihydrofuranyl, pyridonyl, The A is optionally replaced by 1 to 4 R a replace;
[0020] In some embodiments, A is selected from the group consisting of substituted or unsubstituted: When substituted, optionally substituted with 1 to 4 R a replace;
[0021] In some embodiments, A is selected from the group consisting of substituted or unsubstituted: When substituted, optionally substituted with 1 to 4 R a Substituted; In some embodiments, A is selected from the following groups which are substituted or unsubstituted: When substituted, optionally substituted with 1 to 4 R a replace;
[0022] In some embodiments, A is selected from
[0023] In some embodiments, A is selected from C 1-6 Alkyl, the alkyl group is optionally substituted by 1 to 4 R a replace;
[0024] In some embodiments, A is selected from C 1-4 Alkyl, the alkyl group is optionally substituted by 1 to 4 R a replace;
[0025] In some embodiments, A is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, wherein the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl is optionally substituted by 1 to 4 R a replace;
[0026] In some embodiments, A is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl;
[0027] In some embodiments, A is selected from isopropyl, tert-butyl;
[0028] In some embodiments, B is selected from phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, piperidinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, thienyl, oxazolyl, furanyl, benzocyclopentenyl, benzopyrrolyl, benzopyrazolyl, benzopyridinyl, benzopyrimidinyl, benzopyridazinyl, benzothienyl, benzofuranyl, pyridopyrrolyl, pyridoimidazolyl, pyridopyridinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, pyridopyrimidinyl, pyrazolopyrimidinyl, pyrrolopyrimidinyl, thienopyrimidinyl, benzodihydrofuranyl, pyridonyl, and said B is optionally substituted by 1 to 4 R b replace;
[0029] In some embodiments, B is selected from the group consisting of substituted or unsubstituted: When substituted, optionally substituted with 1 to 4 R b replace;
[0030] In some embodiments, B is selected from the group consisting of substituted or unsubstituted: When substituted, optionally substituted with 1 to 4 R b replace;
[0031] In some embodiments, B is selected from the group consisting of substituted or unsubstituted:
[0032] In some embodiments, B is selected from H or C 1-6 Alkyl, the alkyl group is optionally substituted by 1 to 4 R b replace;
[0033] In some embodiments, B is selected from H or C 1-4 Alkyl, the alkyl group is optionally substituted by 1 to 4 R b replace;
[0034] In some embodiments, B is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, wherein the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl is optionally replaced by 1 to 4 R b replace;
[0035] In some embodiments, B is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl;
[0036] In some embodiments, B is selected from H, methyl;
[0037] In some embodiments, Y is selected from C=O, C=S, or a bond;
[0038] In some embodiments, Y is selected from C=O or a bond;
[0039] In some embodiments, X1 is selected from -(CR x1a R x1b ) n1 - or -NH-;
[0040] In some embodiments, X1 is selected from a bond, -NH-, -CH2-, -CHF-, -CF2-, -CH(CH3)-, -C(CH3)2-, In some embodiments, X2 is selected from -(CR x2a R x2b ) n2 -;
[0041] In some embodiments, X2 is selected from -CH2CH2-, -CF2CH2-, -CHFCH2-, -CH2CH2CH2-, -CH2C(CH3)2-, -C(CH3)2CH2-,
[0042] In some embodiments, X3 is selected from -(CR x3a R x3b ) n3 -;
[0043] In some embodiments, X3 is selected from -CH2CH2CH2-, -CH2CH2CH2CH2-, -CH2C(CH3)2CH2-, -CH2CF2CH2-, -CH2CH2C(CH3)2-, -CH2CH2CF2-,
[0044] In some embodiments, X4 is selected from -(CR x4a R x4b ) n4 -;
[0045] In some embodiments, X4 is selected from a bond, -CH2-, -CH2CH2-, -CH(CH3)-, -C(CH3)2-, -CF2-;
[0046] In some embodiments, X4 is selected from a bond, -CH2CH2-, -CH2-, -CH(CH3)-, -C(CH3)2-,
[0047] In some embodiments, X5 is selected from a bond, -NH-, -O-, -S-, -S(=O)2-, -C(=O), -C(=S), -C(=NH), -NHC(=S)NH-, -NHC(=O)NH-, -NHC(=NH)NH-, -NHS(=O)2NH-, -NHC(=S)-, -NHC(=O)-, -NHC(=NH)-, -NHS(=O)2-, -C(=S)NH-, -C(=O)NH-, -C(=NH)NH-, or -S(=O)2NH-;
[0048] In some embodiments, X5 is selected from a bond, -NH-, -NHC(=S)NH-, -NHC(=O)NH-, -NHC(=NH)NH-, or -NHS(=O)2NH-;
[0049] In some embodiments, R 1 Selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6Alkynyl, -C 0-4 Alkylene-C 3-6 Carbocyclic ring, -C 0-4 Alkylene-3 to 7 membered heterocycle, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocycle or heterocycle is optionally substituted by 1 to 4 R 1A replaced by;
[0050] In some embodiments, R 1 Selected from C 1-5 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Carbocyclic ring, 3 to 6 membered heterocyclic ring, said alkyl, alkenyl, alkynyl, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 R 1A replaced by;
[0051] In some embodiments, R 1 is selected from methyl, ethyl, propyl, butyl, vinyl, propenyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, thiazolyl, thienyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, the methyl alkyl, ethyl, propyl, butyl, vinyl, propenyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, thiazolyl, thienyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, optionally substituted with 1 to 4 R 1A replaced by;
[0052] In some embodiments, R 1 is selected from methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, wherein the methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl is optionally substituted by 1 to 4 R 1A replaced by;
[0053] In some embodiments, R 1 Selected from
[0054] In some embodiments, R 1 Selected from
[0055] In some embodiments, R 1AEach independently selected from H, deuterium, halogen, OH, =O, CN, NH2, NO2, COOH, CONH2, C 1-6 Alkyl, OC 1-6 Alkyl, SC 1-6 Alkyl, -SO2C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -CONHC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, -OC 3-6 Carbocycle, -O-3 to 7 membered heterocycle, -NH-C 3-6 Carbocycle, -NH-3 to 7-membered heterocycle, -SC 3-6 Carbocyclic ring, -S-3 to 7 membered heterocyclic ring, -C 0-4 Alkylene-C 3-6 Carbocyclic ring, -C 0-4 Alkylene-3 to 7 membered heterocycle, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocycle or heterocycle is optionally substituted by 1 to 4 R k replaced by;
[0056] In some embodiments, R 1A Each independently selected from H, deuterium, halogen, OH, ═O, CN, NH 2 , NO 2 , COOH, CONH 2 , C 1-4 Alkyl, OC 1-4 Alkyl, SC 1-4 Alkyl, -SO2C 1-4 Alkyl, -NHCOC 1-4 Alkyl, -CONHC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, -OC 3-6 Carbocycle, -O-3 to 6-membered heterocycle, -NH-C 3-6 Carbocycle, -NH-3 to 6-membered heterocycle, -SC 3-6 Carbocyclic ring, -S-3 to 6-membered heterocyclic ring, -C 0-3 Alkylene-C 3-6 Carbocyclic ring, -C 0-3 Alkylene-3 to 7 membered heterocycle, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocycle or heterocycle is optionally substituted by 1 to 4 R k replaced by;
[0057] In some embodiments, R 1AEach independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, NO2, COOH, CONH2, NHCH3, N(CH3)2, NHCOCH3, CONHCH3, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, -O-phenyl, -O-cyclopropyl, -O-pyridyl, methylthio, -SO2-CH3, -SO2-CH2CH3, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, azetidinyl, azopentyl, oxadiazole, oxadiazole, cyclohexane ... Butyl, oxolane, 1,4-dioxane, 1,3-dioxane, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl, pyridinyl, the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, azetidinyl, azetidinyl, oxolane, 1,4-dioxane, 1,3-dioxane, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl, pyridinyl are optionally substituted by 1 to 4 groups selected from R k substituted by a substituent;
[0058] In some embodiments, R 1A Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NHCOCH3, CONHCH3, methyl, ethyl, methoxy, ethoxy, -O-phenyl, -O-cyclopropyl, -O-pyridyl, -SO2-CH3, -SO2-CH2CH3, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, azepanyl, tetrahydrofuranyl, 1,4-dioxane, pyrrolidinyl, piperidinyl, pyrazolyl, the methyl, ethyl, methoxy, ethoxy, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, azepanyl, tetrahydrofuranyl, 1,4-dioxane, pyrrolidinyl, piperidinyl, pyrazolyl, phenyl, pyridinyl is optionally substituted by 1 to 4 selected from R k substituted by a substituent;
[0059] In some embodiments, R a 、R b 、R x1a 、R x1b 、R x2a 、R x2b 、R 3a 、R 3b 、R x3a 、R x3b 、R x4a 、R x4b Each independently selected from H, deuterium, halogen, OH, =O, CN, NH2, NO2, COOH, CONH2, C(=O)NHCH3, S(=O)2CH3, C 1-6 Alkyl, OC1-6 Alkyl, SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, -OC 3-6 Carbocycle, -O-3 to 7 membered heterocycle, -NH-C 3-6 Carbocycle, -NH-3 to 7-membered heterocycle, -SC 3-6 Carbocyclic ring, -S-3 to 7 membered heterocyclic ring, -C 0-4 Alkylene-C 3-6 Carbocyclic ring, -C 0-4 Alkylene-3 to 7 membered heterocycle, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocycle or heterocycle is optionally substituted by 1 to 4 R k replaced by;
[0060] In some embodiments, R a 、R b 、R x1a 、R x1b 、R x2a 、R x2b 、R 3a 、R 3b 、R x3a 、R x3b 、R x4a 、R x4b Each independently selected from H, deuterium, halogen, OH, =O, CN, NH2, NO2, COOH, CONH2, C(=O)NHCH3, S(=O)2CH3, C 1-4 Alkyl, OC 1-4 Alkyl, SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, -OC 3-6 Carbocycle, -O-3 to 7 membered heterocycle, -NH-C 3-6 Carbocycle, -NH-3 to 6-membered heterocycle, -SC 3-6 Carbocyclic ring, -S-3 to 6-membered heterocyclic ring, -C 0-3 Alkylene-C 3-6 Carbocyclic ring, -C 0-3 Alkylene-3 to 7 membered heterocycle, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocycle or heterocycle is optionally substituted by 1 to 4 R k replaced by;
[0061] In some embodiments, R a 、R b 、R x1a 、Rx1b 、R x2a 、R x2b 、R 3a 、R 3b 、R x3a 、R x3b 、R x4a 、R x4b Each is independently selected from H, deuterium, halogen, OH, =O, CN, NH2, NO2, COOH, CONH2, C(=O)NHCH3, S(=O)2CH3, O-cyclopropyl, O-cyclobutyl, O-cyclopentyl, O-cyclohexyl, O-phenyl, NHCH3, NHCH2CH3, NH-propyl, NH-isopropyl, NH-tert-butyl, NH-cyclobutyl, NH-cyclopentyl, NH-cyclohexyl, NH-cyclopropyl, NH-pyrazolyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, pyridinyl, phenyl, imidazolyl, The CH2, CH3, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, imidazolyl, pyridyl, phenyl are optionally substituted by 1 to 4 R k replaced by;
[0062] In some embodiments, R x1a 、R x1b 、R x2a 、R x2b 、R 3a 、R 3b 、R x3a 、R x3b 、R x4a 、R x4b Each independently selected from H, deuterium, F, Cl, Br, I, OH, =O, CN, NH2, methyl, ethyl, methoxy, ethoxy, cyclopropyl, wherein the methyl, ethyl, methoxy, ethoxy, cyclopropyl is optionally substituted by 1 to 4 R k replaced by;
[0063] In some embodiments, R aEach independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, CH2F, CHF2, CF3, CH2OH, OCF3, OCHF2, OCH2OH, C(=O)NHCH3, S(=O)2CH3, O-phenyl, NH-cyclopropyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, propynyl, propargyl, methylthio, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrazolyl, phenyl, pyridyl,
[0064] In some embodiments, R a Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, CH2F, CHF2, CF3, CH2OH, OCF3, OCHF2, OCH2OH, NH-cyclopropyl, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl;
[0065] In some embodiments, R b Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, CH2F, CHF2, CF3, CH2OH, OCF3, OCHF2, OCH2OH, C(=O)NHCH3, S(=O)2CH3, NHCH3, NHCH2CH3, O-cyclopropyl, O-cyclobutyl, O-cyclopentyl, O-cyclohexyl, O-phenyl, NH-propyl, NH-isopropyl, NH- tert-butyl, NH-cyclopropyl, NH-cyclobutyl, NH-cyclopentyl, NH-cyclohexyl, NH-phenyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, propynyl, propargyl, methylthio, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrazolyl, phenyl, pyridinyl, pyrrolidinyl, piperidinyl, imidazolyl,
[0066] In some embodiments, R bEach independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, CH2F, CHF2, CF3, CH2OH, OCF3, OCHF2, OCH2OH, C(=O)NHCH3, S(=O)2CH3, NHCH3, NHCH2CH3, NH-propyl, NH-isopropyl, NH-tert-butyl, NH-cyclopropyl, NH-cyclobutyl, NH-cyclopentyl, NH-cyclohexyl, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, isopropyloxy, cyclopropyl, cyclobutyl, pyrazolyl, O-cyclopropyl, O-cyclobutyl, O-cyclopentyl, O-cyclohexyl, O-phenyl, phenyl, pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, imidazolyl,
[0067] In some embodiments, both R b 、R x1a With R x1b 、R x2a With R x2b 、R 3a With R 3b 、R x3a With R x3b 、R x4a With R x4b The atoms to which they are attached together form a 3- to 8-membered carbocyclic ring or a 4- to 8-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 R k replace;
[0068] In some embodiments, both R b 、R x1a With R x1b 、R x2a With R x2b 、R 3a With R 3b 、R x3a With R x3b 、R x4a With R x4b The atoms to which they are attached together form a 3- to 6-membered carbocyclic ring or a 4- to 6-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 R k replace;
[0069] In some embodiments, both R b 、R x1a With R x1b 、R x2a With R x2b 、R 3a With R 3b 、R x3a With R x3b 、R x4a With Rx4b The atoms connected thereto together form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl, or morpholinyl group, wherein the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl, or morpholinyl group is optionally substituted by 1 to 4 R k replace;
[0070] In some embodiments, both R b 、R x1a With R x1b 、R x2a With R x2b 、R 3a With R 3b 、R x3a With R x3b 、R x4a With R x4b The atoms to which they are respectively attached together form a cyclopropyl group;
[0071] In some embodiments, R k Each independently selected from deuterium, halogen, OH, =O, CN, NH2, NO2, COOH, CONH2, C 1- 6-alkyl, OC 1-6 Alkyl, SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, -OC 3-6 Carbocycle, -O-3 to 7 membered heterocycle, -NH-C 3-6 Carbocycle, -NH-3 to 7-membered heterocycle, -SC 3-6 Carbocyclic ring, -S-3 to 7 membered heterocyclic ring, -C 0-4 Alkylene-C 3-6 Carbocyclic ring, -C 0- 4-alkylene-3 to 7-membered heterocycle, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic or heterocyclic ring is optionally substituted by 1 to 4 deuterium, halogen, =O, CN, OH, NH2, C 1-6 Alkyl, C 1-6 substituted by an alkoxy substituent;
[0072] In some embodiments, R k Each independently selected from deuterium, halogen, OH, =O, CN, NO2, NH2, COOH, CONH2, C 1- 4-alkyl, OC 1-4 Alkyl, SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C1-4 Alkyl)2, -OC 3-6 Carbocycle, -O-3 to 7 membered heterocycle, -NH-C 3-6 Carbocycle, -NH-3 to 7-membered heterocycle, -SC 3-6 Carbocyclic ring, -S-3 to 7 membered heterocyclic ring, -C 0-2 Alkylene-C 3-6 Carbocyclic ring, -C 0- 2-alkylene-3 to 7-membered heterocycle, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic or heterocyclic ring is optionally substituted by 1 to 4 deuterium, halogen, =O, CN, OH, NH2, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;
[0073] In some embodiments, R k Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, NO2, COOH, CONH2, NHCH3, N(CH3)2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl , phenyl, pyridyl, imidazolyl, the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, pyrazolyl, phenyl, pyridyl, imidazolyl are optionally substituted by 1 to 4 groups selected from deuterium, F, Cl, Br, I, =O, CN, OH, NH2, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;
[0074] In some embodiments, R k Deuterium, F, Cl, Br, I, OH, =O, CN, NH2, NO2, NHCH3, N(CH3)2, COOH, CONH2, CH2F, CHF2, CF3, CH2OH, OCF3, OCHF2, OCH2OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, propynyl, propargyl, methylthio, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrazolyl, phenyl, imidazolyl, cyclopentyl, cyclohexyl.
[0075] In some embodiments, n1, n2, n3, n4 are each independently selected from 0, 1, 2, 3, 4 or 5;
[0076] In some embodiments, n1, n2, and n4 are each independently selected from 0, 1, 2, and 3;
[0077] In some embodiments, n3 is selected from 1, 2, 3, 4, or 5;
[0078] Optionally,
[0079] B is not selected
[0080] As a first embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomers, tautomers, deuterated substances, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals,
[0081] A is selected from a 3- to 15-membered carbocyclic ring or a 4- to 15-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 20 R a replace;
[0082] Or A is selected from C 1-6 Alkyl, the alkyl group is optionally substituted by 1 to 4 R a replace;
[0083] B is selected from 3 to 15-membered carbocyclic groups or 4 to 15-membered heterocyclic groups, wherein the carbocyclic groups or heterocyclic groups are optionally substituted by 1 to 4 R b replace;
[0084] or B is selected from H or C 1-6 Alkyl, the alkyl group is optionally substituted by 1 to 4 R b replace;
[0085] Y is selected from C=O, C=S or a bond;
[0086] X1 is selected from -(CR x1a R x1b ) n1 - or -NH-;
[0087] X2 is selected from -(CR x2a R x2b ) n2 -;
[0088] X3 is selected from -(CR x3a R x3b ) n3 -;
[0089] X4 is selected from -(CR x4a R x4b ) n4 -;
[0090] X5 is selected from the group consisting of bonds, -NH-, -O-, -S-, -S(=O)2-, -C(=O), -C(=S), -C(=NH), -NHC(=S)NH-, -NHC(=O)NH-, -NHC(=NH)NH-, -NHS( =O)2NH-, -NHC(=S)-, -NHC(=O)-, -NHC(=NH)-, -NHS(=O)2-, -C(=S)NH-, -C(=O)NH-, -C(=NH)NH- or -S(=O)2NH-;
[0091] n1, n2, n3, n4 are each independently selected from 0, 1, 2, 3, 4 or 5;
[0092] R 1 Selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -C 0-4 Alkylene-C 3-6 Carbocyclic ring, -C 0-4 Alkylene-3 to 7 membered heterocycle, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocycle or heterocycle is optionally substituted by 1 to 4 R 1A replaced by;
[0093] R 1A Each independently selected from H, deuterium, halogen, OH, =O, CN, NH2, NO2, COOH, CONH2, C 1-6 Alkyl, OC 1-6 Alkyl, SC 1-6 Alkyl, -SO2C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -CONHC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, -OC 3-6 Carbocycle, -O-3 to 7 membered heterocycle, -NH-C 3-6 Carbocycle, -NH-3 to 7-membered heterocycle, -SC 3-6 Carbocyclic ring, -S-3 to 7 membered heterocyclic ring, -C 0-4 Alkylene-C 3-6 Carbocyclic ring, -C 0-4 Alkylene-3 to 7 membered heterocycle, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocycle or heterocycle is optionally substituted by 1 to 4 R k replaced by;
[0094] R a 、R b 、R x1a 、R x1b、R x2a 、R x2b 、R 3a 、R 3b 、R x3a 、R x3b 、R x4a 、R x4b Each independently selected from H, deuterium, halogen, OH, =O, CN, NH2, NO2, COOH, CONH2, C(=O)NHCH3, S(=O)2CH3, C 1-6 Alkyl, OC 1-6 Alkyl, SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, -OC 3-6 Carbocycle, -O-3 to 7 membered heterocycle, -NH-C 3-6 Carbocycle, -NH-3 to 7-membered heterocycle, -SC 3-6 Carbocyclic ring, -S-3 to 7 membered heterocyclic ring, -C 0-4 Alkylene-C 3-6 Carbocyclic ring, -C 0-4 Alkylene-3 to 7 membered heterocycle, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocycle or heterocycle is optionally substituted by 1 to 4 R k replaced by;
[0095] Alternatively, two R b 、R x1a With R x1b 、R x2a With R x2b 、R 3a With R 3b 、R x3a With R x3b 、R x4a With R x4b The atoms to which they are attached together form a 3- to 8-membered carbocyclic ring or a 4- to 8-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 R k replace;
[0096] R k Each independently selected from deuterium, halogen, OH, =O, CN, NH2, NO2, COOH, CONH2, C 1-6 Alkyl, OC 1-6 Alkyl, SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, -OC 3-6Carbocycle, -O-3 to 7 membered heterocycle, -NH-C 3-6 Carbocycle, -NH-3 to 7-membered heterocycle, -SC 3-6 Carbocyclic ring, -S-3 to 7 membered heterocyclic ring, -C 0-4 Alkylene-C 3-6 Carbocyclic ring, -C 0-4 Alkylene-3 to 7 membered heterocycle, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic or heterocyclic ring is optionally substituted by 1 to 4 atoms selected from deuterium, halogen, =O, CN, OH, NH2, C 1-6 Alkyl, C 1-6 substituted by an alkoxy substituent;
[0097] Provided that, provided that, B is not selected from
[0098] As a second embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomers, tautomers, deuterated substances, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals,
[0099] A is selected from a 3- to 12-membered carbocyclic ring or a 4- to 12-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 20 R a replace;
[0100] Or A is selected from C 1-4 Alkyl, the alkyl group is optionally substituted by 1 to 4 R a replace;
[0101] B is selected from a 3- to 12-membered carbocyclic ring or a 4- to 12-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 R b replace;
[0102] or B is selected from H or C 1-4 Alkyl, the alkyl group is optionally substituted by 1 to 4 R b replace;
[0103] n1, n2, n4 are each independently selected from 0, 1, 2, 3;
[0104] n3 is selected from 1, 2, 3, 4 or 5;
[0105] R 1 Selected from C 1-5 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Carbocyclic ring, 3 to 6 membered heterocyclic ring, said alkyl, alkenyl, alkynyl, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 R 1A replaced by;
[0106] R 1AEach independently selected from H, deuterium, halogen, OH, =O, CN, NH2, NO2, COOH, CONH2, C 1-4 Alkyl, OC 1-4 Alkyl, SC 1-4 Alkyl, -SO2C 1-4 Alkyl, -NHCOC 1-4 Alkyl, -CONHC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, -OC 3-6 Carbocycle, -O-3 to 6-membered heterocycle, -NH-C 3-6 Carbocycle, -NH-3 to 6-membered heterocycle, -SC 3-6 Carbocyclic ring, -S-3 to 6-membered heterocyclic ring, -C 0-3 Alkylene-C 3-6 Carbocyclic ring, -C 0-3 Alkylene-3 to 7 membered heterocycle, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocycle or heterocycle is optionally substituted by 1 to 4 R k replaced by;
[0107] R a 、R b 、R x1a 、R x1b 、R x2a 、R x2b 、R 3a 、R 3b 、R x3a 、R x3b 、R x4a 、R x4b Each independently selected from H, deuterium, halogen, OH, =O, CN, NH2, NO2, COOH, CONH2, C(=O)NHCH3, S(=O)2CH3, C 1-4 Alkyl, OC 1-4 Alkyl, SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, -OC 3-6 Carbocycle, -O-3 to 7 membered heterocycle, -NH-C 3-6 Carbocycle, -NH-3 to 6-membered heterocycle, -SC 3-6 Carbocyclic ring, -S-3 to 6-membered heterocyclic ring, -C 0-3 Alkylene-C 3-6 Carbocyclic ring, -C 0-3Alkylene-3 to 7 membered heterocycle, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocycle or heterocycle is optionally substituted by 1 to 4 R k replaced by;
[0108] Alternatively, two R b 、R x1a With R x1b 、R x2a With R x2b 、R 3a With R 3b 、R x3a With R x3b 、R x4a With R x4b The atoms to which they are attached together form a 3- to 6-membered carbocyclic ring or a 4- to 6-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 R k replace;
[0109] R k Each independently selected from deuterium, halogen, OH, =O, CN, NO2, NH2, COOH, CONH2, C 1-4 Alkyl, OC 1-4 Alkyl, SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, -OC 3-6 Carbocycle, -O-3 to 7 membered heterocycle, -NH-C 3-6 Carbocycle, -NH-3 to 7-membered heterocycle, -SC 3-6 Carbocyclic ring, -S-3 to 7 membered heterocyclic ring, -C 0-2 Alkylene-C 3-6 Carbocyclic ring, -C 0-2 Alkylene-3 to 7 membered heterocycle, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic or heterocyclic ring is optionally substituted by 1 to 4 atoms selected from deuterium, halogen, =O, CN, OH, NH2, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;
[0110] The remaining definitions are the same as those of the first embodiment of the present invention.
[0111] As a third embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomers, tautomers, deuterated substances, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals,
[0112] A or B is selected from phenyl, naphthyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, thiazolyl, thienyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, oxetanyl, tetrahydrofuranyl, oxahexyl, benzocyclobutenyl, benzocyclopentenyl, benzocyclohexenyl, benzopyrrolyl, benzopyrazolyl, benzimidazolyl, benzopyridine yl, benzopyrimidinyl, benzopyrazinyl, benzopyridazinyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, benzisoxazolyl, benzisothiazolyl, benzofuranyl, pyridopyrrolyl, pyridopyrazolyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridothiazolyl, pyridothiphenyl, pyridoxazolyl, pyridisoxazolyl, pyridisothiazolyl, pyridofuranyl, pyrazolopyrimidinyl, pyrrolopyrimidinyl, thienopyrimidinyl, imidazopyrimidinyl, thiazolopyrimidinyl, furopyrimidinyl, benzodihydrofuranyl, pyridonyl, The A is optionally replaced by 1 to 4 R a substituted, said B is optionally substituted with 1 to 4 R b replace;
[0113] Or A is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, wherein the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl is optionally replaced by 1 to 4 R a replace;
[0114] Or B is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, wherein the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl is optionally replaced by 1 to 4 R b replace;
[0115] R 1is selected from methyl, ethyl, propyl, butyl, vinyl, propenyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, thiazolyl, thienyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, the methyl alkyl, ethyl, propyl, butyl, vinyl, propenyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, thiazolyl, thienyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, optionally substituted with 1 to 4 R 1A replaced by;
[0116] R 1A Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, NO2, COOH, CONH2, NHCH3, N(CH3)2, NHCOCH3, CONHCH3, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, -O-phenyl, -O-cyclopropyl, -O-pyridyl, methylthio, -SO2-CH3, -SO2-CH2CH3, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, azetidinyl, azopentyl, oxadiazole, oxadiazole, cyclohexane ... Butyl, oxolane, 1,4-dioxane, 1,3-dioxane, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl, pyridinyl, the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, azetidinyl, azetidinyl, oxolane, 1,4-dioxane, 1,3-dioxane, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl, pyridinyl are optionally substituted by 1 to 4 groups selected from R k substituted by a substituent;
[0117] R a 、R b 、R x1a 、R x1b 、R x2a 、R x2b 、R 3a 、R 3b 、R x3a 、R x3b 、R x4a 、R x4bEach is independently selected from H, deuterium, halogen, OH, =O, CN, NH2, NO2, COOH, CONH2, C(=O)NHCH3, S(=O)2CH3, O-cyclopropyl, O-cyclobutyl, O-cyclopentyl, O-cyclohexyl, O-phenyl, NHCH3, NHCH2CH3, NH-propyl, NH-isopropyl, NH-tert-butyl, NH-cyclobutyl, NH-cyclopentyl, NH-cyclohexyl, NH-cyclopropyl, NH-pyrazolyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, pyridinyl, phenyl, imidazolyl, The CH2, CH3, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, imidazolyl, pyridyl, phenyl are optionally substituted by 1 to 4 R k replaced by;
[0118] Alternatively, two R b 、R x1a With R x1b 、R x2a With R x2b 、R 3a With R 3b 、R x3a With R x3b 、R x4a With R x4b The atoms connected thereto together form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl, or morpholinyl group, wherein the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl, or morpholinyl group is optionally substituted by 1 to 4 R k replace;
[0119] R kEach independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, NO2, COOH, CONH2, NHCH3, N(CH3)2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl , phenyl, pyridyl, imidazolyl, the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, pyrazolyl, phenyl, pyridyl, imidazolyl are optionally substituted by 1 to 4 groups selected from deuterium, F, Cl, Br, I, =O, CN, OH, NH2, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;
[0120] The remaining definitions are the same as those of the first or second embodiment of the present invention.
[0121] As a fourth embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomers, tautomers, deuterated substances, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals,
[0122] A is selected from phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, azetidinyl, pyrrolidinyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, piperidinyl, piperazinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, thienyl, oxazolyl, furanyl, oxetanyl, tetrahydrofuranyl, oxacyclohexyl, benzocyclopentenyl, benzopyrrolyl , benzopyrazolyl, benzopyridinyl, benzopyrimidinyl, benzopyridazinyl, benzopyrazinyl, benzothiophenyl, benzofuranyl, pyridopyrrolyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrazinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, pyridopyrimidinyl, pyrazolopyrimidinyl, pyrrolopyrimidinyl, thienopyrimidinyl, benzodihydrofuranyl, pyridonyl, The A is optionally replaced by 1 to 4 R a replace;
[0123] or A is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl;
[0124] B is selected from phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, piperidinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, thienyl, oxazolyl, furanyl, benzocyclopentenyl, benzopyrrolyl, benzopyrazolyl, benzopyridinyl, benzopyrimidinyl, benzopyridazinyl, benzothienyl, benzofuranyl, pyridopyrrolyl, pyridoimidazolyl, pyridopyridinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, pyridopyrimidinyl, pyrazolopyrimidinyl, pyrrolopyrimidinyl, thienopyrimidinyl, benzodihydrofuranyl, pyridonyl, said B being optionally substituted by 1 to 4 R b replace;
[0125] or B is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl;
[0126] R 1 is selected from methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, wherein the methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl is optionally substituted by 1 to 4 R 1A replaced by;
[0127] R 1A Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NHCOCH3, CONHCH3, methyl, ethyl, methoxy, ethoxy, -O-phenyl, -O-cyclopropyl, -O-pyridyl, -SO2-CH3, -SO2-CH2CH3, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, azepanyl, tetrahydrofuranyl, 1,4-dioxane, pyrrolidinyl, piperidinyl, pyrazolyl, the methyl, ethyl, methoxy, ethoxy, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, azepanyl, tetrahydrofuranyl, 1,4-dioxane, pyrrolidinyl, piperidinyl, pyrazolyl, phenyl, pyridinyl is optionally substituted by 1 to 4 selected from R k substituted by a substituent;
[0128] R x1a 、R x1b 、R x2a 、R x2b 、R 3a 、R 3b 、R x3a 、R x3b 、R x4a 、R x4b Each independently selected from H, deuterium, F, Cl, Br, I, OH, =O, CN, NH2, methyl, ethyl, methoxy, ethoxy, cyclopropyl, wherein the methyl, ethyl, methoxy, ethoxy, cyclopropyl is optionally substituted by 1 to 4 R k replaced by;
[0129] Ra Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, CH2F, CHF2, CF3, CH2OH, OCF3, OCHF2, OCH2OH, C(=O)NHCH3, S(=O)2CH3, O-phenyl, NH-cyclopropyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, propynyl, propargyl, methylthio, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrazolyl, phenyl, pyridyl,
[0130] R b Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, CH2F, CHF2, CF3, CH2OH, OCF3, OCHF2, OCH2OH, C(=O)NHCH3, S(=O)2CH3, NHCH3, NHCH2CH3, O-cyclopropyl, O-cyclobutyl, O-cyclopentyl, O-cyclohexyl, O-phenyl, NH-propyl, NH-isopropyl, NH- tert-butyl, NH-cyclopropyl, NH-cyclobutyl, NH-cyclopentyl, NH-cyclohexyl, NH-phenyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, propynyl, propargyl, methylthio, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrazolyl, phenyl, pyridinyl, pyrrolidinyl, piperidinyl, imidazolyl,
[0131] Alternatively, two R b 、R x1a With R x1b 、R x2a With R x2b 、R 3a With R 3b 、R x3a With R x3b 、R x4a With R x4b The atoms to which they are respectively attached together form a cyclopropyl group;
[0132] R keach independently deuterium, F, Cl, Br, I, OH, ═O, CN, NH2, NO2, NHCH3, N(CH3)2, COOH, CONH2, CH2F, CHF2, CF3, CH2OH, OCF3, OCHF2, OCH2OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, propynyl, propargyl, methylthio, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrazolyl, phenyl, imidazolyl, cyclopentyl, cyclohexyl;
[0133] The remaining definitions are the same as those of the first, second or third embodiment of the present invention.
[0134] As a fifth embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomers, tautomers, deuterated substances, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals,
[0135] A is selected from the following substituted or unsubstituted groups: When substituted, optionally substituted with 1 to 4 R a replace;
[0136] or A is selected from isopropyl and tert-butyl;
[0137] B is selected from the following substituted or unsubstituted groups: When substituted, optionally substituted with 1 to 4 R b replace;
[0138] or B is selected from H, methyl;
[0139] R a Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, CH2F, CHF2, CF3, CH2OH, OCF3, OCHF2, OCH2OH, C(=O)NHCH3, S(=O)2CH3, NH-cyclopropyl, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, isopropyloxy, cyclopropyl, cyclobutyl, pyrazolyl, O-phenyl, phenyl, pyridyl, R bEach independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, CH2F, CHF2, CF3, CH2OH, OCF3, OCHF2, OCH2OH, C(=O)NHCH3, S(=O)2CH3, NHCH3, NHCH2CH3, NH-propyl, NH-isopropyl, NH-tert-butyl, NH-cyclopropyl, NH-cyclobutyl, NH-cyclopentyl, NH-cyclohexyl, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, isopropyloxy, cyclopropyl, cyclobutyl, pyrazolyl, O-cyclopropyl, O-cyclobutyl, O-cyclopentyl, O-cyclohexyl, O-phenyl, phenyl, pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, imidazolyl,
[0140] R 1 Selected from
[0141] Y is selected from C=O or a bond;
[0142] X1 is selected from a bond, -NH-, -CH2-, -CHF-, -CF2-, -CH(CH3)-, -C(CH3)2-,
[0143] X2 is selected from -CH2CH2-, -CF2CH2-, -CHFCH2-, -CH2CH2CH2-, -CH2C(CH3)2-, -C(CH3)2CH2-,
[0144] X3 is selected from -CH2CH2CH2-, -CH2CH2CH2CH2-, -CH2C(CH3)2CH2-, -CH2CF2CH2-, -CH2CH2C(CH3)2-, -CH2CH2CF2-,
[0145] X4 is selected from a bond, -CH2-, -CH2CH2-, -CH(CH3)-, -C(CH3)2-, -CF2-;
[0146] X5 is selected from a bond, -NH-, -NHC(=S)NH-, -NHC(=O)NH-, -NHC(=NH)NH- or -NHS(=O)2NH-;
[0147] The remaining definitions are the same as those of the first, second, third or fourth embodiment of the present invention.
[0148] As a sixth embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomer, tautomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, the compound represented by the general formula (I) is selected from the compound represented by the general formula (II),
[0149] A, B, Y, R 1 The definitions of X4 and X5 are the same as those of A, B, Y, R in the first, second, third, fourth or fifth embodiments of the present invention. 1 , X4, and X5 are the same as any one of their definitions, and are preferably the same as those in the fifth embodiment of the present invention.
[0150] As a seventh embodiment of the present invention, the compound represented by the aforementioned general formula (I) or (II) or its stereoisomer, tautomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, the compound represented by general formula (I) or (II) is selected from the compounds represented by general formula (III-1) and general formula (III-2),
[0151] A.R. 1 、R b The definitions of A, R and 1 、R b The same as any one of the definitions of
[0152] Preferably,
[0153] A is selected from the following substituted or unsubstituted groups: When substituted, optionally substituted with 1 to 4 R a replace;
[0154] R a Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, CH2F, CHF2, CF3, CH2OH, OCF3, OCHF2, OCH2OH, NH-cyclopropyl, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl;
[0155] R 1 Selected from
[0156] R bEach independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, CH2F, CHF2, CF3, CH2OH, OCF3, OCHF2, OCH2OH, C(=O)NHCH3, S(=O)2CH3, NHCH3, NHCH2CH3, NH-propyl, NH-isopropyl, NH-tert-butyl, NH-cyclopropyl, NH-cyclobutyl, NH-cyclopentyl, NH-cyclohexyl, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, isopropyloxy, cyclopropyl, cyclobutyl, pyrazolyl, O-cyclopropyl, O-cyclobutyl, O-cyclopentyl, O-cyclohexyl, O-phenyl, phenyl, pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, imidazolyl,
[0157] The present invention relates to the following compound or its stereoisomer, tautomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein the compound is selected from one of the structures in Table S below:
[0158] Table S
[0159] The present invention relates to a pharmaceutical composition comprising the above compound or its stereoisomers, tautomers, deuterated substances, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals, and a pharmaceutically acceptable carrier.
[0160] The present invention relates to the use of the above-mentioned compound or its stereoisomers, tautomers, deuterated substances, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals or the above-mentioned pharmaceutical compositions in the preparation of drugs for inhibiting αvβ1 and αvβ6.
[0161] The present invention relates to the use of the above-mentioned compound or its stereoisomers, tautomers, deuterated compounds, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals or the above-mentioned pharmaceutical compositions in preparing drugs for treating idiopathic pulmonary fibrosis.
[0162] The present invention relates to a pharmaceutical composition or pharmaceutical formulation comprising a therapeutically effective amount of a compound of the present invention, or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or cocrystal thereof, and a pharmaceutically acceptable excipient. The pharmaceutical composition may be in the form of a unit dosage form (the amount of the active ingredient in a unit dosage form is also referred to as the "drug strength").
[0163] The present invention also provides a method for treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of the present invention, or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt, cocrystal, or pharmaceutical composition thereof. In some embodiments, the mammal of the present invention comprises a human.
[0164] As used herein, an "effective amount" or "therapeutically effective amount" refers to administering a sufficient amount of a compound disclosed herein to alleviate, to some extent, one or more symptoms of the disease or condition being treated (e.g., idiopathic pulmonary fibrosis). In some embodiments, the result is a reduction and / or alleviation of the signs, symptoms, or causes of the disease, or any other desired change in a biological system. For example, an "effective amount" for therapeutic use is the amount of a compound disclosed herein required to provide a clinically significant reduction in disease symptoms.Examples of therapeutically effective amounts include, but are not limited to, 1-1500 mg, 1-1000 mg, 1-800 mg, 1-600 mg, 2-600 mg, 3-600 mg, 4-600 mg, 5-600 mg, 6-600 mg, 10-600mg, 20-600mg, 25-600mg, 30-600mg, 40-600mg, 50-600mg, 60-600mg, 70-600mg, 75-600mg, 80-600mg, 90-600mg, 100- 600mg, 200-600mg, 1-500mg, 2-500mg, 3-500mg, 4-500mg, 5-500mg, 6-500mg, 10-500mg, 20-500mg, 25-500mg, 30-500mg, 40-5 00mg, 50-500mg, 60-500mg, 70-500mg, 75-500mg, 80-500mg, 90-500mg, 100-500mg, 125-500mg, 150-500mg, 200-500mg, 250- 500mg, 300-500mg, 400-500mg, 5-400mg, 10-400mg, 20-400mg, 25-400mg, 30-400mg, 40-400mg, 50-400mg, 60-400mg, 70-400m g, 75-400mg, 80-400mg, 90-400mg, 100-400mg, 125-400mg, 150-400mg, 200-400mg, 250-400mg, 300-400mg, 1-300mg, 2-300m g, 5-300mg, 10-300mg, 20-300mg, 25-300mg, 30-300mg, 40-300mg, 50-300mg, 60-300mg, 70-300mg, 75-300mg, 80-300mg, 90-3 00mg, 100-300mg, 125-300mg, 150-300mg, 200-300mg, 250-300mg, 1-200mg, 2-200mg, 5-200mg, 10-200mg, 20-200mg, 25-200m g, 30-200mg, 40-200mg, 50-200mg, 60-200mg, 70-200mg, 75-200mg, 80-200mg, 90-200mg, 100-200mg, 125-200mg, 150-200mg.
[0165] In some embodiments, the pharmaceutical composition includes but is not limited to 1-1500 mg, 1-1000 mg, 1-800 mg, 1-600 mg, 20-400 mg, 25-200 mg, 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg g, 95 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 300 mg of a compound of the present invention or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof.
[0166] A method for treating a disease in a mammal, comprising administering to a subject a therapeutically effective amount of a compound of the present invention or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, wherein the therapeutically effective amount is preferably 1-1500 mg, and the disease is preferably idiopathic pulmonary fibrosis.
[0167] A method for treating a disease in a mammal, comprising administering to a subject a compound of the present invention or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof at a daily dose of 1-1500 mg / day, wherein the daily dose may be a single dose or divided doses. In some embodiments, the daily dose includes but is not limited to 10-1500 mg / day, 10-1000 mg / day, 10-800 mg / day, 25-800 mg / day, 50-800 mg / day, In some embodiments, the daily dose includes but is not limited to 10 mg / day, 20 mg / day, 25 mg / day, 50 mg / day, 100-400 mg / day, 200-400 mg / day, and in some embodiments, the daily dose includes but is not limited to 10 mg / day, 20 mg / day, 25 mg / day, 50 mg / day, 100 mg / day, 125 mg / day, 150 mg / day, 200 mg / day, 400 mg / day, 600 mg / day, and 800 mg / day.
[0168] The present invention relates to a kit, which may include a composition in single-dose or multi-dose form, wherein the kit contains a compound of the present invention or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, and the amount of the compound of the present invention or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal is the same as the amount in the above-mentioned pharmaceutical composition.
[0169] The amount of the compound of the invention or its stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal in the present invention is in each case calculated as the free base.
[0170] "Preparation specifications" refers to the weight of the main drug contained in each vial, tablet or other unit preparation.
[0171] Unless otherwise stated, the terms used in the specification and claims have the following meanings.
[0172] The carbon, hydrogen, oxygen, sulfur, nitrogen or F, Cl, Br, I involved in the groups and compounds of the present invention include their isotopes, and the carbon, hydrogen, oxygen, sulfur or nitrogen involved in the groups and compounds of the present invention are optionally further replaced by one or more of their corresponding isotopes, wherein the isotopes of carbon include 12 C. 13 C and 14 C, hydrogen isotopes include protium (H), deuterium (D, also called heavy hydrogen), tritium (T, also called super tritium), oxygen isotopes include 16 O. 17 O and 18 O, sulfur isotopes include 32 S. 33 S. 34 S and 36 S, nitrogen isotopes include 14 N and 15 N, fluorine isotopes include 17 F and 19 F, chlorine isotopes include 35 Cl and 37 Isotopes of Cl, bromine include 79 Br and 81 Br.
[0173] "CN" refers to cyano.
[0174] "Halogen" refers to F, Cl, Br or I.
[0175] "Halogen-substituted" refers to substitution with F, Cl, Br or I, including but not limited to substitution with 1 to 10 substituents selected from F, Cl, Br or I, substitution with 1 to 6 substituents selected from F, Cl, Br or I, and substitution with 1 to 4 substituents selected from F, Cl, Br or I. "Halogen-substituted" is abbreviated as "halo".
[0176] "Alkyl" refers to a substituted or unsubstituted straight or branched chain saturated aliphatic hydrocarbon group, including but not limited to alkyl groups of 1 to 20 carbon atoms, alkyl groups of 1 to 8 carbon atoms, alkyl groups of 1 to 6 carbon atoms, and alkyl groups of 1 to 4 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, neobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, and various branched chain isomers thereof; alkyl groups can be monovalent, divalent, trivalent, or tetravalent.
[0177] "Heteroalkyl" refers to a substituted or unsubstituted alkyl group in which one or more (including but not limited to 2, 3, 4, 5 or 6) carbon atoms are replaced by heteroatoms (including but not limited to N, O or S). Non-limiting examples include -X-(CH2)vX-(CH2)vX-(CH2)vH (v is an integer from 1 to 5, each X is independently selected from a bond or a heteroatom, including but not limited to N, O or S, and at least one X is selected from a heteroatom, and the N or S in the heteroatom can be oxidized to various oxidation states). The heteroalkyl group can be monovalent, divalent, trivalent or tetravalent.
[0178] "Alkylene" refers to substituted or unsubstituted straight-chain and branched divalent saturated hydrocarbon groups, including -(CH2) v -(v is an integer from 1 to 10), examples of alkylene include but are not limited to methylene, ethylene, propylene and butylene.
[0179] "Heteroalkylene" refers to a substituted or unsubstituted alkylene group in which one or more (including but not limited to 2, 3, 4, 5 or 6) carbon atoms are replaced by heteroatoms (including but not limited to N, O or S). Non-limiting examples include -X-(CH2)vX-(CH2)vX-(CH2)v-, where v is an integer from 1 to 5, each X is independently selected from a bond, N, O or S, and at least one X is selected from N, O or S.
[0180] "Cycloalkyl" refers to a substituted or unsubstituted saturated carbocyclic hydrocarbon radical, typically having 3 to 12 carbon atoms. Cycloalkyl groups can be monocyclic, fused, bridged, or spirocyclic. Non-limiting examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutyl-cyclobutyl, cyclobutyl-spirocyclobutyl, and adamantane. Cycloalkyl groups can be monovalent, divalent, trivalent, or tetravalent.
[0181] "Heterocycloalkyl" refers to a substituted or unsubstituted saturated cyclic hydrocarbon radical containing heteroatoms, including but not limited to 3 to 12 atoms, 3 to 8 atoms, comprising 1 to 3 heteroatoms selected from N, O or S, and the C, N, S on the ring of the heterocycloalkyl can be oxidized to various oxidation states. Heterocycloalkyl can be a monocyclic, cyclic, bridged and spirocyclic ring. Heterocycloalkyl can be connected to a heteroatom or carbon atom, and non-limiting examples include oxirane, aziridine, oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, dioxolane, dioxane, pyrrolidinyl, piperidinyl, imidazolidinyl, oxazolidinyl, oxazinyl, morpholinyl, hexahydropyrimidinyl, piperazinyl, The heterocycloalkyl group can be monovalent, divalent, trivalent, or tetravalent.
[0182] "Alkenyl" refers to substituted or unsubstituted straight and branched unsaturated hydrocarbon groups having at least one, typically one, two or three carbon-carbon double bonds, with a backbone of 2 to 10, 2 to 6 or 2 to 4 carbon atoms. Examples of alkenyl groups include, but are not limited to, vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 2-methyl-3-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 1-octenyl, 3-octenyl, 1-nonenyl, 3-nonenyl, 1-decenyl, 4-decenyl, 1,3-butadiene, 1,3-pentadiene, 1,4-pentadiene and 1,4-hexadiene, etc.; the alkenyl group can be monovalent, divalent, trivalent or tetravalent.
[0183] "Alkynyl" refers to substituted or unsubstituted straight and branched unsaturated hydrocarbon groups having at least one, typically one, two or three carbon-carbon triple bonds, with a backbone comprising 2 to 10 carbon atoms, including but not limited to 2 to 6 carbon atoms in the backbone, and 2 to 4 carbon atoms in the backbone. Examples of alkynyl groups include but are not limited to ethynyl, propargyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 5-pentynyl, 6-pentynyl, 7-pentynyl, 8-pentynyl, 9-pentynyl, 10-pentynyl, 11-pentynyl, 12-pentynyl, 13-pentynyl, 14-pentynyl, 15-pentynyl, 16-pentynyl, 17-pentynyl, 18-pentynyl, 19-pentynyl, 20-pentynyl, 21-pentynyl, 22-pentynyl, 23-pentynyl, 24-pentynyl, 25-pentynyl, 26-pentynyl, 27-pentynyl, 28-pentynyl, 29-pentynyl, 30-pentynyl, 31-pentynyl, 32-pentynyl, 33-pentynyl, 34-pentynyl, 35-pentynyl, 36-pentynyl, 37-pentynyl, 38-pentynyl, 39-pentynyl, 40-pentynyl, 41-pentynyl, 42-pentynyl, 43-pentynyl, 44-pentynyl, 45-pentynyl, 46-pentynyl, 47-pentynyl, 48-pentyn Alkynyl, 1-methyl-1-butynyl, 2-methyl-1-butynyl, 2-methyl-3-butynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-1-pentynyl, 2-methyl-1-pentynyl, 1-heptynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 1-octynyl, 3-octynyl, 1-nonynyl, 3-nonynyl, 1-decynyl, 4-decynyl, and the like; an alkynyl group may be monovalent, divalent, trivalent, or tetravalent.
[0184] "Alkoxy" refers to a substituted or unsubstituted -O-alkyl group. Non-limiting examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexoxy, cyclopropyloxy, and cyclobutyloxy.
[0185] "Carbocyclyl" or "carbocycle" refers to a substituted or unsubstituted aromatic or non-aromatic ring, which can be a 3-8 membered monocycle, a 4-12 membered bicycle, a 10-15 membered tricycle, or a 12-18 membered quaternary system. The carbocyclyl can be attached to the aromatic or non-aromatic ring, and the ring can be optionally a monocycle, a cyclic ring, a bridged ring, or a spirocycle. Non-limiting examples include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, 1-cyclopentyl-1-alkenyl, 1-cyclopentyl-2-alkenyl, 1-cyclopentyl-3-alkenyl, cyclohexyl, 1-cyclohexyl-2-alkenyl, 1-cyclohexyl-3-alkenyl, cyclohexenyl, a benzene ring, a naphthalene ring, "Carbocyclyl" or "carbocycle" can be monovalent, divalent, trivalent, or tetravalent.
[0186] "Heterocyclyl" or "heterocycle" refers to a substituted or unsubstituted aromatic or non-aromatic ring, which may be a 3-8 membered monocyclic ring, a 4-12 membered bicyclic ring, a 10-15 membered tricyclic ring, or a 12-18 membered quaternary ring, and contains one or more (including but not limited to 2, 3, 4 or 5) heteroatoms selected from N, O or S. The C, N, S optionally substituted in the heterocyclyl ring may be oxidized to various oxidation states. The heterocyclic group can be attached to a heteroatom or a carbon atom, and can be attached to an aromatic ring or a non-aromatic ring. The heterocyclic group is optionally a monocyclic, bridged, fused or spirocyclic ring. Non-limiting examples include oxirane, aziridine, oxetanyl, azetidinyl, 1,3-dioxolane, 1,4-dioxolane, 1,3-dioxane, azepanyl, pyridyl, furyl, thienyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, piperidinyl, morpholinyl, thiomorpholinyl, 1,3-dithiazyl, dihydrofuranyl, dihydropyranyl, dithiolanyl, tetrahydrofuranyl, tetrahydropyrrolyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydropyranyl, benzimidazolyl, benzopyridinyl, pyrrolopyridinyl, benzodihydrofuranyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, pyrazinyl, indazolyl, benzothiophenyl, benzofuranyl, benzopyrrolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzopyridinyl, benzopyrimidinyl, benzopyrazinyl, piperazinyl, azabicyclo[3.2.1]octyl, azabicyclo[5.2.0]nonyl, oxatricyclo[5.3.1.1]dodecyl, azaadamantyl, oxaspiro[3.3]heptanyl, "Heterocyclyl" or "heterocycle" can be monovalent, divalent, trivalent or tetravalent.
[0187] "Spirocycle" or "spirocyclyl" refers to a polycyclic group in which substituted or unsubstituted monocyclic rings share one atom (called a spiro atom), and the number of ring atoms in the spirocycle system includes but is not limited to 5 to 20, 6 to 14, 6 to 12, 6 to 10, wherein one or more rings may contain 0 or more (including but not limited to 1, 2, 3 or 4) double bonds, and optionally may contain 0 to 5 atoms selected from N, O or S (=O) n (n is 0, 1 or 2).
[0188] "Spirocycle" or "spirocyclyl" can be monovalent, divalent, trivalent or tetravalent.
[0189] "Parallel ring" or "parallel ring group" refers to a polycyclic group in which each ring in the system shares a pair of adjacent atoms with other rings in the system, wherein one or more rings may contain 0 or more (including but not limited to 1, 2, 3 or 4) double bonds and may be substituted or unsubstituted, and each ring in the parallel ring system may contain 0 to 5 heteroatoms or groups containing heteroatoms (including but not limited to N, S(=O) n or O, n is 0, 1 or 2). The number of ring atoms in the cyclic system includes, but is not limited to, 5 to 20, 5 to 14, 5 to 12, and 5 to 10. Non-limiting examples include: "Bicyclic" or "bicyclic group" can be monovalent, divalent, trivalent or tetravalent.
[0190] "Bridged ring" or "bridged ring group" refers to a substituted or unsubstituted polycyclic group containing any two atoms that are not directly connected, and may contain zero or more double bonds. Any ring in the bridged ring system may contain zero to five atoms selected from heteroatoms or groups containing heteroatoms (including but not limited to N, S(=O)n or O, where n is 0, 1, or 2). The number of ring atoms includes but is not limited to 5 to 20, 5 to 14, 5 to 12, or 5 to 10. Non-limiting examples include "Bridged ring" or "bridged ring group" may be monovalent, divalent, trivalent or tetravalent.
[0191] "Carbospirocycle," "spirocarbocyclyl," "spirocarbocyclyl," or "carbospirocyclyl" refers to a "spirocycle" wherein the ring system consists of only carbon atoms.
[0192] "Carbocyclyl," "carbocyclyl," "carbocyclyl," or "carbocyclyl" refers to a "carbocyclyl" ring system consisting of only carbon atoms.
[0193] "Carbobridged ring," "bridged carbocyclic group," "bridged carbocyclic group," or "carbon-bridged cyclic group" refers to a "bridged ring" wherein the ring system consists of only carbon atoms.
[0194] "Heteromonocycle", "monocyclic heterocyclyl" or "heteromonocyclyl" refers to a monocyclic ring system of "heterocyclyl" or "heterocycle".
[0195] "Heterocyclo", "heterocycloalkyl", "cycloheterocyclyl" or "cycloheterocyclyl" refers to a "cyclo" containing a heteroatom.
[0196] "Heterospirocycle," "heterospirocyclyl," "spiroheterocyclyl," or "spiroheterocyclyl" refers to a "spirocycle" containing a heteroatom.
[0197] "Heterobridged ring", "heterobridged cyclic group", "bridged ring heterocyclic group" or "bridged heterocyclic group" refers to a "bridged ring" containing a heteroatom.
[0198] "Aryl" or "aromatic ring" refers to a substituted or unsubstituted aromatic hydrocarbon group having a single ring or a fused ring, wherein the number of ring atoms in the aromatic ring includes, but is not limited to, 6 to 18, 6 to 12, or 6 to 10 carbon atoms. The aryl ring may be fused to a saturated or unsaturated carbon ring, wherein the ring connected to the parent structure is the aryl ring, non-limiting examples of which include benzene ring, naphthalene ring, "Aryl" or "aromatic ring" can be monovalent, divalent, trivalent or tetravalent. When divalent, trivalent or tetravalent, the point of attachment is on the aryl ring.
[0199] "Heteroaryl" or "heteroaromatic ring" refers to a substituted or unsubstituted aromatic hydrocarbon group containing 1 to 5 heteroatoms or groups containing heteroatoms (including but not limited to N, O or S(=O)n, n is 0, 1, 2). The number of ring atoms in the heteroaromatic ring includes but is not limited to 5 to 15, 5 to 10 or 5 to 6. The atoms C, N, and S on the ring are optionally oxidized (i.e., C(=O), NO, S(=O)n, n is 1 or 2). Non-limiting examples of heteroaryl include but are not limited to pyridyl, furyl, thienyl, pyridyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, benzopyrazolyl, benzimidazolyl, benzopyridinyl, pyrrolopyridinyl, pyridonyl, etc. The heteroaryl ring can be fused to a saturated or unsaturated carbocyclic ring or heterocyclic ring, wherein the ring connected to the parent structure is an aryl ring. Non-limiting examples include When heteroaryl appears in this document, its definition is consistent with this definition. Heteroaryl can be monovalent, divalent, trivalent or tetravalent. When it is divalent, trivalent or tetravalent, the attachment point is located on the ring with aromaticity.
[0200] "Substituted" or "substituted" refers to substitution by one or more (including but not limited to 2, 3, 4 or 5) substituents, including but not limited to H, F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxyl, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclic, bridged, spiro, cycloalkyl, hydroxyalkyl, =O, carbonyl, aldehyde, carboxylic acid, formate, -(CH2), m -C(=O)-R a 、-O-(CH2) m -C(=O)-R a 、-(CH2) m -C(=O)-NR b R c 、-(CH2) m S(=O) n R a 、-(CH2) m -alkenyl-R a , OR d or -(CH2) m -alkynyl-R a (wherein m and n are 0, 1 or 2), arylthio, thiocarbonyl, silyl or -NR b R c etc., where R b With R c R is independently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, trifluoromethanesulfonyl, and optionally, b With R c Can form five or six-membered cycloalkyl or heterocyclic group, R a With R d Each is independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged ring, spiro ring or paracyclic group.
[0201] "1 to X substituents selected from..." means substituted by 1, 2, 3, ..., X substituents selected from ..., where X is any integer from 1 to 10. For example, "1 to 4 R k "Substituted" means replaced by 1, 2, 3 or 4 R k Substitution. For example, "substituted by 1 to 5 substituents selected from..." means substituted by 1, 2, 3, 4, or 5 substituents selected from..." For example, "a heterobridged ring is optionally substituted by 1 to 4 substituents selected from H or F" means that the heterobridged ring is optionally substituted by 1, 2, 3, or 4 substituents selected from H or F.
[0202] An XY-membered ring (X and Y are integers, and 3≤X<Y, X<Y≤20 is selected from any integer between 4 and 20) includes rings with X, X+1, X+2, X+3, X+4, ..., Y members. Rings include heterocyclic rings, carbocyclic rings, aromatic rings, aryl groups, heteroaryl groups, cycloalkyl groups, heteromonocyclic rings, heterocyclic rings, heterospirocyclic rings, or heterobridged rings. For example, "4-7 membered heteromonocyclic ring" refers to a 4-, 5-, 6-, or 7-membered heteromonocyclic ring, and "5-10 membered heterocyclic ring" refers to a 5-, 6-, 7-, 8-, 9-, or 10-membered heterocyclic ring.
[0203] C x-y Carbocycles (including aryl, cycloalkyl, monocyclic carbocycle, spirocyclic carbocycle, fused carbocycle or bridged carbocycle) include C x 、C x+1 、C x+2 、C x+3 、C x+4 ….C y A ring of 1-membered ring (x is an integer, and 3≤x<y, y is selected from any integer between 4 and 20), for example. 3-6 "Cycloalkyl" refers to C3, C4, C5 or C6 cycloalkyl;
[0204] When a group has one or more bondable sites, any one or more sites of the group can be connected to other groups through chemical bonds. When the chemical bond connection mode is non-positional and there are hydrogen atoms at the bondable sites, when the chemical bond is connected, the number of H atoms at the site will decrease accordingly with the number of chemical bonds connected, and the group will become a group with the corresponding valence. For example Indicates that any linkable site on the piperidinyl group can be connected to other groups through a chemical bond, including at least These four connection methods, even if the H atom is drawn on -N-, Also included For example Indicates that the R group on the piperidinyl group can be located on C, can be located on N, and at least includes
[0205] When the listed linking groups do not specify their connection direction, their connection directions include connection from left to right and from right to left in the reading order, for example, when ALB, L is selected from -MW-, it includes AMWB and AWMB.
[0206] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs and instances where it does not. For example, "alkyl optionally substituted with F" means that the alkyl group may but need not be substituted with F, and the description includes instances where the alkyl group is substituted with F and instances where the alkyl group is not substituted with F.
[0207] "Pharmaceutically acceptable salt" or "pharmaceutically acceptable salt thereof" refers to a salt of the compound of the present invention that retains the biological effectiveness and properties of the free acid or free base, and the free acid is obtained by reacting with a non-toxic inorganic base or organic base, or the free base is obtained by reacting with a non-toxic inorganic acid or organic acid.
[0208] "Pharmaceutical composition" refers to a mixture of one or more compounds of the present invention, or stereoisomers, tautomers, deuterated forms, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals thereof, and other chemical components, wherein "other chemical components" refers to pharmaceutically acceptable carriers, excipients and / or one or more other therapeutic agents.
[0209] "Preparation specifications" refers to the weight of the main drug contained in each vial, tablet or other unit preparation.
[0210] "Carrier" refers to a material that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
[0211] "Prodrugs" refer to compounds of the present invention that can be converted into biologically active compounds through in vivo metabolism. Prodrugs of the present invention are prepared by modifying amino or carboxyl groups in compounds of the present invention. These modifications can be removed by conventional manipulation or in vivo to yield the parent compound. When the prodrugs of the present invention are administered to a mammalian subject, the prodrugs are cleaved to form free amino or carboxyl groups.
[0212] A "cocrystal" is a crystal formed by the active pharmaceutical ingredient (API) and cocrystal former (CCF) bound together by hydrogen bonds or other non-covalent bonds. Both the API and CCF are solid in their pure form at room temperature, and the components exist in a fixed stoichiometric ratio. A cocrystal is a multi-component crystal, encompassing both binary cocrystals formed between two neutral solids and multi-component cocrystals formed between a neutral solid and a salt or solvate.
[0213] "Animal" is meant to include mammals, such as humans, companion animals, zoo animals, and livestock, preferably humans, horses, or dogs.
[0214] "Stereoisomers" refer to isomers resulting from different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers, diastereomers, and conformational isomers.
[0215] "Tautomers" refer to functional group isomers produced by the rapid movement of an atom in a molecule between two positions, such as keto-enol isomers and amide-imino alcohol isomers.
[0216] “IC 50"It is the concentration of a drug or inhibitor required to inhibit a specified biological process (or a component of the process such as an enzyme, receptor, cell, etc.) by half. DETAILED DESCRIPTION
[0217] The following examples illustrate the technical solutions of the present invention in detail, but the protection scope of the present invention includes but is not limited to them.
[0218] The structures of the compounds were determined by nuclear magnetic resonance (NMR) or / and mass spectrometry (MS). NMR shifts (δ) were expressed in 10 -6 The unit of (ppm) is given. NMR measurements were performed using a Bruker Avance III 400 and Bruker Avance 300 NMR spectrometer. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD). The internal standard was tetramethylsilane (TMS).
[0219] MS was determined using (Agilent 6120B (ESI) and Agilent 6120B (APCI));
[0220] HPLC determination was performed using an Agilent 1260DAD high-pressure liquid chromatograph (Zorbax SB-C18 100 × 4.6 mm, 3.5 μM);
[0221] Thin layer chromatography silica gel plate using Yantai Huanghai HSGF 254 or Qingdao GF 254 Silica gel plates, the specifications of silica gel plates used in thin layer chromatography (TLC) are 0.15mm-0.20mm, and the specifications used for thin layer chromatography separation and purification products are 0.4mm-0.5mm;
[0222] Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier;
[0223] Boc: tert-butoxycarbonyl;
[0224] Ts: p-toluenesulfonyl;
[0225] Cbz: benzyloxycarbonyl;
[0226] TMS: trimethylsilyl.
[0227] Example 1: Preparation of Compound 1
[0228] Step 1: Preparation of 1C
[0229] 1A (1.86 g, 14.98 mmol), 1B (2.25 g, 14.94 mmol), potassium carbonate (4.14 g, 29.95 mmol), and potassium iodide (1.24 g, 7.47 mmol) were added to DMF (30 mL) and heated to 110°C for overnight reaction. After cooling to room temperature, the reaction solution was added with water (200 mL) and extracted with ethyl acetate (100 mL x 2). The organic phase was concentrated under reduced pressure and then purified by column chromatography (mobile phase: methanol / dichloromethane (v / v) = 0-12%) to afford 1C (0.80 g, yield: 22%).
[0230] LCMS m / z=239.3[M+H] +
[0231] Step 2: Preparation of 1E
[0232] 1C (0.80 g, 3.36 mmol) and lithium hydroxide monohydrate (0.41 g, 10.01 mmol) were added to a mixture of tetrahydrofuran / methanol / water (14 mL, V / V / V = 4 / 1 / 1) and allowed to react at room temperature for 3 h. The mixture was concentrated under reduced pressure, and dichloromethane (20 mL) was added to the concentrate for redissolution. The mixture was filtered and the filtrate was concentrated again under reduced pressure. DMF (20 mL), 1D (380 mg, 5.06 mmol), DIPEA (2.61 g, 20.19 mmol), and HATU (1.92 g, 5.05 mmol) were added to the concentrate in sequence. The mixture was stirred at room temperature for 4 h. The reaction mixture was concentrated under reduced pressure and purified by column chromatography (mobile phase: methanol / dichloromethane (V / V) = 0-7%) to afford 1E (0.40 g, yield: 42%).
[0233] LCMS m / z=282.3[M+H] +
[0234] Step 3: Preparation of 1F
[0235] 1E (0.40 g, 3.11 mmol) was added to dioxane (30 mL), followed by a solution of lithium aluminum hydride in tetrahydrofuran (1.25 mL, 2.5 mol / L). The mixture was refluxed under nitrogen for 5 hours. The mixture was cooled to 0°C, 5 mL of water was added, and the mixture was stirred for 5 minutes. The mixture was extracted with ethyl acetate (40 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (mobile phase: methanol / dichloromethane (v / v) = 0-12%) to afford 1F (0.25 g, 66% yield).
[0236] LCMS m / z=268.4[M+H]
[0237] Step 4: Preparation of 1H
[0238] 1F (300 mg, 1.12 mmol), 1G (259 mg, 1.12 mmol), acetic acid (0.16 mL), and sodium cyanoborohydride (106 mg, 1.69 mmol) were added sequentially to methanol (20 mL). The mixture was reacted at room temperature overnight. The reaction solution was concentrated under reduced pressure, and the residue was separated and purified by column chromatography (mobile phase: methanol / dichloromethane (V / V) = 0-10%) to give 1H (250 mg, yield: 46%).
[0239] LCMS m / z=483.4[M+H]
[0240] Step 5: Preparation of 1J
[0241] 1H (250 mg, 0.52 mmol) was added to a solution of hydrogen chloride in 1,4-dioxane (10 mL, 4 mol / L). The reaction was allowed to proceed at room temperature for 2 hours, followed by concentration under reduced pressure. To the concentrate were added isopropanol (4 mL), DIPEA (570 mg, 4.18 mmol), and 1I (130 mg, 0.79 mmol), and the mixture was allowed to react at 60°C overnight. The reaction solution was concentrated under reduced pressure, and the residue was purified by column chromatography (mobile phase: methanol / dichloromethane (v / v) = 0-10%) to afford 1J (200 mg, 76% yield).
[0242] LCMS m / z=511.3[M+H] +
[0243] Step 6: Preparation of compound 1
[0244] 1J (200 mg, 0.39 mmol) was added to a mixed solvent of tetrahydrofuran / methanol / water (7 mL, V / V / V=5 / 1 / 1), and lithium hydroxide monohydrate (65 mg, 1.56 mmol) was added. The mixture was reacted at room temperature for 2 hours, concentrated under reduced pressure, and further purified by preparative HPLC (instrument: Waters 2767, preparative column: SunFire@Prep C18 (19 mm×150 mm); mobile phase composition: acetonitrile, water (containing 5 mmol / L ammonium acetate)) to give compound 1 (25 mg, yield: 13%).
[0245] LCMS m / z=497.3[M+H] +
[0246] 1H NMR(400MHz,TFA-d)δ8.84(s,1H),8.36(d,1H),8.22–8.14(m,1H),8.02–7.90(m,3H),7.81(d,1H),7.06(d,1H),7.00–6.92(m,1H),5 .58–5.49(m,1H),3.98–3.61(m,6H),3.57–3.38(m,7H),3.01–2.87(m,1H),2.78–2.63(m,1H),2.02–1.80(m,4H),1.66–1.54(m,2H).
[0247] Example 2: Preparation of Compound 2
[0248] Referring to the synthetic method of Example 1, compound 2 (25 mg) was obtained.
[0249] LCMS m / z=467.5[M+H] +
[0250] 1 H NMR(400MHz,CF3COOD)δ8.93(s,1H),8.45(d,1H),8.28(t,1H),8.08–7.99(m,2H),7 .72(d,1H),6.69–6.63(m,1H),6.40–6.33(m,1H),5.66–5.57(m,1H),4.10(s,3H),4. 05–3.96(m,2H),3.95–3.76(m,2H),3.74–3.67(m,2H),3.65–3.60(m,3H),3.58–3.46 (m,4H),3.10–2.95(m,1H),2.87–2.71(m,1H),2.10–1.86(m,4H),1.73–1.61(m,2H).
[0251] Example 3: Preparation of trifluoroacetate salt of compound 3
[0252] Step 1: Preparation of 3C
[0253] 3B (1.50 g, 10.26 mmol) was added to dichloromethane (30 mL), followed by oxalyl chloride (2.60 g, 20.48 mmol) and DMF (0.05 mL). The mixture was allowed to react at room temperature for 1 hour. The mixture was concentrated under reduced pressure, and the concentrate was added to 3A (1.03 g, 10.05 mmol) and pyridine (1.50 g, 10.26 mmol) in dichloromethane (30 mL). The reaction was allowed to react at room temperature for 1 hour. Silica gel was added, the mixture was concentrated under reduced pressure, and the mixture was purified by column chromatography (mobile phase: methanol / dichloromethane (v / v) = 0-10%) to afford 3C (1.10 g, yield: 47%).
[0254] LCMS m / z=229.2[M+H] +
[0255] Step 2: 3D preparation
[0256] Referring to the synthesis method of step 2 in Example 1, 3D (1.40 g) was obtained.
[0257] LCMS m / z=272.4[M+H] +
[0258] Step 3: Preparation of 3E
[0259] 3D (1.40 g, 5.16 mmol) was added to tetrahydrofuran (30 mL), followed by a solution of lithium aluminum hydride in tetrahydrofuran (9.08 mL, 2.5 mol / L). The mixture was refluxed under nitrogen for 4 hours. The mixture was cooled to 0°C, 5 mL of water was added, and the mixture was stirred for 5 minutes. The mixture was extracted with dichloromethane (40 mL x 2). The organic phases were combined and concentrated under reduced pressure. The residue was purified by column chromatography (mobile phase: methanol / dichloromethane (v / v) = 0-12%) to afford 3E (0.26 g, 21% yield).
[0260] LCMS m / z=244.2[M+H]
[0261] Step 4: Preparation of 3F
[0262] Referring to the synthesis method of step 4 in Example 1, 3F (370 mg) was obtained.
[0263] LCMS m / z=459.2[M+H]
[0264] Step 5: Preparation of 3G
[0265] Referring to the synthesis method of step 5 of Example 1, 3G (250 mg) was obtained.
[0266] LCMS m / z=487.3[M+H]
[0267] Step 6: Preparation of trifluoroacetate salt of compound 3
[0268] 3G (200 mg, 0.41 mmol) was added to a mixed solvent of tetrahydrofuran / methanol / water (7 mL, V / V / V = 5 / 1 / 1), and lithium hydroxide monohydrate (69 mg, 1.64 mmol) was added. The mixture was reacted at room temperature for 2 hours, concentrated under reduced pressure, and further purified by preparative HPLC (instrument: Waters 2767 preparative liquid phase; chromatographic column: XBridge@Prep C18 (30 mm × 150 mm); mobile phase composition: acetonitrile / water (containing 0.1% trifluoroacetic acid)) to give the trifluoroacetate salt of compound 3 (30 mg).
[0269] LCMS m / z=473.6[M+H] +
[0270] 1 H NMR(400MHz,DMSO-d6)δ9.77–9.54(m,1H),8.82(s,1H),8.53(d,1H),8.43–8.28( m,1H),8.04–7.98(m,1H),7.87–7.82(m,1H),7.79–7.73(m,1H),7.12(d,1H),6.7 1(d,1H),5.09–4.99(m,1H),3.66–3.63(m,2H),3.37–3.33(m,2H),3.27–3.21(m, 6H),3.15–3.09(m,2H),2.47–2.31(m,3H),1.70–1.52(m,4H),1.38–1.29(m,2H).
[0271] Example 4: Preparation of trifluoroacetate salt of compound 4
[0272] Step 1: Preparation of 4B
[0273] Compound 4A (3000 mg, 14.08 mmol) was added to tetrahydrofuran (100 mL), followed by 4-dimethylaminopyridine (172 mg, 1.41 mmol) and di-tert-butyl dicarbonate (4003 mg, 18.34 mmol). The mixture was allowed to react overnight at 50°C. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 0-17%) to afford compound 4B (4 g, 91% yield).
[0274] LCMS m / z=257.10 and 259.10 [M-55] +
[0275] Step 2: 4D preparation
[0276] Zinc powder (6266 mg, 95.8 mmol) was added to DMA (50 mL). 1.2-Dibromoethane (540 mg, 2.87 mmol) and trimethylsilyl chloride (312 mg, 2.87 mmol) were slowly added under a nitrogen atmosphere. The mixture was stirred at room temperature for 0.5 h, followed by the addition of 4C (5203 mg, 28.74 mmol). Stirring was continued at 30°C for 2 h. 4B (3000 mg, 9.58 mmol), cuprous iodide (365 mg, 1.92 mmol), and 1,1-bis(diphenylphosphino)ferrocenepalladium dichloride (701 mg, 0.86 mmol) were added to the reaction mixture under a nitrogen atmosphere. The temperature was raised to 90°C and the reaction was allowed to react overnight. The mixture was cooled to room temperature, and water (100 mL) was added. The mixture was extracted with ethyl acetate (30 mL × 3). The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (mobile phase: ethyl acetate / petroleum ether (V / V) = 0-33%) to give 4D (2.2 g, yield: 69%).
[0277] LCMS m / z=335.2[M+1] +
[0278] Step 3: Preparation of 4E
[0279] 4D (2.2 g, 6.58 mmol) and lithium hydroxide monohydrate (0.83 g, 19.78 mmol) were added to a mixture of tetrahydrofuran / methanol / water (30 mL, V / V / V = 4 / 1 / 1) and stirred at room temperature for 2 hours. The mixture was concentrated under reduced pressure to approximately 5 mL. Dilute hydrochloric acid solution (1 M) was added dropwise to the concentrate to adjust the pH to 5-6. The mixture was extracted with dichloromethane (20 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain crude product 4E (2.2 g).
[0280] LCMS m / z=321.60[M+1] +
[0281] Step 4: Preparation of 4F
[0282] The crude product 4E (2.1 g) was added to dichloromethane (30 mL), followed by 1D (494 mg, 6.58 mmol), DIPEA (2551 mg, 19.74 mmol), and HATU (3753 mg, 9.87 mmol). The mixture was stirred at room temperature for 2 hours. Water (50 mL) was added, and the mixture was extracted with dichloromethane (50 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to afford the crude product 4F (3 g).
[0283] LCMS m / z=378.80[M+1]+
[0284] Step 5: Preparation of 4G
[0285] The crude product of 4F (3 g) was added to 1,4-dioxane (50 mL). Under a nitrogen atmosphere, a solution of lithium aluminum hydride in tetrahydrofuran (7 mL, 2.5 M) was slowly added, and the mixture was stirred at 100°C for 4 hours. After cooling to room temperature, water (30 mL) was added, and the mixture was extracted with dichloromethane (50 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (mobile phase: dichloromethane / methanol (v / v) = 0-17%) to obtain 4G (1.3 g).
[0286] LCMS m / z=264.40[M-99] +
[0287] Step 6: Preparation of 4H
[0288] Refer to the fourth step synthesis method of Example 1 to obtain 4H (0.5 g).
[0289] LCMS m / z=479.4[M-99] +
[0290] Step 7: Preparation of 4I
[0291] The fifth step of the synthesis method of Reference Example 1 was used to obtain crude product 4I (650 mg).
[0292] LCMS m / z=508.10[M+1] +
[0293] Step 8: Preparation of compound 4
[0294] Crude product 4I (500 mg) and lithium hydroxide monohydrate (208 mg, 4.96 mmol) were added to a mixture of tetrahydrofuran / methanol / water (30 mL, V / V / V = 4 / 1 / 1) and stirred at room temperature for 2 hours. The mixture was concentrated under reduced pressure and the concentrate was purified by preparative liquid chromatography (instrument: Waters 2767 preparative liquid chromatography; column: XBridge@Prep C18 (30 mm × 150 mm); mobile phase composition: acetonitrile / (containing 0.1% trifluoroacetic acid)) to obtain the trifluoroacetate salt of compound 4 (15 mg).
[0295] LCMS m / z=493.3[M+1] +
[0296] 1H NMR(400MHz,DMSO-d6)δ9.95–9.53(m,1H),8.88(s,1H),8.84(s,1H),8.53(d,1H ),8.06–7.98(m,1H),7.90–7.81(m,2H),7.81–7.74(m,1H),6.95(d,1H),6.74(d, 1H),5.10–4.99(m,1H),3.67–3.59(m,2H),3.39–3.29(m,3H),3.25(s,3H),3.24– 3.08(m,3H),2.78–2.70(m,2H),2.69–2.64(m,1H),2.46–2.31(m,2H),1.74–1.53
[0297] Example 5: Preparation of Compound 5
[0298] Step 1: Preparation of 5B
[0299] 5A (1.2 g, 5.10 mmol) (synthesis method reference patent CN113999164), 1D (0.57 g, 7.59 mmol), acetic acid (0.20 mL), and sodium cyanoborohydride (0.43 g, 6.68 mmol) were added sequentially to methanol (20 mL), and the reaction was allowed to react at room temperature overnight. The reaction solution was concentrated under reduced pressure, and the residue was separated and purified by column chromatography (mobile phase: methanol / dichloromethane (V / V) = 0-6%) to give 5B (1.00 g, yield: 67%).
[0300] LCMS m / z=295.3[M+H]
[0301] Step 2: Preparation of 5C
[0302] Referring to the synthesis method of step 4 in Example 1, 5C (1.30 g) was obtained.
[0303] LCMS m / z=510.2[M+H]
[0304] Step 3: 5D preparation
[0305] Referring to the synthesis method of step 5 in Example 1, 5D (0.1 g) was obtained.
[0306] LCMS m / z=538.2[M+H]
[0307] Step 4: Preparation of 5E
[0308] 5D (100 mg, 0.39 mmol) was added to methanol (15 mL), followed by palladium on carbon (100 mg, wt% = 10%). The mixture was reacted at room temperature under a hydrogen atmosphere for 12 hours. The mixture was filtered and the filtrate was concentrated under reduced pressure to give 5E (75 mg, yield: 98%).
[0309] LCMS m / z=404.2[M+H]
[0310] Step 5: 5G preparation
[0311] 5E (200 mg, 0.50 mmol) was added to dichloromethane (15 mL), followed by 5F (50 mg, 0.50 mmol). The mixture was reacted at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by column chromatography (mobile phase: methanol / dichloromethane (v / v) = 0-12%) to give 5G (160 mg, yield: 64%).
[0312] LCMS m / z=503.7[M+H]
[0313] Step 6: Preparation of trifluoroacetate salt of compound 5
[0314] 5G (160 mg, 0.32 mmol) was added to a mixed solvent of tetrahydrofuran / water (6 mL, V / V = 5 / 1), and lithium hydroxide monohydrate (54 mg, 1.29 mmol) was added, and the mixture was reacted at room temperature for 2 hours. The mixture was concentrated under reduced pressure and further purified by preparative HPLC (instrument: Waters 2767 preparative liquid phase; chromatographic column: XBridge@Prep C18 (30 mm × 150 mm); mobile phase composition: acetonitrile / water (containing 0.1% trifluoroacetic acid)) to give the trifluoroacetate salt of compound 5 (12 mg).
[0315] LCMS m / z=489.3[M+H] +
[0316] 1H NMR(400MHz,DMSO-d6)δ9.83–9.48(m,2H),8.83(s,1H),8.53(d,1H),8.06–7.98(m,1H),7.8 8–7.74(m,3H),7.56–7.49(m,1H),5.08–5.00(m,1H),3.67–3.63(m,2H),3.49–3.42(m,2H), 3.37–3.30(m,3H),3.26(s,3H),3.24–3.07(m,3H),2.59–2.51(m,1H),2.46–2.32(m,2H),1. 72–1.61(m,2H),1.58–1.48(m,2H),1.33–1.22(m,2H),0.70–0.64(m,2H),0.49–0.43(m,2H).
[0317] Example 6: Preparation of Compound 6
[0318] Step 1: Preparation of 6B
[0319] Referring to the first step of the synthesis method of Example 4, 6B (4.5 g) was obtained.
[0320] LCMS m / z = 231.0 and 233.0 [M-55] +
[0321] Step 2: Preparation of 6C
[0322] Referring to the second step synthesis method of Example 4, 6C (3.8 g) was obtained.
[0323] LCMS m / z=309.20[M+1] +
[0324] Step 3: Preparation of 6D
[0325] Referring to the third step of the synthesis method of Example 4, 6D (3.2 g) was obtained.
[0326] LCMS m / z=295.2[M+1] +
[0327] Step 4: Preparation of 6E
[0328] Refer to the fourth step of the synthesis method of Example 4 to obtain 6E (2.3 g).
[0329] LCMS m / z=352.2[M+1] +
[0330] Step 5: Preparation of 6F
[0331] 6E (2.3 g, 6.54 mmol) was added to a solution of hydrogen chloride in dioxane (4 mol / L, 30 mL) and 1,4-dioxane (10 mL), stirred at room temperature for 3 h, and concentrated under reduced pressure. Dichloromethane (10 mL) and triethylamine (1 mL) were added to the concentrate, and the mixture was concentrated under reduced pressure. The concentrate was dissolved in dichloromethane (100 mL), washed with saturated sodium bicarbonate solution (50 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was added to 1,4-dioxane (40 mL), and a solution of lithium aluminum hydride in tetrahydrofuran (6 mL, 2.5 M) was slowly added under a nitrogen atmosphere. The mixture was stirred at 100°C for 12 h. The mixture was cooled to room temperature, and water (30 mL) was added, followed by extraction with dichloromethane (50 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (mobile phase: methanol / dichloromethane (V / V) = 0-20%) to give a crude product of 6F (1.86 g).
[0332] LCMS m / z=238.30[M+1] +
[0333] Step 6: Preparation of 6G
[0334] Refer to the fourth step of the synthesis method in Example 1 to obtain 6G (610 mg).
[0335] LCMS m / z=453.40[M+1] +
[0336] Step 7: Preparation of 6H
[0337] Refer to the fifth step of the synthesis method in Example 1 to obtain 6H (320 mg).
[0338] LCMS m / z=481.30[M+1] +
[0339] Step 8: Preparation of trifluoroacetate salt of compound 6
[0340] Referring to the eighth step of the synthesis method of Example 4, trifluoroacetic acid salt of compound 6 (55 mg) was obtained.
[0341] LCMS m / z=467.2[M+1] +
[0342] Preparation of compound 6 free base
[0343] The crude product of 6H (16.7 g) and lithium hydroxide monohydrate (4.37 g, 104.15 mmol) were added to a mixture of tetrahydrofuran / methanol / water (120 mL, V / V / V = 4 / 1 / 1) and stirred at room temperature for 2 hours. The mixture was concentrated under reduced pressure and the concentrate was purified by preparative liquid chromatography (instrument: SHIMADZU LC-20AP preparative liquid chromatography; chromatographic column: C18; mobile phase composition: water (10 mmol NH4HCO3 in H2O) / acetonitrile) to obtain compound 6 (1.3 g).
[0344] LCMS m / z=467.3[M+1] +
[0345] 1 H NMR(400MHz,TFA-d)δ8.79(s,1H),8.31(d,1H),8.17–8.09(m,1H),7.92–7.84( m,3H),6.83(d,1H),6.72(d,1H),5.51–5.44(m,1H),3.91–3.83(m,2H),3.79–3 .63(m,2H),3.61–3.55(m,2H),3.50–3.47(m,3H),3.47–3.39(m,2H),3.06(s,3 H),2.94–2.83(m,3H),2.71–2.58(m,1H),2.03–1.91(m,2H),1.89–1.76(m,2H).
[0346] Example 7: Preparation of trifluoroacetate salt of compound 7
[0347] Step 1: Preparation of 7C
[0348] 7A (8.20 g, 30.72 mmol), 7B (5.26 g, 92.12 mmol), cesium carbonate (10.01 g, 30.72 mmol), and potassium iodide (0.51 g, 3.07 mmol) were added to DMSO (50 mL) and reacted at 90°C overnight. After cooling to room temperature, water (100 mL) was added and the mixture was extracted with ethyl acetate (100 mL). The organic phase was concentrated under reduced pressure, and the residue was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 0-40%) to afford 7C (4.0 g, 54% yield).
[0349] LCMS m / z=243.0[M+H] +
[0350] Step 2: Preparation of 7D
[0351] Referring to the first step of the synthesis method of Example 4, 7D (4.0 g) was obtained.
[0352] LCMS m / z=345.3[M+H] +
[0353] Step 3: Preparation of 7F
[0354] Referring to the second step synthesis method of Example 4, 7F (2.0 g) was obtained.
[0355] LCMS m / z=379.2[M+H] +
[0356] Step 4: Preparation of 7G
[0357] 7F (2.0 g, 5.28 mmol) was added to hydrochloric acid (30 mL, 6 mol / L) and stirred at 60°C for 4 hours. The mixture was concentrated under reduced pressure, and the concentrate was added to dichloromethane (30 mL). 1D (0.59 g, 7.86 mmol), DIPEA (4.09 g, 31.64 mmol), and HATU (3.01 g, 7.92 mmol) were then added and stirred at room temperature for 2 hours. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (mobile phase: methanol / dichloromethane (v / v) = 0-7%) to obtain 7G (1.20 g, 74% yield).
[0358] LCMS m / z=308.2[M+H] +
[0359] Step 5: Preparation of 7H
[0360] Referring to the fifth step of the synthesis method of Example 4, 7G was reduced with a tetrahydrofuran solution of lithium aluminum hydride (2.2 equivalents) to obtain 7H (0.66 g).
[0361] LCMS m / z=294.4[M+H] +
[0362] Step 6: Preparation of 7I
[0363] Referring to the fourth step of the synthesis method of Example 1, 7I (0.80 g) was obtained.
[0364] LCMS m / z=509.4[M+H] +
[0365] Step 7: Preparation of 7J
[0366] Refer to the fifth step of the synthesis method in Example 1 to obtain 7J (0.50 g).
[0367] LCMS m / z=537.3[M+H] +
[0368] Step 8: Preparation of trifluoroacetate salt of compound 7
[0369] Referring to the sixth step of the synthesis method of Example 5, trifluoroacetic acid salt of compound 7 (100 mg) was obtained.
[0370] LCMS m / z=523.3[M+H] +
[0371] 1 H NMR(400MHz,TFA-d)δ8.82(s,1H),8.34(d,1H),8.20–8.13(m,1H),7.96–7.88(m,2H),6. 46–6.36(m,2H),5.55–5.47(m,1H),4.04–3.98(m,3H),3.95–3.87(m,2H),3.85–3.66(m, 2H),3.66–3.58(m,2H),3.53–3.41(m,5H),2.98–2.85(m,1H),2.84–2.75(m,2H),2.74–2 .59(m,2H),2.05–1.91(m,2H),1.89–1.73(m,2H),1.08–0.97(m,2H),0.79–0.70(m,2H).
[0372] Example 8: Preparation of trifluoroacetate salt of compound 8
[0373] Step 1: Preparation of 8B
[0374] Referring to the second step synthesis method of Example 4, 8B (1.36 g) was obtained.
[0375] LCMS m / z=291.2
[0376] Step 2: Preparation of 8C
[0377] 8B (1.36 g, 4.68 mmol) was added to hydrochloric acid (20 mL, 6 mol / L) and refluxed overnight. The mixture was cooled to room temperature and concentrated under reduced pressure. The concentrate was added to dichloromethane (50 mL), followed by 1D (352 mg, 4.68 mmol), DIPEA (1.81 g, 14.0 mmol), and HATU (3.56 g, 9.36 mmol). The mixture was stirred at room temperature overnight. Water (50 mL) was added and the mixture was extracted with dichloromethane (50 mL x 3). The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (mobile phase: dichloromethane / methanol (v / v) = 10 / 1) to afford 8C (1 g, 67% yield).
[0378] LCMS m / z=320.3[M+H] +
[0379] Step 3: Preparation of 8D
[0380] Refer to the fifth step of the synthesis method of Example 4 to obtain 8D (0.6 g).
[0381] LCMS m / z=306.5[M+H] +
[0382] Step 4: Preparation of 8E
[0383] Refer to the fourth step of the synthesis method in Example 1 to obtain 8E (300 mg).
[0384] LCMS m / z=521.4[M+H] +
[0385] Step 5: Preparation of 8F
[0386] Referring to the fifth step of the synthesis method of Example 1, 8F (240 mg) was obtained.
[0387] LCMS m / z=549.4[M+H] +
[0388] Step 6: Preparation of compound 8
[0389] Referring to the sixth step of the synthesis method in Example 5, trifluoroacetic acid salt of compound 8 (20 mg) was obtained.
[0390] LCMS m / z=535.4[M+H] +
[0391] 1H NMR(400MHz,DMSO-d6)δ9.93(s,1H),8.90(s,1H),8.68(s,1H),8.57(d,1H),8.15– 7.98(m,1H),7.95–7.72(m,3H),6.93(d,1H),6.70–6.56(m,1H),5.14–5.01(m,1H), 3.82–3.55(m,3H),3.44–3.27(m,4H),3.25(s,3H),3.23–3.09(m,2H),2.83–2.67( m,2H),2.48–2.27(m,2H),1.99–1.83(m,2H),1.83–1.53(m,7H),1.47–1.04(m,5H).
[0392] Example 9: Preparation of trifluoroacetate salt of compound 9
[0393] Step 1: Preparation of 9C
[0394] 9A (5.00 g, 28.41 mmol), 9B (2.22 g, 31.21 mmol), and potassium carbonate (11.76 g, 85.09 mmol) were added to DMSO (23 mL) and the temperature was raised to 90°C for 5 h. After the reaction was complete, the mixture was cooled to room temperature and diluted with water. The mixture was extracted with ethyl acetate (100 mL x 2). The organic phase was concentrated under reduced pressure and purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 0-5%) to afford 9C (5.49 g, yield: 85%).
[0395] LCMS m / z=227.1[M+H] +
[0396] Step 2: Preparation of 9D
[0397] Referring to the first step of the synthesis method of Example 4, 9D (5.06 g) was obtained.
[0398] LCMS m / z=271.0[M-55] +
[0399] Step 3: Preparation of 9E
[0400] Referring to the second step synthesis method of Example 4, 9E (3.32 g) was obtained.
[0401] LCMS m / z=349.2[M+H] +
[0402] Step 4: Preparation of 9F
[0403] The third step of the synthesis method of Reference Example 4 was used to obtain crude 9F (3.05 g).
[0404] LCMS m / z=335.3[M+H] +
[0405] Step 5: Preparation of 9G
[0406] Refer to the fourth step of the synthesis method of Example 4 to obtain 9G (2.55 g).
[0407] LCMS m / z=392.3[M+H] +
[0408] Step 6: Preparation of 9H
[0409] Refer to the fifth step synthesis method of Example 4 to obtain 9H (1.26 g).
[0410] LCMS m / z=278.3[M+H] +
[0411] Step 7: Preparation of 9I
[0412] The fourth step of the synthesis method of Reference Example 1 was used to obtain 9I (1.09 g).
[0413] LCMS m / z=493.3[M+H] +
[0414] Step 8: Preparation of 9J
[0415] Refer to the fifth step of the synthesis method in Example 1 to obtain 9J (0.73 g).
[0416] LCMS m / z=521.4[M+H] +
[0417] Step 9: Preparation of trifluoroacetate salt of compound 9
[0418] Referring to the eighth step of the synthesis method of Example 4, the trifluoroacetic acid salt of the target compound 9 (35 mg) was obtained.
[0419] LCMS m / z=507.2[M+H] +
[0420] 1H NMR(400MHz, Methanol-d4)δ8.84(s,1H),8.56–8.47(m,1H),8.15–8.06(m,1H),7. 90–7.79(m,3H),6.81(d,1H),6.73(d,1H),5.32(t,1H),4.29–4.15(m,1H),3.74(t ,2H),3.56(d,1H),3.52–3.40(m,3H),3.37(m,4H),2.89–2.79(m,2H),2.74–2.61( m,1H),2.53–2.39(m,3H),2.15–2.01(m,2H),1.94–1.84(m,3H),1.84–1.74(m,3H).
[0421] Example 10: Preparation of trifluoroacetate salt of compound 10
[0422] Referring to the synthesis method of Example 9, the trifluoroacetic acid salt of the target compound 10 (42 mg) was obtained.
[0423] LCMS m / z=507.3[M+H] +
[0424] 1 H NMR(400MHz, Methanol-d4)δ8.84(s,1H),8.61–8.46(m,1H),8.15–8.02(m,1H),7.91–7. 74(m,3H),6.92(d,1H),6.72(d,1H),5.37–5.24(m,1H),3.74(t,2H),3.62–3.52(m,1H),3 .51–3.41(m,3H),3.38–3.34(m,3H),3.25(d,2H),2.89–2.80(m,2H),2.73–2.61(m,1H), 2.48(s,1H),1.94–1.72(m,4H),1.22–1.05(m,1H),0.68–0.56(m,2H),0.36–0.28(m,2H).
[0425] Example 11: Preparation of trifluoroacetate salt of compound 11
[0426] Step 1: Preparation of 11B
[0427] 7I (225 mg, 0.44 mmol) was added to a solution of hydrogen chloride in 1,4-dioxane (10 mL, 4 mol / L). The mixture was allowed to react at room temperature for 2 hours, then concentrated under reduced pressure. The concentrate was added to dichloromethane (30 mL), followed by 11A (62 mg, 0.43 mmol), DIPEA (280 mg, 2.17 mmol), and HATU (330 mg, 0.87 mmol). The mixture was stirred at room temperature for 4 hours. Water (50 mL) was added, and the mixture was extracted with dichloromethane (50 mL x 2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to afford crude product 11B (200 mg).
[0428] LCMS m / z=519.7[M+H] +
[0429] Step 2: Preparation of trifluoroacetate salt of compound 11
[0430] Referring to the sixth step of the synthesis method in Example 5, trifluoroacetic acid salt of compound 11 (100 mg) was obtained.
[0431] LCMS m / z=505.7[M+H] +
[0432] Example 11-1: Preparation of Compound 11
[0433] The crude product of 11B (3.8 g) and lithium hydroxide monohydrate (1.54 g, 36.70 mmol) were added to a tetrahydrofuran / water mixture (40 mL, V / V = 4 / 1) and stirred at room temperature for 2 hours. The mixture was concentrated under reduced pressure and purified using preparative liquid chromatography (Waters 2767 preparative liquid chromatography; Xbridge Prep C18 5 μm 19*250 mm column); the mobile phase consisted of acetonitrile / water (containing 5 mmol / L ammonium bicarbonate) to yield compound 11 (1.08 g).
[0434] LCMS m / z=505.4[M+H] +
[0435] 1H NMR(400MHz, CDCl3)δ7.99(br.s,1H),6.89(d,1H),6.14(d,1H),6.07(d,1H),4.20 (ddd,1H),3.87(s,3H),3.61–3.47(m,2H),3.32(s,3H),2.96–2.84(m,1H),2.83–2 .52(m,7H),2.51–2.41(m,1H),2.26–2.09(m,2H),2.03–1.83(m,3H),1.82–1.58(m ,6H),1.58–1.38(m,3H),1.34–1.16(m,3H),0.84–0.74(m,2H),0.69–0.58(m,2H).
[0436] Example 12: Preparation of trifluoroacetate salt of compound 12
[0437] Referring to the synthesis method of Example 11, trifluoroacetate salt of Compound 12 (100 mg) was obtained.
[0438] LCMS m / z=535.6[M+H] +
[0439] 1 H NMR(400MHz,DMSO-d6)δ9.02–8.88(m,1H),8.69–8.60(m,1H),7.76–7.64(m,1H),7.4 2–7.31(m,1H),7.24–7.15(m,1H),6.50–6.45(m,1H),6.39–6.34(m,1H),4.54–4.45(m ,1H),3.94(s,3H),3.67–3.61(m,2H),3.38–3.24(m,6H),3.20–3.07(m,3H),2.74–2.6 2(m,3H),2.31–2.04(m,2H),1.73–1.58(m,4H),0.94–0.82(m,2H),0.62–0.51(m,2H).
[0440] Example 13: Preparation of trifluoroacetate salt of compound 13
[0441] Step 1: Preparation of 13B
[0442] 9A (5.0 g, 28.41 mmol), 13A (2.42 g, 28.42 mmol), and potassium carbonate (5.88 g, 42.55 mmol) were added to DMSO (50 mL) and reacted at 90°C overnight. The mixture was cooled to room temperature, and water (100 mL) was added. The mixture was extracted with ethyl acetate (100 mL). The organic phase was concentrated under reduced pressure, and the residue was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 0-40%) to afford 13B (6.0 g, 88% yield).
[0443] LCMS m / z=243.1[M+H] +
[0444] Step 2: Preparation of 13C
[0445] Referring to the second step synthesis method of Example 4, 13C (1.60 g) was obtained.
[0446] LCMS m / z=277.2[M+H] +
[0447] Step 3: 13D preparation
[0448] Refer to the fourth step of the synthesis method of Example 7 to obtain 13D (1.80 g).
[0449] LCMS m / z=306.2[M+H] +
[0450] Step 4: Preparation of 13E
[0451] Refer to the fifth step of the synthesis method of Example 4 to obtain 13E (0.72 g).
[0452] LCMS m / z=292.2[M+H] +
[0453] Step 5: Preparation of 13F
[0454] Referring to the fourth step of the synthesis method of Example 1, 13F (1.20 g) was obtained.
[0455] LCMS m / z=507.3[M+H] +
[0456] Step 6: Preparation of 13G
[0457] Referring to the fifth step of the synthesis method of Example 1, 13G (220 mg) was obtained.
[0458] LCMS m / z=535.7[M+H] +
[0459] Step 7: Preparation of trifluoroacetate salt of compound 13
[0460] Referring to the sixth step of the synthesis method in Example 5, trifluoroacetic acid salt of compound 13 (40 mg) was obtained.
[0461] LCMS m / z=521.7[M+H] +
[0462] 1 H NMR(400MHz,TFA-d)δ8.80(s,1H),8.32(d,1H),8.19–8.11(m,1H),7.96–7. 80(m,3H),6.86(d,1H),6.69(d,1H),5.60–5.40(m,1H),4.06–3.96(m,1H),3 .92–3.56(m,6H),3.53–3.40(m,5H),2.97–2.80(m,3H),2.74–2.56(m,1H), 2.21–2.10(m,2H),2.04–1.91(m,2H),1.88–1.69(m,6H),1.67–1.57(m,2H).
[0463] Example 14: Preparation of trifluoroacetate salt of compound 14
[0464] Referring to the synthesis method of Example 9, the trifluoroacetic acid salt of the target compound 14 (17 mg) was obtained.
[0465] LCMS m / z=481.3[M+H] +
[0466] 1 H NMR(400MHz,DMSO-d6)δ10.02(s,1H),8.91(s,1H),8.78(br.s,1H),8.62–8 .55(m,1H),8.06(ddd,1H),7.92–7.86(m,1H),7.86–7.77(m,2H),6.88(d,1H ),6.67(d,1H),5.07(dd,1H),3.65(t,2H),3.43–3.30(m,5H),3.30–3.10(m ,6H),2.78–2.69(m,2H),2.48–2.33(m,2H),1.79–1.58(m,4H),1.19(t,3H).
[0467] Example 14-1: Preparation of the free base of compound 14
[0468] The concentrate after the final reaction was purified using the same method as in Example 9 using a preparative liquid chromatography system (Waters 2767 preparative liquid chromatography system; Xbridge Prep C18 5 μm 19*250 mm column); mobile phase: acetonitrile / water (containing 5 mmol / L ammonium bicarbonate) to obtain the target compound 14 (71 mg).
[0469] LCMS m / z=481.3[M+H] +
[0470] 1 H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.40(br.s,1H),8.25(d,1H),7.78(ddd,1H),7. 73–7.67(m,1H),7.53(ddd,1H),7.19(dd,1H),6.25–6.14(m,3H),4.75–4.66(m,1H),3 .45–3.37(m,2H),3.23–3.15(m,2H),3.14(s,3H),2.87–2.74(m,2H),2.74–2.60(m,3H ),2.57–2.52(m,1H),2.41(t,2H),2.16–1.94(m,2H),1.64–1.37(m,4H),1.09(t,3H).
[0471] Example 15: Preparation of Compound 15
[0472] Step 1: Preparation of 15B
[0473] Referring to the first step of the synthesis method of Example 11, 15B (0.30 g) was obtained.
[0474] LCMS m / z=593.6[MH] -
[0475] Step 2: Preparation of compound 15
[0476] The crude product of 15B (300 mg) and lithium hydroxide monohydrate (208 mg, 4.96 mmol) were added to a tetrahydrofuran / water mixture (30 mL, V / V = 4 / 1) and stirred at room temperature for 2 hours. The mixture was concentrated under reduced pressure and purified using preparative liquid chromatography (Waters 2767 Preparative Liquid Chromatography; Xbridge Prep C18 5 μm 19*250 mm column); the mobile phase consisted of acetonitrile / water (containing 5 mmol / L ammonium bicarbonate) to afford compound 15 (100 mg).
[0477] LCMS m / z=581.4[M+H] +
[0478] 1 H NMR (400MHz, CDCl3) δ8.29–7.94(m,1H),7.47–7.41(m,2H),7.35–7.28(m,2H),7.22–7.17(m, 1H),6.95–6.86(m,1H),6.14–6.09(m,1H),6.06–6.01(m,1H),4.21–4.10(m,1H),3.86(s,3H) ,3.51–3.35(m,2H),3.28(s,3H),2.75–2.48(m,8H),2.46–2.29(m,3H),2.15–1.98(m,2H),1. 96–1.85(m,2H),1.71–1.49(m,8H),1.48–1.30(m,2H),0.84–0.74(m,2H),0.67–0.56(m,2H).
[0479] Example 16: Preparation of Compound 16
[0480] Step 1: Preparation of 16C
[0481] 16B (0.64 g, 13.89 mmol) was added to anhydrous tetrahydrofuran (50 mL), followed by sodium hydride (0.57 g, 14.25 mmol, wt% = 60%). The reaction was allowed to proceed at room temperature for 15 minutes, followed by the addition of 16A (3.0 g, 10.64 mmol), and the reaction was continued for 2 hours. Water (100 mL) was added, and the mixture was extracted with ethyl acetate (100 mL). The organic phase was concentrated under reduced pressure, and the residue was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 0-20%) to afford 16C (2.9 g, 97% yield).
[0482] LCMS m / z=282.0[M+H] +
[0483] Step 2: Preparation of 16D
[0484] Referring to the first step of the synthesis method of Example 9, 16D (2.5 g) was obtained.
[0485] LCMS m / z=257.2[M+H] +
[0486] Step 3: Preparation of 16E
[0487] Referring to the first step of the synthesis method of Example 4, 16E (3.0 g) was obtained.
[0488] LCMS m / z=359.3[M+H] +
[0489] Step 4: Preparation of 16F
[0490] Referring to the second step synthesis method of Example 4, 16F (1.2 g) was obtained.
[0491] LCMS m / z=393.1[M+H] +
[0492] Step 5: Preparation of 16G
[0493] Refer to the fourth step synthesis method of Example 7 to obtain 16G (0.9 g).
[0494] LCMS m / z=322.3[M+H] +
[0495] Step 6: Preparation of 16H
[0496] Refer to the fifth step of the synthesis method of Example 4 to obtain 16H (0.8 g).
[0497] LCMS m / z=308.3[M+H] +
[0498] Step 7: Preparation of 16I
[0499] Refer to the fourth step of the synthesis method in Example 1 to obtain 16I (400 mg).
[0500] LCMS m / z=523.2[M+H] +
[0501] Step 8: Preparation of 16J
[0502] Refer to the fifth step of the synthesis method in Example 1 to obtain 16J (300 mg).
[0503] LCMS m / z=551.5[M+H] +
[0504] Step 9: Preparation of compound 16
[0505] Referring to the second step synthesis method of Example 15, compound 16 (10 mg) was obtained.
[0506] LCMS m / z=537.3[M+H] +
[0507] 1 H NMR (400MHz, DMSO-d6) δ8.46–8.33(m,2H),8.27–8.21(m,1H),7.82–7.74(m,1H),7.72–7.66(m,1H ),7.56–7.49(m,1H),6.60(s,1H),6.04–5.98(m,1H),5.94–5.89(m,1H),4.75–4.66(m,1H),4.03–3 .93(m,2H),3.46–3.37(m,2H),3.13(s,3H),2.85–2.59(m,5H),2.57–2.51(m,1H),2.42–2.31(m,3 H),2.14–1.95(m,2H),1.60–1.38(m,4H),1.32–1.25(m,3H),0.70–0.59(m,2H),0.43–0.32(m,2H).
[0508] Example 17: Preparation of Compound 17
[0509] Referring to the synthetic method of Example 16, compound 17 (10 mg) was obtained.
[0510] LCMS m / z=551.3[M+H] +
[0511] 1 H NMR(400MHz,DMSO-d6)δ8.48–8.35(m,2H),8.24(d,1H),7.81–7.74(m,1H),7.72–7.67(m,1H),7 .57–7.49(m,1H),6.59(s,1H),6.02–5.98(m,1H),5.93–5.87(m,1H),4.75–4.67(m,1H),4.65–4 .55(m,1H),3.44–3.38(m,2H),3.13(s,3H),2.86–2.60(m,5H),2.57–2.52(m,1H),2.41–2.32(m ,3H),2.14–1.95(m,2H),1.61–1.38(m,4H),1.24(d,6H),0.69–0.60(m,2H),0.42–0.34(m,2H).
[0512] Example 18: Preparation of Compound 18
[0513] Step 1: Preparation of 18B
[0514] 18A (4.4 g, 16.48 mmol), methylamine hydrochloride (1.22 g, 18.07 mmol), potassium carbonate (11.38 g, 82.34 mmol), and potassium iodide (0.27 g, 1.63 mmol) were added to DMSO (50 mL) and reacted at 100°C overnight. After cooling to room temperature, water (50 mL) was added and the mixture was extracted with ethyl acetate (50 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 0-5%) to afford 18B (2.0 g, 56% yield).
[0515] LCMS m / z=219.1[M+H] +
[0516] Step 2: Preparation of 18C
[0517] Referring to the synthetic method of step 1 of Example 4, 18C (2.33 g) was obtained.
[0518] LCMS m / z=319.0[M+H] +
[0519] Step 3: Preparation of 18D
[0520] Referring to the synthesis method of step 2 of Example 4, 18D (1.82 g) was obtained.
[0521] LCMS m / z=339.4[M+H] +
[0522] Step 4: Preparation of 18E
[0523] Referring to the synthesis method of step 3 of Example 4, 18E (1.67 g) was obtained.
[0524] LCMS m / z=325.2[M+H] +
[0525] Step 5: Preparation of 18F
[0526] Referring to the synthesis method of step 4 of Example 4, 18F (3.5 g) was obtained.
[0527] LCMS m / z=382.4[M+H] +
[0528] Step 6: Preparation of 18G
[0529] Referring to the synthesis method of step 5 of Example 6, 18G (1.05 g) was obtained.
[0530] LCMS m / z=268.2[M+H]+
[0531] Step 7: Preparation of 18H
[0532] Refer to the fourth step synthesis method of Example 1 to obtain 18H (1.6 g).
[0533] LCMS m / z=483.5[M+H] +
[0534] Step 8: Preparation of 18I
[0535] Refer to the fifth step of the synthesis method in Example 1 to obtain 18I (2 g).
[0536] LCMS m / z=511.1[M+H] +
[0537] Step 9: Preparation of compound 18
[0538] Referring to the second step synthesis method of Example 15, compound 18 (120 mg) was obtained.
[0539] LCMS m / z=497.3[M+H] +
[0540] 1 H NMR(400MHz,DMSO-d6)δ8.42(s,1H),8.38(s,1H),8.23(d,1H),7.81–7.73(m,1H),7.69(d, 1H),7.57–7.49(m,1H),6.25(s,1H),5.95(s,1H),5.73–5.70(m,1H),4.72–4.66(m,1H),3.6 8(s,3H),3.41(t,2H),3.14(s,3H),2.86–2.75(m,2H),2.72–2.62(m,6H),2.57–2.51(m,1H ),2.37(t,2H),2.14–2.05(m,1H),2.04–1.95(m,1H),1.60–1.52(m,2H),1.49–1.39(m,2H).
[0541] Example 19: Preparation of Compound 19
[0542] Referring to the synthesis method of Example 9, the trifluoroacetic acid salt of the target compound 19 (35 mg) was obtained.
[0543] LCMS m / z=507.4[M+H] +
[0544] 1 H NMR(400MHz,DMSO-d6)δ8.91–8.82(m,1H),8.62–8.51(m,1H),8.08–8.00(m ,1H),7.97–7.84(m,2H),7.79(t,1H),7.02(t,1H),6.76(t,1H),5.14–4.94 (m,2H),3.64(t,2H),3.40–3.31(m,3H),3.25(d,4H),3.20–3.12(m,2H),2. 73(d,2H),2.47–2.30(m,2H),1.67(d,4H),1.36(s,3H),0.85–0.72(m,4H).
[0545] Example 20: Preparation of Compound 20
[0546] Step 1: Preparation of 20C
[0547] 20A (8.00 g, 29.97 mmol), 20B (6.40 g, 89.99 mmol), cesium carbonate (9.77 g, 29.99 mmol), and potassium iodide (0.50 g, 3.01 mmol) were added to DMSO (50 mL) and reacted at 90°C overnight. After cooling to room temperature, water (100 mL) was added and the mixture was extracted with ethyl acetate (100 mL). The organic phase was concentrated under reduced pressure, and the residue was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 0-40%) to afford 20C (5.28 g, 69% yield).
[0548] LCMS m / z=259.0[M+H] +
[0549] Step 2: Preparation of 20D
[0550] Referring to the second step synthesis method of Example 9, 20D (6.12 g) was obtained.
[0551] LCMS m / z=301.0[M-55] +
[0552] Step 3: Preparation of 20E
[0553] Referring to the third step of the synthesis method of Example 9, 20E (4.5 g) was obtained.
[0554] LCMS m / z=379.3[M+H] +
[0555] Step 4: Preparation of 20F
[0556] Referring to the fourth step of the synthesis method of Example 9, 20F (4.3 g) was obtained.
[0557] LCMS m / z=365.1[M+H] +
[0558] Step 5: Preparation of 20G
[0559] The fifth step of the synthesis method of the reference example was used to obtain 20G crude product (3.14g).
[0560] LCMS m / z=322.3[M-99] +
[0561] Step 6: Preparation of 20H
[0562] Refer to the sixth step synthesis method of Example 9 to obtain 20H (1.4 g).
[0563] LCMS m / z=308.2[M+H] +
[0564] Step 7: Preparation of 20I
[0565] Refer to the seventh step of the synthesis method in Example 9 to obtain 20I (0.45 g).
[0566] LCMS m / z=523.8[M+H] +
[0567] Step 8: Preparation of 20J
[0568] The eighth step of the synthesis method of Reference Example 9 was used to obtain a crude product of 20J (1.33 g).
[0569] LCMS m / z=551.2[M+H] +
[0570] Step 9: Preparation of trifluoroacetate salt of compound 20
[0571] Referring to the ninth step of the synthesis method of Example 9, trifluoroacetic acid salt of compound 20 (168 mg) was obtained.
[0572] LCMS m / z=537.2[M+H] +
[0573] 1H NMR(400MHz,DMSO-d6)δ10.31(d,1H),8.99(s,1H),8.70–8.57(m,2H),8.16–8.06(m,1H),7.94 –7.89(m,1H),7.89–7.82(m,1H),6.38(d,1H),6.32(d,1H),5.16–5.06(m,1H),3.91(s,3H),3.6 5(t,2H),3.40–3.31(m,3H),3.25(s,3H),3.21(dd,2H),3.18–3.13(m,2H),2.73–2.63(m,2H), 2.47–2.34(m,2H),1.74–1.60(m,4H),1.15–1.02(m,1H),0.57–0.48(m,2H),0.30–0.23(m,2H).
[0574] Example 21: Preparation of Compound 21
[0575] Step 1: Preparation of 21A
[0576] Referring to the first step of the synthesis method of Example 9, 21A (4.0 g) was obtained.
[0577] LCMS m / z=231.2[M+H] +
[0578] Step 2: Preparation of 21B
[0579] Referring to the first step of the synthesis method of Example 4, 21B (5.0 g) was obtained.
[0580] LCMS m / z=275.2[M-55] +
[0581] Step 3: Preparation of 21C
[0582] Referring to the second step synthesis method of Example 4, 21C (2.8 g) was obtained.
[0583] LCMS m / z=367.2[M+H] +
[0584] Step 4: Preparation of 21D
[0585] Refer to the fourth step of the synthesis method of Example 7 to obtain 21D (2.0 g).
[0586] LCMS m / z=296.4[M+H] +
[0587] Step 5: Preparation of 21E
[0588] Refer to the fifth step of the synthesis method of Example 4 to obtain 21E (2.0 g).
[0589] LCMS m / z=282.3[M+H] +
[0590] Step 6: Preparation of 21F
[0591] Referring to the fourth step of the synthesis method of Example 1, 21F (0.5 g) was obtained.
[0592] LCMS m / z=497.3[M+H] +
[0593] Step 7: Preparation of 21G
[0594] Refer to the fifth step of the synthesis method in Example 1 to obtain 21G (500 mg).
[0595] LCMS m / z=525.3[M+H] +
[0596] Step 8: Preparation of compound 21
[0597] Referring to the second step synthesis method of Example 15, compound 21 (20 mg) was obtained.
[0598] LCMS m / z=511.3[M+H] +
[0599] 1 H NMR(400MHz, CDCl3)δ8.60(s,1H),7.94(d,1H),7.82–7.77(m,1H),7.74–7.68(m,1H),7.62–7.55(m ,1H),7.47–7.42(m,1H),7.38–7.32(m,1H),6.42(d,1H),6.28(d,1H),5.63–5.43(m,1H),4.51–4.43 (m,1H),3.79–3.71(m,1H),3.69–3.63(m,1H),3.61–3.55(m,2H),3.48–3.32(m,9H),3.11–2.97(m, 4H),2.95–2.86(m,1H),2.70–2.61(m,2H),2.50–2.41(m,1H),2.09–1.99(m,1H),1.86–1.68(m,4H).
[0600] Example 22: Preparation of Compound 22
[0601] Step 1: Preparation of 22C
[0602] Referring to the first step of the synthesis method of Example 9, 22C (4.26 g) was obtained.
[0603] LCMS m / z=229.1[M+H] +
[0604] Step 2: Preparation of 22D
[0605] The third step of the synthesis method of Reference Example 9 was used to obtain 22D (2.30 g).
[0606] LCMS m / z=251.3[M+H] +
[0607] Step 3: Preparation of 22E
[0608] The fourth step of the synthesis method of Reference Example 9 was used to obtain crude product 22E (4.39 g).
[0609] LCMS m / z=237.1[M+H] +
[0610] Step 4: Preparation of 22F
[0611] Referring to the fifth step of the synthesis method of Example 9, 22F (4.5 g) was obtained.
[0612] LCMS m / z=294.4[M+H] +
[0613] Step 5: Preparation of 20G
[0614] The crude product of 22F (4.5 g) was added to 1,4-dioxane (50 mL). Under a nitrogen atmosphere, a solution of lithium aluminum hydride in tetrahydrofuran (13.5 mL, 2.5 M) was slowly added, and the mixture was stirred at 100°C overnight. After cooling to room temperature, water (30 mL) was added, and the mixture was extracted with dichloromethane (50 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (mobile phase: dichloromethane / methanol (v / v) = 0-10%) to obtain 22G (1.4 g).
[0615] LCMS m / z=280.2[M+H] +
[0616] Step 6: Preparation of 22H
[0617] Refer to the seventh step synthesis method of Example 9 to obtain 22H (0.35 g).
[0618] LCMS m / z=495.2[M+H] +
[0619] Step 7: Preparation of 22I
[0620] Refer to the eighth step of the synthesis method in Example 9 to obtain 22I (0.52 g).
[0621] LCMS m / z=523.2[M+H] +
[0622] Step 8: Preparation of trifluoroacetate salt of compound 22
[0623] Referring to the ninth step of the synthesis method of Example 9, trifluoroacetic acid salt of compound 22 (118 mg) was obtained.
[0624] LCMS m / z=509.3[M+H] +
[0625] 1 H NMR(400MHz,DMSO-d6)δ10.03(s,1H),8.92(s,1H),8.58(d,1H),8.12–8.01 (m,1H),7.91–7.86(m,1H),7.86–7.80(m,1H),7.77(s,1H),6.98(d,1H),6.6 6(d,1H),5.13–5.03(m,1H),3.64(t,3H),3.40–3.30(m,3H),3.25(s,4H),3 .16(d,2H),2.74–2.65(m,2H),2.47–2.30(m,2H),1.67(d,4H),1.40(s,9H).
[0626] Example 23: Preparation of Compound 23
[0627] Referring to the synthetic method of Example 22, the trifluoroacetic acid salt of the target compound 23 (198 mg) was obtained.
[0628] LCMS m / z=495.4[M+H] +
[0629] 1H NMR(400MHz,DMSO-d6)δ10.08(s,1H),8.94(s,1H),8.75(s,1H),8.62–8.55(m,1H), 8.12–8.05(m,1H),7.91–7.87(m,1H),7.86–7.79(m,2H),6.90(d,1H),6.67(d,1H), 5.14–5.02(m,1H),4.06–3.91(m,2H),3.64(t,2H),3.40–3.30(m,3H),3.25(s,3H), 3.16(d,2H),2.78–2.70(m,2H),2.48–2.33(m,2H),1.74–1.60(m,4H),1.20(d,6H).
[0630] Example 24: Preparation of Compound 24
[0631] Referring to the synthetic method of Example 18, compound 24 (130 mg) was obtained.
[0632] LCMS m / z=525.3[M+H] +
[0633] 1 H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.42(s,1H),8.22(d,1H),7.80–7.74(m,1H),7.73–7.66(m,1H),7.5 5–7.47(m,1H),6.12(d,1H),5.91(d,1H),5.74(d,1H),4.73–4.66(m,1H),3.94–3.84(m,1H),3.67(s,3H) ,3.41(t,2H),3.13(s,3H),2.86–2.74(m,2H),2.73–2.60(m,3H),2.58–2.51(m,1H),2.36(t,2H),2.14–2 .04(m,1H),2.04–1.95(m,1H),1.62–1.51(m,2H),1.49–1.38(m,2H),1.09(d,J=3.7Hz,3H),1.08(s,3H).
[0634] Example 25: Preparation of Compound 25
[0635] Step 1: Preparation of 25B
[0636] 25A (3 g, 15.79 mmol), 7B (0.99 g, 17.34 mmol), and potassium carbonate (6.56 g, 47.47 mmol) were added to DMSO (30 mL) and reacted at 90°C for 5 h. The mixture was cooled to room temperature, and water (50 mL) was added. The mixture was extracted with ethyl acetate (50 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 0-33%) to obtain crude product 25B (3.98 g).
[0637] LCMS m / z=229.1[M+H] +
[0638] Step 2: Preparation of 25C
[0639] Referring to the synthesis method of step 1 of Example 4, 25C (5.8 g) was obtained.
[0640] LCMS m / z=329.1[M+H] +
[0641] Step 3: Preparation of 25D
[0642] Referring to the synthesis method of step 2 of Example 4, 25D (3 g) was obtained.
[0643] LCMS m / z=349.3[M+H] +
[0644] Step 4: Preparation of 25E
[0645] Referring to the synthesis method of step 3 of Example 4, 25E (2.3 g) was obtained.
[0646] LCMS m / z=335.4[M+H] +
[0647] Step 5: Preparation of 25F
[0648] Referring to the synthesis method of step 4 of Example 4, 25F (3.5 g) was obtained.
[0649] LCMS m / z=392.3[M+H] +
[0650] Step 6: Preparation of 25G
[0651] Referring to the synthesis method of step 5 of Example 6, 25G (1.05 g) was obtained.
[0652] LCMS m / z=278.6[M+H] +
[0653] Step 7: Preparation of 25H
[0654] Refer to the fourth step synthesis method of Example 1 to obtain 25H (880 mg).
[0655] LCMS m / z=493.3[M+H] +
[0656] Step 8: Preparation of 25I
[0657] Refer to the fifth step of the synthesis method in Example 1 to obtain 25I (650 mg).
[0658] LCMS m / z=521.3[M+H] +
[0659] Step 7: Preparation of compound 25
[0660] Referring to the second step synthesis method of Example 15, compound 25 (120 mg) was obtained.
[0661] LCMS m / z=507.3[M+H] +
[0662] 1 H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.39(s,1H),8.24(d,1H),7.81–7.75(m,1H),7.70(d,1H),7.56– 7.50(m,1H),6.46–6.42(m,1H),6.24(s,1H),6.18(s,1H),4.73–4.67(m,1H),3.41(t,2H),3.14(s,3H) ,2.86–2.74(m,2H),2.71–2.61(m,3H),2.55–2.51(m,1H),2.42–2.34(m,3H),2.12(s,3H),2.11–2.04( m,1H),2.03–1.96(m,1H),1.59–1.50(m,2H),1.48–1.38(m,2H),0.68–0.61(m,2H),0.40–0.34(m,2H).
[0663] Example 26: Preparation of Compound 26
[0664] Referring to the synthetic method of Example 18, compound 26 (80 mg) was obtained.
[0665] LCMS m / z=511.2[M+H] +
[0666] 1 H NMR (400MHz, DMSO-d6) δ8.44(s,1H),8.39(s,1H),8.24(d,1H),7.80–7.75(m,1H),7.69(d,1H),7. 56–7.49(m,1H),6.25(s,1H),5.93(d,1H),5.73(d,1H),4.73–4.66(m,1H),3.68(s,3H),3.41(t,2 H),3.22–3.15(m,2H),3.14(s,3H),2.86–2.74(m,2H),2.73–2.61(m,3H),2.57–2.51(m,1H),2.37 (t,2H),2.14–2.05(m,1H),2.03–1.95(m,1H),1.62–1.52(m,2H),1.51–1.38(m,2H),1.08(t,3H).
[0667] Example 27: Preparation of Compound 27
[0668] Referring to the synthetic method of Example 7, compound 27 (20 mg) was obtained.
[0669] LCMS m / z=541.2[M+H] +
[0670] 1 H NMR(400MHz, CDCl3)δ8.61(s,1H),7.93(d,1H),7.82–7.77(m,1H),7.72–7.67(m,1H),7.6 6–7.60(m,1H),7.46–7.40(m,1H),6.06–6.02(m,1H),5.86–5.81(m,1H),4.64–4.55(m,1H) ,3.82(s,3H),3.65–3.51(m,4H),3.44–3.35(m,5H),3.29(s,3H),3.11–3.02(m,1H),2.90 –2.79(m,4H),2.76–2.57(m,3H),2.52–2.41(m,1H),2.21–2.11(m,1H),1.88–1.57(m,4H).
[0671] Example 28: Preparation of Compound 28
[0672] Step 1: Preparation of 28B
[0673] Referring to the first step of the synthesis method of Example 16, 28B (7.33 g) was obtained.
[0674] LCMS m / z=294.0[M+H] +
[0675] Step 2: Preparation of 28C
[0676] Referring to the first step of the synthesis method of Example 18, 28C (2.95 g) was obtained.
[0677] LCMS m / z=243.0[M+H] +
[0678] Step 3: Preparation of 28D
[0679] Referring to the first step of the synthesis method of Example 4, 28D (3.53 g) was obtained.
[0680] LCMS m / z=345.1[M+H] +
[0681] Step 4: Preparation of 28E
[0682] Referring to the second step synthesis method of Example 4, 28E (1.75 g) was obtained.
[0683] LCMS m / z=365.3[M+H] +
[0684] Step 5: Preparation of 28F
[0685] Referring to the third step of the synthesis method of Example 4, 28F (1.79 g) was obtained.
[0686] LCMS m / z=351.1[M+H] +
[0687] Step 6: Preparation of 28G
[0688] Referring to the fourth step of the synthesis method of Example 4, 28G (2.5 g) was obtained.
[0689] LCMS m / z=408.6[M+H] +
[0690] Step 7: Preparation of 28H
[0691] Referring to the fifth step of the synthesis method of Example 6, 28H (2.3 g) was obtained.
[0692] LCMS m / z=294.2[M+H] +
[0693] Step 8: Preparation of 28I
[0694] Referring to the fourth step of the synthesis method of Example 1, 28I (0.85 g) was obtained.
[0695] LCMS m / z=509.4[M+H] +
[0696] Step 9: Preparation of 28J
[0697] Referring to the fifth step of the synthesis method of Example 1, 28J (0.86 g) was obtained.
[0698] LCMS m / z=537.3[M+H] +
[0699] Step 10: Preparation of compound 28
[0700] Referring to the second step synthesis method of Example 15, compound 28 (170 mg) was obtained.
[0701] LCMS m / z=523.3[M+H] +
[0702] 1 H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.39(s,1H),8.24(d,1H),7.81–7.75(m,1H),7.69(d,1H),7.58– 7.50(m,1H),6.27–6.19(m,1H),6.01(d,1H),5.88(d,1H),4.72–4.66(m,1H),3.80–3.75(m,1H),3.41( t,2H),3.14(s,3H),2.87–2.75(m,2H),2.72–2.63(m,6H),2.57–2.51(m,1H),2.37(t,2H),2.12–2.05( m,1H),2.03–1.96(m,1H),1.61–1.52(m,2H),1.50–1.40(m,2H),0.76–0.70(m,2H),0.64–0.59(m,2H).
[0703] Example 29: Preparation of trifluoroacetate salt of compound 29
[0704] Step 1: Preparation of 29C
[0705] Compound 29A (5.0 g, 28.41 mmol), 29B (2.53 g, 31.21 mmol), and potassium carbonate (11.76 g, 85.09 mmol) were added to DMSO (50 mL) and reacted at 90°C overnight. The mixture was cooled to room temperature, and water (100 mL) was added. The mixture was extracted with ethyl acetate (100 mL). The organic phase was concentrated under reduced pressure, and the residue was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 0-40%) to afford 29C (4.82 g, 72% yield).
[0706] LCMS m / z=237.1[M+H] +
[0707] The second to ninth steps were carried out with reference to the synthesis method of Example 6 to obtain the trifluoroacetic acid salt of the target compound 29 (85 mg).
[0708] LCMS m / z=517.6[M+H] +
[0709] 1 H NMR(400MHz,DMSO-d6)δ10.14(s,1H),8.96(s,1H),8.60(d,1H),8.09(t,1H ),7.94–7.80(m,2H),7.69–7.57(m,1H),6.75(d,1H),6.62(d,1H),6.33–5.9 8(m,1H),5.09(d,1H),3.80(t,2H),3.64(t,2H),3.40–3.30(m,3H),3.25(s ,3H),3.21–3.09(m,2H),2.67(d,2H),2.47–2.30(m,2H),1.76–1.54(m,4H).
[0710] Example 30: Preparation of Compound 30
[0711] Step 1: Preparation of 30C
[0712] Referring to the first step of the synthesis method of Example 9, 30C (5.3 g) was obtained.
[0713] LCMS m / z=215.1[M+H] +
[0714] Step 2: Preparation of 30D
[0715] Referring to the synthesis method of the first step in Example 4, 30D (7 g) was obtained.
[0716] LCMS m / z=259.1[M-55]+
[0717] Step 3: Preparation of 30E
[0718] Referring to the synthesis method of step 2 of Example 4, 30E (7.1 g) was obtained.
[0719] LCMS m / z=337.2[M+H] +
[0720] Step 4: Preparation of 30F
[0721] Compound 30E was added to THF (200 mL), followed by methanol (40 mL), water (40 mL), and lithium hydroxide monohydrate (2.62 g, 62.44 mmol). The mixture was allowed to react at room temperature for 3 h, then concentrated. The concentrate was redissolved in dichloromethane (200 mL), filtered, and the filtrate was concentrated again under reduced pressure. DCM (300 mL), compound 1D (1.56 g, 20.76 mmol), DIPEA (8.07 g, 62.43 mmol), and HATU (15.83 g, 41.63 mmol) were added to the concentrate in sequence. The mixture was allowed to react at room temperature overnight. The reaction solution was concentrated under reduced pressure and then purified by column chromatography (mobile phase: methanol / dichloromethane (v / v) = 0-5%) to afford crude compound 30F (14 g).
[0722] LCMS m / z=380.2[M+H] +
[0723] Step 5: Preparation of 30G
[0724] Compound 30F was added to a flask, and a hydrogen chloride-1,4-dioxane solution (50 mL, 4 mol / L) was added. The reaction was allowed to react at room temperature overnight, and the mixture was concentrated. Dichloromethane (50 mL) and a saturated sodium bicarbonate solution (50 mL) were added, and the mixture was extracted with dichloromethane (50 mL×3). The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product of compound 30G (12 g).
[0725] LCMS m / z=280.3[M+H] +
[0726] Steps 6 to 9: Compound 30 (20 mg) was obtained by following the synthetic method of Steps 6 to 9 of Example 16.
[0727] LCMS m / z=495.3[M+H] +
[0728] 1H NMR(400MHz,DMSO-d6)δ8.45(s,1H),8.42(s,1H),8.25(d,1H),7.85–7.74(m,1H),7.70 (d,1H),7.60–7.47(m,1H),7.28–7.12(m,1H),6.33–6.16(m,3H),4.75–4.67(m,1H),3.4 8–3.35(m,2H),3.20–3.07(m,5H),2.91–2.75(m,2H),2.75–2.61(m,3H),2.59–2.52(m, 1H),2.41(t,2H),2.19–2.06(m,1H),2.06–1.93(m,1H),1.68–1.37(m,6H),0.88(t,3H).
[0729] Example 31: Preparation of Compound 31
[0730] Step 1: Preparation of 31A
[0731] Referring to the first step of the synthesis method of Example 18, compound 31A (4.8 g) was obtained.
[0732] LCMS m / z=245.1[M+H] +
[0733] Steps 2 to 9: Compound 31 (24 mg) was obtained by following the synthetic methods of Steps 2 to 9 of Example 30.
[0734] LCMS m / z=525.3[M+H] +
[0735] 1 H NMR (400MHz, DMSO-d6) δ8.66–8.31(m,2H),8.24(d,1H),7.83–7.74(m,1H),7.74–7.63( m,1H),7.57–7.47(m,1H),6.44–6.21(m,1H),5.93(s,1H),5.75(s,1H),4.83–4.61(m,1H ),3.68(s,3H),3.48–3.38(m,2H),3.19–3.05(m,5H),2.91–2.74(m,2H),2.74–2.59(m, 3H),2.59–2.52(m,1H),2.36(t,2H),2.21–1.93(m,2H),1.66–1.34(m,6H),0.87(t,3H).
[0736] Example 32: Preparation of Compound 32
[0737] Referring to the synthetic method of Example 28, the target compound 32 (16 mg) was obtained.
[0738] LCMS m / z=551.5[M+H] +
[0739] 1 H NMR(400MHz,DMSO-d6)δ8.44(d,1H),8.42–8.32(m,1H),8.22(d,1H),7.77(t,1H),7.69(d,1H),7.56–7.4 6(m,1H),6.24(s,1H),5.93(d,1H),5.71(d,1H),4.71–4.63(m,1H),3.74(d,3H),3.40(t,2H),3.20–3.09( m,5H),2.86–2.72(m,2H),2.72–2.58(m,3H),2.36(t,2H),2.15–2.05(m,1H),2.04–1.94(m,1H),1.61–1. 50(m,2H),1.50–1.37(m,2H),1.21–1.12(m,1H),1.11–1.04(m,3H),0.58–0.50(m,2H),0.31–0.25(m,2H).
[0740] Example 33: Preparation of Compound 33
[0741] Referring to the synthetic method of Example 32, the target compound 33 (11 mg) was obtained.
[0742] LCMS m / z=537.5[M+H] +
[0743] 1H NMR (400MHz, DMSO-d6) δ8.44(s,1H),8.36(s,1H),8.24–8.18(m,1H),7.81–7.74(m,1H),7.72–7.66(m,1H),7. 57–7.48(m,1H),6.22(d,1H),5.94(d,1H),5.69(d,1H),4.65(s,1H),3.75(d,2H),3.43–3.37(m,4H),3.13(s,3 H),2.84–2.72(m,2H),2.69(d,3H),2.66–2.59(m,2H),2.36(t,2H),2.14–2.04(m,1H),2.04–1.93(m,1H),1.6 2–1.51(m,2H),1.49–1.38(m,2H),1.30–1.22(m,1H),1.21–1.12(m,1H),0.58–0.51(m,2H),0.31–0.26(m,2H).
[0744] Example 34: Preparation of Compound 34
[0745] Step 1: Referring to the first step synthesis method of Example 11, a crude product of 34B (450 mg) was obtained.
[0746] LCMS m / z=503.4[M+H] +
[0747] Step 2: Crude 34B (450 mg) and lithium hydroxide monohydrate (113 mg, 2.7 mmol) were added to a mixture of tetrahydrofuran / water / methanol (30 mL, V / V / V = 4 / 1 / 1) and stirred at room temperature for 2 hours. The mixture was concentrated under reduced pressure and purified by preparative HPLC (Waters 2767 Preparative HPLC; Xbridge Prep C18 5 μm 19*250 mm column); mobile phase composition: acetonitrile / water (containing 5 mmol / L ammonium bicarbonate) to afford compound 34 (34 mg).
[0748] LCMS m / z=489.4[M+H] +
[0749] 1H NMR(400MHz,DMSO-d6)δ7.77(d,1H),7.38–7.30(m,1H),6.58(s,1H),6.43– 6.34(m,2H),4.15–4.07(m,1H),3.41(t,2H),3.21(d,3H),2.77–2.68(m,1H) ,2.68–2.63(m,2H),2.63–2.53(m,3H),2.47(d,2H),2.19–2.09(m,1H),1.90 –1.79(m,1H),1.73–1.63(m,5H),1.63–1.53(m,3H),1.50–1.39(m,2H),1.35 –1.27(m,5H),1.27–1.09(m,4H),0.64(t,2H),0.60(t,2H).
[0750] Example 35: Preparation of Compound 35
[0751] Step 1: Preparation of 35A
[0752] Referring to the first step of the synthesis method of Example 18, 35A (1.5 g) was obtained.
[0753] LCMS m / z=271.0[M+H] +
[0754] Step 2: Preparation of 35B
[0755] 35A (1.5 g, 5.57 mmol) was added to tetrahydrofuran (30 mL), followed by 4-dimethylaminopyridine (0.82 g, 6.71 mmol) and di-tert-butyl dicarbonate (1.82 g, 8.34 mmol). The mixture was reacted at 50°C overnight. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 0-17%) to afford crude product 35B (2.1 g), which was directly used in the next step.
[0756] LCMS m / z=371.1[M+H] +
[0757] Steps 3 to 8 were synthesized by referring to the steps 4 to 9 of compound 16 to obtain compound 35 (105 mg).
[0758] LCMS m / z=549.3[M+H] +
[0759] 1H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.41–8.35(m,1H),8.27–8.20(m,1H),7.84–7.73(m,1H),7.72–7.64(m,1H) ,7.59–7.45(m,1H),6.65–6.50(m,1H),6.16–6.03(m,2H),4.79–4.65(m,1H),3.84–3.74(m,1H),3.45–3.34(m,2H ),3.14(s,3H),2.89–2.74(m,2H),2.72–2.58(m,3H),2.57–2.53(m,1H),2.43–2.30(m,3H),2.17–2.05(m,1H),2 .05–1.94(m,1H),1.64–1.51(m,2H),1.50–1.32(m,2H),0.79–0.71(m,2H),0.69–0.54(m,4H),0.43–0.33(m,2H).
[0760] Example 36: Preparation of Compound 36
[0761] Step 1: Preparation of 36B
[0762] 28B (3.6 g, 12.29 mmol), 36A (2.64 g, 24.54 mmol), potassium carbonate (8.49 g, 61.43 mmol), and potassium iodide (0.20 g, 1.20 mmol) were added to DMSO (50 mL) and reacted at 130°C for 60 h. The mixture was cooled to room temperature, and water (50 mL) was added. The mixture was extracted with ethyl acetate (50 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 0-5%) to afford 36B (0.95 g, 27% yield).
[0763] LCMS m / z=285.0[M+H] +
[0764] Steps 2 to 8: Referring to the synthetic method of step 2 to step 8 of compound 35, compound 36 (40 mg) was obtained.
[0765] LCMS m / z=563.5[M+H] +
[0766] 1H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.42–8.35(m,1H),8.28–8.19(m,1H),7.82–7.74(m,1H),7.73–7.65(m,1H),7 .57–7.45(m,1H),6.59(s,1H),6.17–5.85(m,2H),4.82–4.48(m,1H),3.86–3.67(m,1H),3.50–3.35(m,2H),3.13(s ,3H),2.87–2.73(m,2H),2.72–2.59(m,3H),2.57–2.52(m,1H),2.40–2.28(m,2H),2.14–2.05(m,1H),2.04–1.93(m ,1H),1.60–1.50(m,2H),1.50–1.37(m,2H),1.28(s,3H),0.82–0.69(m,2H),0.68–0.61(m,4H),0.61–0.55(m,2H).
[0767] Example 37: Preparation of Compound 37
[0768] Referring to the synthetic method of Example 28, compound 37 (70 mg) was obtained.
[0769] LCMS m / z=537.5[M+H] +
[0770] 1 H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.39(s,1H),8.24(d,1H),7.81–7.74(m,1H),7.69(d,1H),7.56–7.49(m,1H) ,6.28–6.21(m,1H),6.00–5.97(m,1H),5.92–5.89(m,1H),4.73–4.67(m,1H),3.77–3.74(m,1H),3.41(t,2H),3.2 0–3.15(m,2H),3.14(s,3H),2.85–2.76(m,2H),2.71–2.62(m,3H),2.57–2.52(m,1H),2.36(t,2H),2.14–2.05(m, 1H),2.04–1.96(m,1H),1.60–1.53(m,2H),1.51–1.42(m,2H),1.08(t,3H),0.76–0.70(m,2H),0.64–0.58(m,2H).
[0771] Example 38: Preparation of Compound 38
[0772] Referring to the synthetic method of Example 17, compound 38 (30 mg) was obtained.
[0773] LCMS m / z=525.5[M+H] +
[0774] 1 H NMR (400MHz, CDCl3) δ9.21–8.97(m,1H),8.62(s,1H),7.93(d,1H),7.82–7.75(m,1H),7.73–7.6 3(m,2H),7.47–7.37(m,1H),6.02–5.94(m,1H),5.72–5.64(m,1H),4.77–4.69(m,1H),4.69–4.58 (m,1H),3.56–3.39(m,2H),3.24(s,3H),2.90–2.83(m,3H),2.82–2.60(m,7H),2.54–2.44(m,2H) ,2.34–2.22(m,1H),1.92–1.79(m,1H),1.72–1.57(m,2H),1.55–1.44(m,1H),1.41–1.35(m,6H).
[0775] Example 39: Preparation of Compound 39
[0776] Step 1: Preparation of 39B
[0777] Referring to the first step of the synthesis method of Example 16, 39B (8.2 g) was obtained.
[0778] LCMS m / z=337.9[M+H] +
[0779] Steps 2 to 9 were synthesized according to the first to eighth steps of compound 35 to obtain compound 39 (120 mg).
[0780] LCMS m / z=581.4[M+H] +
[0781] 1H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.42–8.35(m,1H),8.27–8.20(m,1H),7.81–7.74(m,1H),7.73–7.66(m ,1H),7.58–7.49(m,1H),6.26–6.10(m,1H),6.04–5.92(m,1H),5.81–5.71(m,1H),4.73–4.63(m,1H),4.57–4 .43(m,1H),3.88–3.73(m,2H),3.55–3.34(m,4H),3.24–3.08(m,5H),2.90–2.72(m,2H),2.71–2.59(m,3H), 2.58–2.52(m,1H),2.43–2.27(m,2H),2.18–2.05(m,1H),2.05–1.87(m,3H),1.66–1.35(m,6H),1.08(t,3H).
[0782] Example 40: Preparation of Compound 40
[0783] The synthetic method from the second step to the ninth step of Reference Example 39 was used to obtain compound 40 (60 mg).
[0784] LCMS m / z=593.4[M+H] +
[0785] 1 H NMR (400MHz, DMSO-d6) δ8.44(s,1H),8.43–8.31(m,1H),8.26–8.19(m,1H),7.82–7.74(m,1H),7.74–7.65(m,1H),7. 59–7.48(m,1H),6.60–6.52(m,1H),6.12–6.05(m,1H),5.99–5.88(m,1H),4.75–4.63(m,1H),4.62–4.52(m,1H),3.8 2(m,2H),3.52–3.43(m,2H),3.43–3.35(m,2H),3.13(s,3H),2.87–2.73(m,2H),2.72–2.58(m,3H),2.57–2.51(m,1H ),2.43–2.31(m,3H),2.16–1.89(m,4H),1.66–1.50(m,4H),1.49–1.36(m,2H),0.70–0.58(m,2H),0.44–0.32(m,2H).
[0786] Example 41: Preparation of Compound 41
[0787] Step 1: Preparation of 41B
[0788] Compound 41A (5 g, 22.41 mmol), cyclopropylboronic acid (9.63 g, 112.11 mmol), anhydrous sodium carbonate (7.13 g, 67.27 mmol), 2,2'-bipyridine (5.25 g, 33.61 mmol), and copper acetate (8.14 g, 44.82 mmol) were added to dichloromethane (300 mL) and reacted at room temperature overnight. The mixture was filtered through celite and concentrated. The residue was purified by silica gel column chromatography (mobile phase: petroleum ether / ethyl acetate (v / v) = 0-10%) to obtain 41B (2 g, yield: 34%).
[0789] LCMS m / z=263.0[M+H] +
[0790] Step 2: Preparation of 41C
[0791] Referring to the synthesis method of the first step of Example 4, 41C (3.5 g) was obtained.
[0792] LCMS m / z=307.0[M-55] +
[0793] Step 3: Preparation of 41D
[0794] Referring to the synthesis method of the second step of Example 4, 41D (2.5 g) was obtained.
[0795] LCMS m / z=385.1[M+H] +
[0796] Step 4: Preparation of 41E
[0797] Compound 41D (2.5 g, 6.55 mmol) was added to THF (50 mL), followed by methanol (10 mL), water (10 mL), and lithium hydroxide monohydrate (0.82 g, 19.5 mmol). The mixture was allowed to react at room temperature for 3 h, then concentrated. The concentrate was redissolved in dichloromethane (200 mL), filtered, and the filtrate was concentrated again under reduced pressure. DCM (300 mL), compound 1D (0.49 g, 6.5 mmol), DIPEA (2.52 g, 19.5 mmol), and HATU (4.94 g, 13 mmol) were added sequentially to the concentrate. The reaction mixture was stirred at room temperature overnight. The reaction solution was concentrated under reduced pressure and then purified by column chromatography (mobile phase: methanol / dichloromethane (v / v) = 0-5%) to afford crude compound 41E (4 g).
[0798] LCMS m / z=428.4[M+H] +
[0799] Step 5: Preparation of 41F
[0800] Compound 41E (4 g, 9.36 mmol) was added to a flask, and a solution of hydrogen chloride in 1,4-dioxane (15 mL, 4 mol / L) was added. The reaction was allowed to react at room temperature overnight, and the mixture was concentrated. Dichloromethane (30 mL) and saturated sodium bicarbonate (20 mL) were added, and the mixture was extracted with dichloromethane (30 mL × 3). The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product of compound 41F (2.1 g).
[0801] LCMS m / z=328.3[M+H] +
[0802] Step 6: Preparation of 41G
[0803] Compound 41F (1.9 g, 5.80 mmol) was added to anhydrous 1,4-dioxane (100 mL). Under a nitrogen atmosphere, a solution of lithium aluminum hydride in tetrahydrofuran (4.76 ml, 2.5 mol / L) was slowly added, and the mixture was stirred at 50°C for 3 hours. The temperature was raised to 70°C and the reaction was allowed to proceed overnight. The mixture was then cooled to room temperature, and ethyl acetate (50 mL) was added. The mixture was filtered through celite, concentrated, and purified by silica gel column chromatography (mobile phase: dichloromethane / methanol (v / v) = 0-20%) to afford 41G (150 mg).
[0804] LCMS m / z=314.2[M+H] +
[0805] Steps 7 to 9: Compound 41 (8 mg) was obtained by following the synthetic method of Steps 7 to 9 of Example 18.
[0806] LCMS m / z=543.3[M+H] +
[0807] 1H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.41(s,1H),8.26(d,1H),7.88(d,1H),7.82–7.74(m,1H),7.70(d,1H), 7.58(d,1H),7.56–7.49(m,1H),7.47–7.40(m,1H),7.16–7.09(m,1H),6.62(s,1H),6.55(s,1H)4.79–4.67(m ,1H),3.42(t,2H),3.14(s,3H),2.98(t,2H),2.91–2.77(m,2H),2.76–2.63(m,3H),2.62–2.53(m,1H),2.46– 2.38(m,1H),2.17–1.95(m,2H),1.78–1.63(m,2H),1.62–1.47(m,2H),0.78–0.64(m,2H),0.55–0.38(m,2H).
[0808] Example 42: Preparation of Compound 42
[0809] Referring to the synthetic method of Example 15, compound 42 (10 mg) was obtained.
[0810] LCMS m / z=517.3[M+H] +
[0811] 1 H NMR(400MHz, CDCl3)δ8.24–7.91(m,1H),6.84–6.77(m,1H),6.16–6.13(m,1H) ,6.08–6.05(m,1H)4.23–4.16(m,1H),3.87(s,3H),3.60–3.48(m,2H),3.32(s, 3H),2.94–2.82(m,2H),2.81–2.53(m,7H),2.50–2.43(m,1H),2.27–2.13(m,5H ),2.05–1.89(m,5H),1.82–1.48(m,6H),0.85–0.76(m,2H),0.69–0.60(m,2H).
[0812] Example 43: Preparation of Compound 43
[0813] Referring to the synthetic method of Example 17, compound 43 (30 mg) was obtained.
[0814] LCMS m / z=539.3[M+H] +
[0815] 1 H NMR (400MHz, CDCl3) δ8.96–8.72(m,1H),8.61(s,1H),7.92(d,1H),7.80–7.76(m,1H ),7.73–7.64(m,2H),7.47–7.36(m,1H),6.01–5.93(m,1H),5.73–5.65(m,1H),4.73 –4.54(m,2H),3.58–3.42(m,2H),3.27–3.13(m,5H),2.90–2.52(m,8H),2.51–2.42( m,1H),2.32–2.20(m,1H),1.91–1.78(m,1H),1.71–1.48(m,3H),1.39–1.28(m,9H).
[0816] Example 44: Preparation of Compound 44
[0817] Referring to the synthetic method of Example 34, the target compound 44 (71 mg) was obtained.
[0818] LCMS m / z=519.4[M+H] +
[0819] 1 H NMR(400MHz,DMSO-d6)δ8.37(t,1H),7.85–7.73(m,1H),7.41–7.30(m,2H),7.23–7.14(m, 1H),6.57(s,1H),6.44–6.33(m,2H),4.26–4.20(m,1H),3.44(t,2H),3.19(s,3H),2.88–2 .77(m,2H),2.76–2.64(m,3H),2.63–2.54(m,1H),2.46(d,2H),2.04–1.92(m,1H),1.92–1 .81(m,1H),1.66–1.53(m,2H),1.53–1.40(m,2H),1.29(s,3H),0.63(t,2H),0.60(t,2H).
[0820] Example 45: Preparation of Compound 45
[0821] Referring to the synthetic method of Example 32, the target compound 45 (30 mg) was obtained.
[0822] LCMS m / z=579.3[M+H] +
[0823] 1 H NMR (400MHz, DMSO-d6) δ8.44(s,1H),8.39(s,1H),8.26–8.21(m,1H),7.80–7.75(m,1H),7.71–7.68(m,1H),7.54–7.49( m,1H),6.61(d,1H),6.00(d,1H),5.90(d,1H),5.01–4.97(m,1H),4.70(s,1H),3.89–3.83(m,1H),3.83–3.77(m,1H),3. 77–3.69(m,2H),3.43–3.38(m,2H),3.13(s,3H),2.86–2.73(m,2H),2.72–2.59(m,3H),2.44–2.32(m,3H),2.26–2.15(m ,1H),2.15–2.05(m,1H),2.04–1.89(m,2H),1.60–1.51(m,2H),1.50–1.38(m,2H),0.68–0.62(m,2H),0.41–0.36(m,2H).
[0824] Example 46: Preparation of Compound 46
[0825] Referring to the synthetic method of Example 32, the target compound 46 (35 mg) was obtained.
[0826] LCMS m / z=567.2[M+H] +
[0827] 1H NMR (400MHz, DMSO-d6) δ8.44(s,1H),8.39(s,1H),8.26–8.21(m,1H),7.81–7.75(m,1H),7.73–7.67(m,1H),7.56–7.49(m ,1H),6.23(s,1H),5.91(d,1H),5.69(d,1H),4.96–4.90(m,1H),4.70(s,1H),3.87–3.81(m,2H),3.81–3.77(m,1H),3.77– 3.68(m,3H),3.45–3.39(m,2H),3.21–3.15(m,2H),3.14(s,3H),2.89–2.75(m,2H),2.75–2.61(m,3H),2.37(t,2H),2.23– 2.12(m,1H),2.12–2.05(m,1H),2.05–1.96(m,1H),1.96–1.87(m,1H),1.63–1.51(m,2H),1.51–1.38(m,2H),1.08(t,3H).
[0828] Example 47: Preparation of Compound 47
[0829] Referring to the synthetic method of Example 28, compound 47 (35 mg) was obtained.
[0830] LCMS m / z=563.3[M+H] +
[0831] 1 H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.39(s,1H),8.24(d,1H),7.81–7.74(t,1H),7.72–7.67(m,1H),7.5 7–7.49(m,1H),6.57(s,1H),5.92(s,1H),5.84(s,1H),4.73–4.63(m,2H),3.43–3.40(m,2H),3.14(s,3H) ,2.86–2.77(m,2H),2.72–2.62(m,3H),2.57–2.52(m,1H),2.41–2.34(m,5H),2.10–1.96(m,4H),1.79–1. 72(m,1H),1.67–1.59(m,1H),1.58–1.51(m,2H),1.49–1.41(m,2H),0.68–0.62(m,2H),0.40–0.34(m,2H).
[0832] Example 48: Preparation of Compound 48
[0833] Referring to the synthetic method of Example 28, Compound 48 (41 mg) was obtained.
[0834] LCMS m / z=551.3[M+H] +
[0835] 1 H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.40(s,1H),8.24(d,1H),7.81–7.75(m,1H),7.72–7.66(m,1H),7.57– 7.49(m,1H),6.23–6.16(m,1H),5.89–5.81(m,1H),5.66–5.59(m,1H),4.74–4.65(m,1H),4.65–4.56(m,1H), 3.42(t,2H),3.17–3.12(m,5H),2.85–2.76(m,2H),2.72–2.63(m,3H),2.58–2.53(m,1H),2.40–2.32(m,4H), 2.12–1.93(m,4H),1.79–1.70(m,1H),1.68–1.59(m,1H),1.59–1.52(m,2H),1.49–1.40(m,2H),1.08(t,3H).
[0836] Example 49: Preparation of Compound 49
[0837] Step 1: Preparation of 49B
[0838] Referring to the first step of the synthesis method of Example 16, 49B (4.71 g) was obtained.
[0839] LCMS m / z=322.9[M+H] +
[0840] Step 2: Preparation of 49C
[0841] 49B (2.3 g, 7.14 mmol), ethylamine hydrochloride (1.16 g, 14.23 mmol), potassium carbonate (4.93 g, 35.67 mmol), and potassium iodide (0.12 g, 0.72 mmol) were added to DMSO (25 mL) and reacted at 120°C for 4 days. The mixture was cooled to room temperature, and water (50 mL) was added. The mixture was extracted with ethyl acetate (50 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 0-5%) to afford 49C (1.1 g, 54% yield).
[0842] LCMS m / z=286.1[M+H] +
[0843] Step 3: Preparation of 49D
[0844] Referring to the first step of the synthesis method of Example 4, 49D (1.36 g) was obtained.
[0845] LCMS m / z=386.1[M+H] +
[0846] Step 4: Preparation of 49E
[0847] Referring to the second step of the synthesis method of Example 4, 49E (1.2 g) was obtained.
[0848] LCMS m / z=408.2[M+H] +
[0849] Step 5: Preparation of 49F
[0850] Referring to the third step of the synthesis method of Example 4, 49F (1.2 g) was obtained.
[0851] LCMS m / z=394.2[M+H] +
[0852] Step 6: Preparation of 49G
[0853] Referring to the fourth step of the synthesis method of Example 4, 49G (1.9 g) was obtained.
[0854] LCMS m / z=451.4[M+H] +
[0855] Step 7: Preparation of 49H
[0856] Referring to the fifth step of the synthesis method of Example 6, 49H (1.2 g) was obtained.
[0857] LCMS m / z=337.3[M+H] +
[0858] Step 8: Preparation of 49I
[0859] Referring to the fourth step of the synthesis method of Example 1, 49I (410 mg) was obtained.
[0860] LCMS m / z=552.4[M+H] +
[0861] Step 9: Preparation of 49J
[0862] Referring to the fifth step of the synthesis method of Example 1, 49J (580 mg) was obtained.
[0863] LCMS m / z=580.3[M+H] +
[0864] Step 10: Preparation of compound 49
[0865] Referring to the second step synthesis method of Example 15, compound 49 (20 mg) was obtained.
[0866] LCMS m / z=566.3[M+H] +
[0867] 1 H NMR(400MHz,DMSO-d6)δ8.42(s,1H),8.28(d,1H),8.17(d,1H),7.80–7.73(m,1H),7.68(d,1H),7.63– 7.43(m,2H),6.13(s,1H),5.68–5.61(m,1H),4.69–4.61(m,1H),3.70–3.63(m,4H),3.38(t,2H),3.31– 3.22(m,4H),3.20–3.13(m,2H),3.11(s,3H),2.78–2.67(m,2H),2.64–2.53(m,3H),2.52–2.51(m,1H), 2.43(t,2H),2.16–1.98(m,2H),1.76–1.65(m,1H),1.61–1.50(m,1H),1.47–1.34(m,2H),1.11(t,3H).
[0868] Example 50: Preparation of Compound 50
[0869] Referring to the synthetic method of Example 15, compound 50 (30 mg) was obtained.
[0870] LCMS m / z=533.4[M+H] +
[0871] 1 H NMR (400MHz, CDCl3) δ8.50–8.24(m,1H),6.91–6.84(m,1H),6.16–6.09(m,1H),6.05–5.99(m,1 H),4.71–4.59(m,1H),4.27–4.18(m,1H),3.57–3.44(m,2H),3.32(s,3H),2.86–2.51(m,8H),2 .49–2.40(m,1H),2.28–2.10(m,2H),2.02–1.94(m,1H),1.93–1.83(m,2H),1.81–1.71(m,3H), 1.68–1.55(m,3H),1.53–1.34(m,9H),1.32–1.20(m,3H),0.84–0.75(m,2H),0.70–0.59(m,2H).
[0872] Example 51: Preparation of Compound 51
[0873] Referring to the synthetic method of Example 15, compound 51 (50 mg) was obtained.
[0874] LCMS m / z=563.3[M+H] +
[0875] 1 H NMR(400MHz, CDCl3)δ9.31–9.16(m,1H),8.14–7.94(m,2H),7.00–6.92(m,1H),6.92–6.81 (m,1H),6.16–6.12(m,1H),6.06–6.01(m,1H),4.70–4.62(m,1H),4.53–4.46(m,1H),3.53– 3.41(m,2H),3.25(s,3H),2.87–2.30(m,10H),2.20–2.11(m,1H),1.83–1.74(m,1H),1.72 –1.56(m,2H),1.53–1.43(m,1H),1.42–1.36(m,6H),0.84–0.77(m,2H),0.71–0.64(m,2H).
[0876] Example 52: Preparation of Compound 52
[0877] Referring to the synthetic method of Example 15, compound 52 (250 mg) was obtained.
[0878] LCMS m / z=609.3[M+H] +
[0879] 1 H NMR (400MHz, CDCl3) δ8.67–8.33(m,1H),7.50–7.41(m,2H),7.32(t,2H),7.23–7.16(m,1H),6 .92–6.82(m,1H),6.11–6.07(m,1H),6.02–5.97(m,1H),4.70–4.58(m,1H),4.20–4.11(m,1H) ,3.45–3.34(m,2H),3.27(s,3H),2.72–2.40(m,9H),2.38–2.29(m,2H),2.15–1.98(m,2H),1. 96–1.83(m,2H),1.72–1.49(m,8H),1.46–1.31(m,8H),0.83–0.74(m,2H),0.66–0.58(m,2H).
[0880] Example 53: Preparation of Compound 53
[0881] Referring to the synthetic method of Example 15, compound 53 (50 mg) was obtained.
[0882] LCMS m / z=545.3[M+H] +
[0883] 1 H NMR(400MHz, CDCl3)δ8.65–8.29(m,1H),6.84–6.75(m,1H),6.13(s,1H),6.02 (s,1H),4.71–4.59(m,1H),4.28–4.16(m,1H),3.58–3.45(m,2H),3.32(s,3H) ,2.94–2.40(m,10H),2.30–2.12(m,5H),2.05–1.86(m,5H),1.83–1.70(m,3H) ,1.68–1.44(m,3H),1.42–1.35(m,6H),0.85–0.73(m,2H),0.69–0.54(m,2H).
[0884] Example 54: Preparation of Compound 54
[0885] Referring to the synthetic method of Example 36, compound 54 (20 mg) was obtained.
[0886] LCMS m / z=537.3[M+H] +
[0887] 1 H NMR (400MHz, CDCl3) δ8.64–8.58(m,1H),8.52–8.21(m,1H),7.98–7.90(m,1H),7.82–7.73( m,1H),7.73–7.62(m,2H),7.48–7.38(m,1H),6.15–6.09(m,1H),6.07–6.02(m,1H),4.70–4. 56(m,1H),3.87(s,3H),3.60–3.45(m,2H),3.26(s,3H),2.97–2.55(m,8H),2.50–2.37(m,1H ),2.28–2.16(m,1H),1.87–1.52(m,4H),1.40(s,3H),0.94–0.82(m,2H),0.74–0.65(m,2H).
[0888] Example 55: Preparation of Compound 55
[0889] Step 1: Preparation of 55B
[0890] 17I (300 mg, 0.56 mmol) was added to a solution of hydrogen chloride in 1,4-dioxane (10 mL, 4 mol / L). The mixture was reacted at room temperature for 2 hours, concentrated under reduced pressure, and the concentrate was added to dichloromethane (30 mL). 55A (99 mg, 0.67 mmol) and DIPEA (360 mg, 2.79 mmol) were then added and stirred at room temperature for 12 hours. Water (50 mL) was added and the mixture was extracted with dichloromethane (50 mL x 2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain crude product 55B (300 mg).
[0891] LCMS m / z=548.4[M+H] +
[0892] Step 2: Preparation of compound 55
[0893] Referring to the second step synthesis method of Example 15, compound 55 (30 mg) was obtained.
[0894] LCMS m / z=534.3[M+H] +
[0895] 1H NMR(400MHz,CF3COOD)δ6.41–6.36(m,1H),6.33–6.28(m,1H),4.93–4.84(m,1H),4.81–4.68(m,1H),3.91–3.52(m,10H),3.51 –3.34(m,5H),2.80–2.70(m,2H),2.66–2.52(m,3H),1.98–1.74(m,10H),1.42(d,,6H),1.02–0.90(m,2H),0.74–0.64(m,2H).
[0896] Example 56: Preparation of Compound 56
[0897] Referring to the synthetic method of compound 39, compound 56 (28 mg) was obtained.
[0898] LCMS m / z=565.3[M+H] +
[0899] 1 H NMR(400MHz,Chloroform-d)δ8.90(s,1H),8.61(s,1H),8.00–7.89(m,1H),7.84–7.76(m ,1H),7.75–7.65(m,2H),7.47–7.38(m,1H),6.04–5.92(m,1H),5.77–5.63(m,1H),4.87–4 .76(m,1H),4.73–4.66(m,1H),3.58–3.44(m,2H),3.31–3.13(m,5H),2.96–2.42(m,9H), 2.35–2.21(m,1H),2.05–1.76(m,7H),1.75–1.60(m,4H),1.59–1.47(m,1H),1.32(t,3H).
[0900] Example 57: Preparation of Compound 57
[0901] Referring to the synthetic method of compound 39, compound 57 (36 mg) was obtained.
[0902] LCMS m / z=579.3[M+H] +
[0903] 1H NMR(400MHz,Chloroform-d)δ8.85(s,1H),8.62(s,1H),8.01–7.88(m,1H),7.85–7.75(m, 1H),7.75–7.64(m,2H),7.48–7.39(m,1H),6.05–5.90(m,1H),5.79–5.63(m,1H),4.74–4.6 2(m,1H),4.40–4.30(m,1H),3.61–3.42(m,2H),3.35–3.13(m,5H),2.99–2.80(m,2H),2.79 –2.41(m,7H),2.38–2.17(m,1H),2.12–1.75(m,5H),1.75–1.51(m,6H),1.49–1.20(m,6H).
[0904] Example 58: Preparation of Compound 58
[0905] Referring to the synthetic method of compound 39, compound 58 (52 mg) was obtained.
[0906] LCMS m / z=577.3[M+H] +
[0907] 1 H NMR(400MHz,Chloroform-d)δ9.08(s,1H),8.62(s,1H),7.99–7.87(m,1H),7.85–7.75(m,1H),7.7 4–7.60(m,2H),7.50–7.38(m,1H),6.19–6.09(m,1H),6.08–5.99(m,1H),4.91–4.80(m,1H),4.74–4 .60(m,1H),3.55–3.44(m,2H),3.25(s,3H),3.03–2.53(m,8H),2.52–2.41(m,2H),2.34–2.20(m,1 H),2.09–1.76(m,7H),1.75–1.60(m,4H),1.60–1.45(m,1H),0.93–0.76(m,2H),0.74–0.60(m,2H).
[0908] Example 59: Preparation of Compound 59
[0909] Referring to the synthesis method of compound 39, compound 59 (25 mg) was obtained.
[0910] LCMS m / z=591.3[M+H]+
[0911] 1 H NMR(400MHz,Chloroform-d)δ8.93(s,1H),8.61(s,1H),8.02–7.88(m,1H),7.85–7.76(m,1H), 7.74–7.61(m,2H),7.50–7.37(m,1H),6.18–6.11(m,1H),6.09–6.00(m,1H),4. 75–4.63(m,1H),4.45–4.32(m,1H),3.61–3.43(m,2H),3.25(s,3H),3.01–2.54( m,8H),2.51–2.37(m,2H),2.34–2.16(m,1H),2.06–1.93(m,2H),1.91–1.76(m,3 H),1.75–1.48(m,6H),1.47–1.29(m,3H),0.92–0.75(m,2H),0.73–0.60(m,2H).
[0912] Example 60: Preparation of Compound 60
[0913] Referring to the synthetic method of Example 36, compound 60 (20 mg) was obtained.
[0914] LCMS m / z=565.3[M+H] +
[0915] 1 H NMR(400MHz, CDCl3)δ9.09–8.79(m,1H),8.61(s,1H),7.94(d,1H),7.81–7.76(m, 1H),7.72–7.64(m,2H),7.46–7.39(m,1H),6.15–6.08(m,1H),6.03–5.98(m,1H),4 .72–4.57(m,2H),3.60–3.42(m,2H),3.25(s,3H),2.89–2.38(m,9H),2.30–2.18(m ,1H),1.88–1.50(m,4H),1.43–1.36(m,9H),0.94–0.84(m,2H),0.75–0.66(m,2H).
[0916] Example 61: Preparation of Compound 61
[0917] Referring to the synthetic method of Example 15, compound 61 (50 mg) was obtained.
[0918] LCMS m / z=523.3[M+H] +
[0919] 1 H NMR (400MHz, CDCl3) δ7.01–6.64(m,2H),6.05–6.00(m,1H),5.84–5.78(m,1 H),4.22–4.09(m,1H),3.81(s,3H),3.66–3.49(m,4H),3.44–3.27(m,8H),3 .10–2.98(m,1H),2.92–2.69(m,5H),2.67–2.51(m,2H),2.28–2.09(m,2H), 2.01–1.83(m,3H),1.79–1.54(m,7H),1.51–1.37(m,2H),1.34–1.19(m,3H).
[0920] Example 62: Preparation of Compound 62
[0921] Referring to the synthetic method of Example 15, compound 62 (30 mg) was obtained.
[0922] LCMS m / z=553.2[M+H] +
[0923] 1 H NMR (400MHz, CDCl3) δ8.36–7.97(m,3H),6.99–6.92(m,1H),6.89–6.80(m,1H),6.08–5.96(m,1H),5 .91–5.80(m,1H),4.51–4.38(m,1H),3.83(s,3H),3.65–3.59(m,2H),3.56–3.47(m,2H),3.43–3.35 (m,5H),3.27(s,3H),2.99–2.89(m,1H),2.83–2.73(m,4H),2.69–2.55(m,3H),2.40–2.30(m,1H),2.18–2.08(m,1H),1.83–1.49(m,4H).
[0924] Example 63: Preparation of Compound 63
[0925] Referring to the synthetic method of Example 15, compound 63 (30 mg) was obtained.
[0926] LCMS m / z=535.3[M+H] +
[0927] 1 H NMR (400MHz, CDCl3) δ7.08–6.77(m,2H),6.03(m,1H),5.81(m,1H),4.19–4.11(m,1H),3.81(s,3H),3.63–3.48(m,4H),3.45–3.36(m, 5H),3.33(s,3H),3.09–2.97(m,1H),2.91–2.68(m,6H),2.66–2.52(m,2H),2.28–2.12(m,5H),2.05–1.85(m,5H),1.82–1.53(m,6H).
[0928] Example 64: Preparation of Compound 64
[0929] Referring to the synthetic method of Example 55, compound 64 (40 mg) was obtained.
[0930] LCMS m / z=524.3[M+H] +
[0931] 1 H NMR (400MHz, CDCl3) δ6.14–5.84(m,3H),5.77(d,1H),4.12–4.04(m,1H),3.79(s,3H),3.70–3.53(m,4H),3.47–3.27(m,1 2H),3.22–3.10(m,1H),3.02–2.71(m,5H),2.64–2.50(m,2H),2.29–2.18(m,1H),2.01–1.88(m,1H),1.81–1.44(m,10H).
[0932] Example 65: Preparation of Compound 65
[0933] Referring to the synthetic method of Example 55, compound 65 (30 mg) was obtained.
[0934] LCMS m / z=506.3[M+H] +
[0935] 1H NMR(400MHz, CDCl3)δ7.05–6.72(m,1H),6.16–6.11(m,1H),6.09–5.98(m,2H),4 .18–4.02(m,1H),3.84(s,3H),3.70–3.52(m,2H),3.43–3.25(m,7H),3.12–3.00( m,1H),2.94–2.70(m,5H),2.67–2.53(m,2H),2.51–2.39(m,1H),2.29–2.19(m,1 H),2.04–1.89(m,1H),1.81–1.46(m,10H),0.82–0.72(m,2H),0.65–0.54(m,2H).
[0936] Example 66: Preparation of Compound 66
[0937] Referring to the synthetic method of Example 15, compound 66 (30 mg) was obtained.
[0938] LCMS m / z=599.3[M+H] +
[0939] 1 H NMR(400MHz, CDCl3)δ7.46–7.40(m,2H),7.31(t,2H),7.23–7.14(m,1H),7.00–6.92(m,1H), 6.05–5.97(m,1H),5.82–5.76(m,1H),4.15–4.04(m,1H),3.81(s,3H),3.63–3.43(m,4H),3.41–3.33(m,5H),3.29(s,3H),2.96– 2.49(m,8H),2.41–2.28(m,2H),2.15–2.07(m,1H),2.06–1.96(m,1H),1.94–1.79(m,2H),1.73–1.49(m,9H),1.40–1.28(m,1H).
[0940] Example 67: Preparation of Compound 67
[0941] Referring to the synthetic method of Example 49, compound 67 (10 mg) was obtained.
[0942] LCMS m / z=578.3[M+H] +
[0943] 1H NMR(400MHz,DMSO-d6)δ8.41(s,1H),8.23(s,1H),8.15(d,1H),7.77–7.72(m,1H),7.73–7.62(m,2H),7 .53–7.47(m,1H),6.17–6.11(m,1H),5.91–5.83(m,1H),4.59–4.55(m,1H),3.70–3.66(m,4H),3.35(t,2 H),3.28–3.23(m,4H),3.10(s,3H),2.72–2.63(m,2H),2.58–2.51(m,3H),2.46–2.37(m,4H),2.11–1.98 (m,2H),1.70–1.60(m,1H),1.59–1.51(m,1H),1.43–1.34(m,2H),0.70–0.64(m,2H),0.44–0.37(m,2H).
[0944] Example 68: Preparation of Compound 68
[0945] Referring to the synthetic method of Example 15, compound 68 (75 mg) was obtained.
[0946] LCMS m / z=565.4[M+H] +
[0947] 1 H NMR(400MHz,DMSO-d6)δ7.45(d,1H),7.40–7.34(m,2H),7.29(t,2H),7.18(t,1H),6. 52–6.46(m,1H),6.27(s,2H),4.07–4.02(m,1H),3.37(t,2H),3.19(s,3H),2.76–2.5 4(m,5H),2.43(t,4H),2.37–2.29(m,2H),2.16(s,3H),1.83–1.61(m,4H),1.60–1.49 (m,6H),1.48–1.33(m,3H),1.31–1.22(m,1H),0.70–0.63(m,2H),0.42–0.35(m,2H).
[0948] Example 69: Preparation of Compound 69
[0949] Referring to the synthetic method of Example 15, compound 69 (30 mg) was obtained.
[0950] LCMS m / z=519.4[M+H]+
[0951] 1 H NMR (400MHz, CDCl3) δ8.39–8.00(m,1H),6.92–6.86(m,1H),6.16–6.12(m,1H),6.07– 6.04(m,1H),4.26–4.17(m,1H),4.15–4.06(m,2H),3.60–3.48(m,2H),3.31(s,3H),2 .97–2.52(m,8H),2.50–2.41(m,1H),2.26–2.10(m,2H),2.02–1.83(m,3H),1.81–1.5 9(m,6H),1.56–1.39(m,6H),1.33–1.18(m,3H),0.84–0.74(m,2H),0.70–0.58(m,2H).
[0952] Example 70: Preparation of Compound 70
[0953] Referring to the synthetic method of Example 15, compound 70 (50 mg) was obtained.
[0954] LCMS m / z=549.3[M+H] +
[0955] 1 H NMR (400MHz, CDCl3) δ9.29–8.94(m,1H),8.14–7.98(m,2H),7.01–6.92(m,1H),6.90–6.80(m,1 H),6.17–6.12(m,1H),6.08–6.03(m,1H),4.55–4.44(m,1H),4.17–4.08(m,2H),3.50–3.39(m, 2H),3.25(s,3H),2.84–2.57(m,7H),2.52–2.41(m,2H),2.41–2.31(m,1H),2.20–2.11(m,1H), 1.85–1.73(m,1H),1.70–1.52(m,2H),1.49–1.38(m,4H),0.86–0.77(m,2H),0.70–0.61(m,2H).
[0956] Example 71: Preparation of Compound 71
[0957] Referring to the synthetic method of Example 15, compound 71 (60 mg) was obtained.
[0958] LCMS m / z=595.4[M+H] +
[0959] 1 H NMR(400MHz, CDCl3)δ8.50–8.16(m,1H),7.48–7.41(m,2H),7.32(t,2H),7.22– 7.17(m,1H),6.92–6.86(m,1H),6.12–6.08(m,1H),6.05–6.00(m,1H),4.17–4.0 8(m,3H),3.47–3.36(m,2H),3.27(s,3H),2.75–2.27(m,11H),2.15–1.97(m,2H ),1.97–1.82(m,2H),1.71–1.30(m,13H),0.84–0.73(m,2H),0.66–0.54(m,2H).
[0960] Example 72: Preparation of Compound 72
[0961] Referring to the synthetic method of Example 15, compound 72 (50 mg) was obtained.
[0962] LCMS m / z=531.4[M+H] +
[0963] 1 H NMR (400MHz, CDCl3) δ8.39–8.14(m,1H),6.81(d,1H),6.16–6.12(m,1H),6.07–6.03(m,1 H),4.26–4.19(m,1H),4.17–4.06(m,2H),3.57–3.46(m,2H),3.32(s,3H),2.93–2.81(m, 2H),2.79–2.52(m,7H),2.47–2.42(m,1H),2.27–2.11(m,5H),2.05–1.88(m,5H),1.83–1 .71(m,3H),1.67–1.55(m,2H),1.54–1.40(m,4H),0.83–0.74(m,2H),0.69–0.58(m,2H).
[0964] Example 73: Preparation of Compound 73
[0965] Referring to the synthetic method of Example 55, compound 73 (30 mg) was obtained.
[0966] LCMS m / z=520.4[M+H]+
[0967] 1 H NMR (400MHz, CDCl3) δ7.21–6.98(m,1H),6.15–6.10(m,1H),6.08–5.97(m,2H),4 .16–4.03(m,3H),3.68–3.51(m,2H),3.41–3.26(m,7H),3.08–2.96(m,1H),2.89– 2.68(m,5H),2.64–2.51(m,2H),2.49–2.40(m,1H),2.28–2.18(m,1H),2.00–1.8 8(m,1H),1.78–1.49(m,10H),1.43(t,3H),0.82–0.72(m,2H),0.66–0.54(m,2H).
[0968] Example 74: Preparation of Compound 74
[0969] Step 1: Preparation of 74C
[0970] Referring to the first step of the synthesis method of Example 16, 74C (9.5 g) was obtained.
[0971] LCMS m / z=329.9[M+H] +
[0972] Steps 2 to 5: Compound 74G (1.5 g) was obtained by following the synthetic method of steps 1 to 4 of Example 31.
[0973] LCMS m / z=470.3[M+H] +
[0974] Step 6: Preparation of 74H
[0975] Compound 74G (1.4 g, 2.98 mmol) was dissolved in DCM (10 mL), TFA (10 mL) was added, and the mixture was reacted at room temperature for 3 h. The reaction was concentrated, and saturated sodium bicarbonate solution (30 mL) was added. The mixture was extracted with dichloromethane (30 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 74H (1 g, yield: 91%).
[0976] LCMS m / z=370.2[M+H] +
[0977] Step 7: Preparation of 74I
[0978] Compound 74H (1 g, 2.71 mmol) was added to anhydrous 1,4-dioxane (50 mL). Under a nitrogen atmosphere, a solution of lithium aluminum hydride in tetrahydrofuran (2.5 mL, 2.5 mol / L) was slowly added, and the mixture was stirred at 100°C for 3 hours. After cooling to room temperature, water (0.5 mL) was added, the mixture was filtered through celite, and concentrated to afford compound 74I (450 mg, yield: 47%).
[0979] LCMS m / z=356.1[M+H] +
[0980] Steps 8 to 10 were prepared by following the synthetic method of steps 7 to 9 of Example 18 to obtain compound 74 (5 mg).
[0981] LCMS m / z=585.2[M+H] +
[0982] 1 H NMR (400MHz, DMSO-d6) δ8.44(s,1H),8.38(s,1H),8.23(d,1H),7.82–7.72(m,1H),7.72–7.65(m,1H),7.57–7.48( m,1H),7.48–7.39(m,2H),7.27–7.18(m,1H),7.14–7.07(m,2H),6.68(d,1H),5.96(d,1H),5.90(d,1H),4.77–4.6 4(m,1H),3.40(t,2H),3.13(s,3H),2.87–2.73(m,2H),2.73–2.58(m,3H),2.55–2.46(m,1H),2.43–2.29(m,3H),2 .17–2.03(m,1H),2.03–1.91(m,1H),1.63–1.49(m,2H),1.49–1.35(m,2H),0.63–0.51(m,2H),0.41–0.27(m,2H).
[0983] Example 75: Preparation of Compound 75
[0984] Compound 74C was used as the starting material to obtain compound 75 (50 mg) by following the second to tenth steps of the synthesis method of Example 74.
[0985] LCMS m / z=573.2[M+H] +
[0986] 1H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.40(s,1H),8.24(d,1H),7.80–7.74(m,1H),7.69(d,1H),7.55–7.49(m, 1H),7.46–7.38(m,2H),7.25–7.18(m,1H),7.11–7.05(m,2H),6.36–6.28(m,1H),5.93(d,1H),5.64(d,1H),4. 78–4.64(m,1H),3.46–3.36(m,2H),3.23–3.07(m,5H),2.90–2.74(m,2H),2.73–2.61(m,3H),2.60–2.51(m,1H ),2.46–2.32(m,2H),2.17–2.04(m,1H),2.04–1.92(m,1H),1.62–1.50(m,2H),1.50–1.36(m,2H),1.05(t,3H).
[0987] Example 76: Preparation of Compound 76
[0988] Step 1: Preparation of 76C
[0989] Referring to the first step of the synthesis method of Example 16, 76C (11 g) was obtained.
[0990] LCMS m / z=344.0[M+H] +
[0991] Step 2: Preparation of 76D
[0992] Compound 76C (5 g, 14.58 mmol), ethylamine hydrochloride (1.78 g, 21.83 mmol), potassium carbonate (10.08 g, 72.9 mmol), and potassium iodide (0.24 g, 1.45 mmol) were added to DMSO (50 mL), reacted at 130°C overnight, cooled to room temperature, added with water (50 mL), extracted with ethyl acetate (50 mL × 3), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (mobile phase: petroleum ether / ethyl acetate (v / v) = 0-20%) to give 76D (1.5 g, 33%).
[0993] LCMS m / z=307.1[M+H] +
[0994] Steps 3 to 10: Compound 76 (6 mg) was obtained by the synthesis method of Steps 3 to 10 of Example 74.
[0995] LCMS m / z=587.3[M+H] +
[0996] 1 H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.40(s,1H),8.24(d,1H),7.80–7.73(m,1H),7.72–7.66(m,1H),7.5 6–7.49(m,1H),7.44–7.29(m,5H),6.32–6.18(m,1H),6.02(d,1H),5.81(d,1H),5.04(s,2H),4.76–4.66( m,1H),3.50–3.37(m,2H),3.25–3.08(m,5H),2.91–2.75(m,2H),2.74–2.62(m,3H),2.62–2.52(m,1H),2. 43–2.33(m,2H),2.16–2.05(m,1H),2.05–1.93(m,1H),1.65–1.51(m,2H),1.51–1.36(m,2H),1.08(t,3H).
[0997] Example 77: Preparation of Compound 77
[0998] Compound 76C was used as the starting material to obtain compound 77 (5 mg) by following the second to tenth steps of Example 76.
[0999] LCMS m / z=599.3[M+H] +
[1000] 1H NMR(400MHz,DMSO-d6)δ8.28(s,1H),8.23(s,1H),8.07(d,1H),7.64–7.56(m,1H),7.53(d,1H),7.41–7.31 (m,1H),7.29–7.12(m,5H),6.49(s,1H),5.96(d,1H),5.86(d,1H),4.92(s,2H),4.64–4.45(m,1H),3.35–3. 20(m,2H),2.97(s,3H),2.76–2.59(m,2H),2.59–2.43(m,3H),2.43–2.36(m,1H),2.25–2.12(m,3H),2.02–1 .90(m,1H),1.90–1.77(m,1H),1.53–1.34(m,2H),1.34–1.18(m,2H),0.54–0.39(m,2H),0.33–0.16(m,2H).
[1001] Example 78: Preparation of Compound 78
[1002] Step 1 to Step 2 The synthetic method of compound 35 from Step 1 to Step 2 was followed to obtain 78C (7.5 g).
[1003] LCMS m / z=293.0[M-55] +
[1004] Step 3: Preparation of 78D
[1005] Zinc powder (3.06 g, 46.80 mmol) was added to DMA (100 mL). 1.2-Dibromoethane (700 mg, 3.73 mmol) and trimethylsilyl chloride (410 mg, 3.77 mmol) were slowly added under a nitrogen atmosphere. The mixture was stirred at room temperature for 0.5 h, followed by the addition of 7E (5.47 g, 28.04 mmol) and continued stirring at 30°C for 2 h. 78C (6.5 g, 18.70 mmol), cuprous iodide (710 mg, 3.73 mmol), and 1,1-bis(diphenylphosphino)ferrocenepalladium dichloride (1.37 g, 1.87 mmol) were added to the reaction solution under a nitrogen atmosphere, and the temperature was raised to 90°C and allowed to react overnight. The reaction mixture was cooled to room temperature, and water (100 mL) was added. The mixture was extracted with ethyl acetate (30 mL × 3). The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (mobile phase: ethyl acetate / petroleum ether (V / V) = 0-33%) to give 78D (6.1 g, yield: 85%).
[1006] LCMS m / z=383.2[M+H]+
[1007] Step 4 to Step 8: Referring to the synthesis method of step 4 to step 8 of compound 35, compound 78 (0.14 g) was obtained.
[1008] LCMS m / z=527.3[M+H] +
[1009] 1 H NMR (400MHz, DMSO-d6) δ8.50–8.34(m,2H),8.31–8.19(m,1H),7.83–7.75(m,1H),7.73–7.66(m ,1H),7.57–7.49(m,1H),7.39–7.32(m,1H),6.38–6.32(m,1H),6.32–6.27(m,1H),4.80–4.62(m ,1H),3.49–3.35(m,2H),3.13(s,3H),2.91–2.61(m,6H),2.58–2.52(m,1H),2.49–2.44(m,2H), 2.15–1.94(m,2H),1.71–1.55(m,2H),1.53–1.37(m,2H),0.72–0.59(m,2H),0.55–0.41(m,2H).
[1010] Example 79: Preparation of Compound 79
[1011] Referring to the synthetic method of compound 78, compound 79 (40 mg) was obtained.
[1012] LCMS m / z=511.4[M+H] +
[1013] 1H NMR(400MHz,DMSO-d6)δ8.45(s,1H),8.42–8.36(m,1H),8.28–8.22(m,1H),7.82–7.75(m,1H ),7.73–7.66(m,1H),7.57–7.48(m,1H),7.24–7.15(m,1H),6.33–6.14(m,3H),4.75–4.65(m ,1H),3.52–3.38(m,4H),3.28–3.18(m,2H),3.14(s,3H),2.89–2.75(m,2H),2.73–2.62(m,3 H),2.59–2.52(m,2H),2.40(t,2H),2.17–1.93(m,2H),1.69–1.51(m,4H),1.50–1.36(m,2H).
[1014] Example 80: Preparation of Compound 80
[1015] Referring to the synthetic method of Example 34, the target compound 80 (95 mg) was obtained.
[1016] LCMS m / z=565.6[M+H] +
[1017] 1 H NMR(400MHz,DMSO-d6)δ7.45(d,1H),7.40–7.32(m,3H),7.31–7.26(m,2H),7.21–7.15(m,1H), 6.58(s,1H),6.42–6.33(m,2H),4.10–4.01(m,1H),3.36(t,2H),3.18(s,3H),2. 76–2.68(m,1H),2.68–2.63(m,1H),2.63–2.53(m,3H),2.49–2.43(m,2H),2.37– 2.28(m,2H),1.86–1.77(m,1H),1.77–1.60(m,3H),1.60–1.48(m,6H),1.48–1.3 4(m,3H),1.29(s,3H),1.28–1.19(m,1H),0.67–0.62(m,2H),0.62–0.57(m,2H).
[1018] Example 81: Preparation of Compound 81
[1019] Referring to the synthetic method of Example 34, the target compound 81 (109 mg) was obtained.
[1020] LCMS m / z=529.3[M+H] +
[1021] 1 H NMR (400MHz, DMSO-d6) δ8.41(t,1H),7.83–7.75(m,1H),7.38–7.33(m,1H),7.33–7.26(m,1H),7. 21–7.14(m,1H),6.77(t,1H),6.43–6.33(m,2H),6.25–5.92(m,2H),4.32–4.23(m,1H),3.73–3.6 0(m,2H),3.51–3.43(m,2H),3.20(s,3H),2.95–2.83(m,2H),2.82–2.70(m,3H),2.69–2.58(m,1H ),2.55–2.51(m,1H),2.05–1.95(m,1H),1.95–1.84(m,1H),1.68–1.57(m,2H),1.56–1.44(m,2H).
[1022] Example 82: Preparation of Compound 82
[1023] Referring to the synthetic method of Example 32, the target compound 82 (150 mg) was obtained.
[1024] LCMS m / z=579.6[M+H] +
[1025] 1H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.39(s,1H),8.26–8.20(m,1H),7.80–7.74(m,1H),7.71–7.67(m,1H),7.55–7.48(m,1H),6 .61(d,1H),6.00(d,1H),5.89(d,1H),5.02–4.96(m,1H),4.69(s,1H),3.89–3.83(m,1H),3.80(d,1H),3.78–3.74(m,1H),3.74– 3.68(m,2H),3.44–3.36(m,2H),3.13(s,3H),2.86–2.72(m,2H),2.72–2.59(m,3H),2.42–2.32(m,3H),2.25–2.14(m,1H),2.14– 2.04(m,1H),2.04–1.98(m,1H),1.97–1.88(m,1H),1.61–1.50(m,2H),1.49–1.36(m,2H),0.69–0.62(m,2H),0.42–0.35(m,2H).
[1026] Example 83: Preparation of Compound 83
[1027] Referring to the synthetic method of Example 34, the target compound 83 (102 mg) was obtained.
[1028] LCMS m / z=501.6[M+H] +
[1029] 1 H NMR (400MHz, DMSO-d6) δ7.49–7.22(m,2H),6.57(s,1H),6.38(t,2H),3.93–3.86(m,1H),3. 37–3.31(m,2H),3.20(s,3H),2.89–2.80(m,1H),2.60–2.52(m,1H),2.48–2.42(m,3H),2.4 2–2.34(m,2H),2.09–2.00(m,4H),2.00–1.93(m,2H),1.85–1.77(m,3H),1.77–1.68(m,3H) ,1.66–1.51(m,3H),1.43–1.33(m,2H),1.29(s,3H),0.67–0.62(m,2H),0.62–0.57(m,2H).
[1030] Example 84: Preparation of Compound 84
[1031] Step 1: Preparation of 84B
[1032] 19I (400 mg, 0.81 mmol) was added to a solution of hydrogen chloride in 1,4-dioxane (10 mL, 4 mol / L). The mixture was allowed to react at room temperature for 2 hours, then concentrated under reduced pressure. The concentrate was added to dichloromethane (30 mL), followed by 84A (120 mg, 0.81 mmol) and DIPEA (280 mg, 2.17 mmol). The mixture was stirred at room temperature for 4 hours. Water (50 mL) was added, and the mixture was extracted with dichloromethane (50 mL x 2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to afford crude product 84B (330 mg).
[1033] LCMS m / z=504.4[M+H] +
[1034] Step 2: Preparation of Compound 84
[1035] Referring to the second step synthesis method of Example 34, the target compound 84 (134 mg) was obtained.
[1036] LCMS m / z=490.6[M+H] +
[1037] 1 H NMR(400MHz,DMSO-d6)δ7.38–7.31(m,1H),6.61–6.52(m,2H),6.42–6.35(m,2H),4.01–3.93 (m,1H),3.41(t,2H),3.27–3.22(m,3H),3.22(s,3H),2.76–2.69(m,1H),2.69–2.62(m,2H), 2.61–2.54(m,2H),2.48–2.43(m,2H),1.89–1.78(m,1H),1.77–1.67(m,1H),1.65–1.56(m,2 H),1.56–1.48(m,2H),1.48–1.34(m,6H),1.29(s,3H),0.67–0.62(m,2H),0.62–0.57(m,2H).
[1038] Example 85: Preparation of Compound 85
[1039] Step 1: Preparation of 85A
[1040] Referring to the first step of the synthesis method of Example 11, a crude product of 85A (480 mg) was obtained.
[1041] LCMS m / z=503.3[M+H] +
[1042] Step 2: Preparation of Compound 85
[1043] The crude product of 85A (480 mg) and lithium hydroxide monohydrate (120 mg, 2.86 mmol) were added to a mixture of tetrahydrofuran / water / methanol (24 mL, V / V = 4 / 1 / 1) and stirred at room temperature for 2 hours. The mixture was concentrated under reduced pressure and purified by preparative liquid chromatography (Waters 2767 Preparative Liquid Chromatography; Xbridge Prep C18 5 μm 19*250 mm column); the mobile phase consisted of acetonitrile / water (containing 5 mmol / L ammonium bicarbonate) to afford compound 85 (45 mg).
[1044] LCMS m / z=489.4[M+H] +
[1045] 1 H NMR (400MHz, CDCl3) δ7.27–7.12(m,1H),6.90(d,1H),6.49(s,1H),6.29(s,1H),4.18–4.12(m ,1H),3.62–3.49(m,2H),3.30(s,3H),3.04–2.92(m,1H),2.85–2.67(m,5H),2.64–2.53(m,2H ),2.48–2.41(m,1H),2.27(s,3H),2.19–2.08(m,2H),2.00–1.91(m,1H),1.90–1.82(m,2H),1 .78–1.54(m,7H),1.49–1.37(m,2H),1.30–1.17(m,3H),0.81–0.72(m,2H),0.62–0.52(m,2H).
[1046] Example 86: Preparation of Compound 86
[1047] Referring to the synthetic method of Example 85, Compound 86 (43 mg) was obtained.
[1048] LCMS m / z=501.3[M+H] +
[1049] 1H NMR (400MHz, CDCl3) δ7.36–7.24(m,1H),6.86–6.74(m,1H),6.49(s,1H),6.28(s,1H),4.1 8–4.11(m,1H),3.61–3.48(m,2H),3.30(s,3H),3.02–2.91(m,1H),2.90–2.68(m,6H),2.63 –2.54(m,2H),2.47–2.40(m,1H),2.27(s,3H),2.21–2.09(m,5H),2.03–1.97(m,2H),1.96 –1.85(m,3H),1.81–1.73(m,2H),1.72–1.53(m,4H),0.81–0.71(m,2H),0.62–0.53(m,2H).
[1050] Example 87: Preparation of Compound 87
[1051] Step 1: Preparation of 87A
[1052] Referring to the first step of the synthesis method of Example 11, 87A (630 mg) was obtained.
[1053] LCMS m / z=504.3[M+H] +
[1054] Step 2: Preparation of Compound 87
[1055] Referring to the second step synthesis method of Example 85, compound 87 (120 mg) was obtained.
[1056] LCMS m / z=490.4[M+H] +
[1057] 1 H NMR(400MHz, CDCl3)δ6.46(s,1H),6.26(s,1H),6.21–6.11(m,1H),6.06(s,1H),4.11–4. 03(m,1H),3.70–3.53(m,2H),3.46–3.32(m,4H),3.32(s,3H),3.19–3.09(m,1H),2.97–2 .76(m,5H),2.64–2.51(m,2H),2.48–2.41(m,1H),2.26(s,3H),2.25–2.17(m,1H),1.96– 1.85(m,1H),1.78–1.61(m,4H),1.60–1.50(m,6H),0.79–0.72(m,2H),0.59–0.52(m,2H).
[1058] Example 88: Preparation of Compound 88
[1059] Referring to the synthetic method of Example 85, Compound 88 (168 mg) was obtained.
[1060] LCMS m / z=519.3[M+H] +
[1061] 1 H NMR (400MHz, CDCl3) δ8.29–7.93(m,3H),6.98–6.89(m,1H),6.89–6.81(m,1H),6.52(s,1H), 6.30(s,1H),4.49–4.41(m,1H),3.58–3.45(m,2H),3.26(s,3H),2.96–2.87(m,1H),2.82–2.73(m,4H),2.71–2.56(m,3H),2. 50–2.43(m,1H),2.37–2.31(m,1H),2.30(s,3H),2.19–2.07(m,1H),1.78–1.50(m,4H),0.86–0.74(m,2H),0.65–0.59(m,2H).
[1062] Example 89: Preparation of Compound 89
[1063] Referring to the synthetic method of Example 85, compound 89 (67 mg) was obtained.
[1064] LCMS m / z=493.4[M+H] +
[1065] 1 H NMR(400MHz, CDCl3)δ7.94(s,1H),6.88(d,1H),6.06–5.95(m,1H),5.78–5.62(m,1H ),4.26–4.16(m,1H),3.83(s,3H),3.57–3.45(m,2H),3.30(s,3H),3.24–3.14(m,2H ),2.88–2.79(m,1H),2.78–2.54(m,7H),2.21–2.08(m,2H),2.03–1.92(m,1H),1.91 –1.82(m,2H),1.79–1.69(m,3H),1.67–1.40(m,6H),1.28(t,3H),1.26–1.17(m,3H).
[1066] Example 90: Preparation of Compound 90
[1067] Referring to the synthetic method of Example 85, compound 90 (53 mg) was obtained.
[1068] LCMS m / z=569.4[M+H] +
[1069] 1 H NMR (400MHz, CDCl3) δ8.29–7.89(m,1H),7.50–7.39(m,2H),7.36–7.27(m,2H),7.23–7.1 1(m,1H),6.94–6.79(m,1H),5.99(s,1H),5.68(s,1H),4.21–4.09(m,1H),3.83(s,3H),3 .48–3.34(m,2H),3.27(s,3H),3.22–3.11(m,2H),2.76–2.57(m,5H),2.56–2.42(m,3H), 2.41–2.28(m,2H),2.11–1.87(m,4H),1.72–1.49(m,8H),1.46–1.32(m,2H),1.27(t,3H).
[1070] Example 91: Preparation of Compound 91
[1071] Referring to the synthetic method of Example 85, compound 91 (83 mg) was obtained.
[1072] LCMS m / z=505.4[M+H] +
[1073] 1 H NMR (400MHz, CDCl3) δ8.16–7.91(m,1H),6.80(d,1H),6.00(s,1H),5.70(s,1H ),4.26–4.16(m,1H),3.83(s,3H),3.55–3.47(m,2H),3.30(s,3H),3.23–3.16 (m,2H),2.91–2.81(m,2H),2.74–2.51(m,7H),2.25–2.11(m,5H),2.02–1.87( m,5H),1.80–1.71(m,3H),1.67–1.55(m,2H),1.53–1.46(m,1H),1.28(t,3H).
[1074] Example 92: Preparation of Compound 92
[1075] Referring to the synthetic method of Example 87, compound 92 (66 mg) was obtained.
[1076] LCMS m / z=494.4[M+H] +
[1077] 1 H NMR(400MHz, CDCl3)δ6.94(s,1H),6.08–5.99(m,1H),5.99–5.94(m,1H),5.70– 5.58(m,1H),4.15–4.07(m,1H),3.78(s,3H),3.62–3.49(m,2H),3.38–3.30(m,4 H),3.29(s,3H),3.17(s,2H),3.03–2.92(m,1H),2.85–2.68(m,5H),2.62–2.52 (m,2H),2.21–2.10(m,1H),1.99–1.88(m,1H),1.74–1.48(m,10H),1.24(t,3H).
[1078] Example 93: Preparation of Compound 93
[1079] Referring to the synthetic method of Example 85, compound 93 (70 mg) was obtained.
[1080] LCMS m / z=523.3[M+H] +
[1081] 1 H NMR (400MHz, CDCl3) δ9.06–8.54(m,1H),8.12–7.95(m,2H),7.03–6.89(m,1H ),6.89–6.77(m,1H),6.00(s,1H),5.71(s,1H),4.54–4.42(m,1H),3.85(s,3H ),3.49–3.40(m,2H),3.28–3.17(m,5H),2.80–2.59(m,7H),2.52–2.45(m,1H) ,2.34–2.25(m,1H),2.20–2.11(m,1H),1.79–1.47(m,4H),1.33–1.26(m,3H).
[1082] Example 94: Preparation of Compound 94
[1083] Step 1: Preparation of 94B
[1084] The first step of the synthesis method of Reference Example 16 was used to obtain 94B (7.2 g).
[1085] LCMS m / z=307.0[M+H] +
[1086] Step 2: Preparation of 94C
[1087] The second step synthesis method of Reference Example 49 was used to obtain 94C (1.1 g).
[1088] LCMS m / z=272.0[M+H] +
[1089] Step 3: Preparation of 94D
[1090] Referring to the first step of the synthesis method of Example 4, 94D (1.16 g) was obtained.
[1091] LCMS m / z=370.3[M+H] +
[1092] Step 4: Preparation of 94E
[1093] Referring to the second step synthesis method of Example 4, 94E (930 mg) was obtained.
[1094] LCMS m / z=406.2[M+H] +
[1095] Step 5: Preparation of 94F
[1096] Referring to the fourth step of the synthesis method of Example 7, 94F (1.3 g) was obtained.
[1097] LCMS m / z=335.2[M+H] +
[1098] Step 6: Preparation of 94G
[1099] Referring to the fifth step of the synthesis method of Example 7, 94G (1.1 g) was obtained.
[1100] LCMS m / z=321.3[M+H] +
[1101] Step 7: Preparation of 94H
[1102] Referring to the fourth step of the synthesis method of Example 1, 94H (850 mg) was obtained.
[1103] LCMS m / z=536.6[M+H] +
[1104] Step 8: Preparation of 94I
[1105] Referring to the fifth step of the synthesis method in Example 1, 94I (0.8 g) was obtained.
[1106] LCMS m / z=564.3[M+H] +
[1107] Step 9: Preparation of Compound 94
[1108] Referring to the second step synthesis method of Example 15, compound 94 (32 mg) was obtained.
[1109] LCMS m / z=550.4[M+H] +
[1110] 1 H NMR(400MHz, CDCl3)δ9.15(s,1H),8.62(s,1H),7.91(d,1H),7.81–7.74(m,2H),7.70–7.64(m,1H) ,7.44–7.37(m,1H),5.70–5.67(m,1H),5.16–5.12(m,1H),4.78–4.69(m,1H),3.46–3.34(m,6H),3 .21(s,3H),3.19–3.14(m,2H),2.78–2.58(m,7H),2.48–2.40(m,2H),2.36–2.31(m,1H),2.08–2.0 4(m,4H),1.98–1.94(m,1H),1.71–1.67(m,1H),1.60–1.54(m,1H),1.50–1.43(m,1H),1.33(t,3H).
[1111] Example 95: Preparation of Compound 95
[1112] Step 1: Preparation of 95A
[1113] Referring to the first step of the synthesis method of Example 18, 95A (2.7 g) was obtained.
[1114] LCMS m / z=261.0[M+H] +
[1115] Step 2: Preparation of 95B
[1116] 95A (2.2 g, 8.43 mmol), imidazole (0.86 g, 12.63 mmol), and TBSCl (1.65 g, 10.95 mmol) were added to tetrahydrofuran (30 mL), and the mixture was reacted at room temperature for 4 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 0-40%) to give crude product 95B (3.5 g).
[1117] LCMS m / z=375.5[M+H] +
[1118] Steps 3 to 9 were synthesized with reference to the second to eighth steps of compound 35 to obtain compound 95 (80 mg).
[1119] LCMS m / z=541.3[M+H] +
[1120] 1 H NMR(400MHz,Chloroform-d)δ8.60(s,1H),7.96–7.90(m,1H),7.81–7.76(m,1H),7.75–7.54(m,3H),7 .47–7.39(m,1H),6.05–6.00(m,1H),5.78–5.71(m,1H),4.67–4.59(m,1H),3.82(s,3H),3.73(t,2H), 3.66–3.52(m,2H),3.48–3.40(m,2H),3.29(s,3H),3.14–2.99(m,1H),2.94–2.72(m,5H),2.68–2.57( m,2H),2.50–2.36(m,1H),2.25–2.12(m,1H),1.97–1.79(m,3H),1.78–1.66(m,2H),1.65–1.54(m,1H).
[1121] Example 96: Preparation of Compound 96
[1122] Referring to the synthetic method of Example 85, compound 96 (73 mg) was obtained.
[1123] LCMS m / z=463.3[M+H] +
[1124] 1H NMR (400MHz, CDCl3) δ7.43–7.35(m,1H),6.99–6.92(m,1H),6.39(d,1H),6.25(d, 1H),5.87–5.48(m,1H),4.16–4.07(m,1H),3.70–3.54(m,2H),3.33(s,3H),3.28–3 .20(m,2H),3.19–3.11(m,1H),2.97–2.76(m,5H),2.69–2.55(m,2H),2.26–2.08(m ,2H),1.95–1.82(m,3H),1.80–1.62(m,7H),1.49–1.37(m,2H),1.31–1.17(m,6H).
[1125] Example 97: Preparation of Compound 97
[1126] Referring to the synthetic method of Example 85, compound 97 (85 mg) was obtained.
[1127] LCMS m / z=539.3[M+H] +
[1128] 1 H NMR (400MHz, CDCl3) δ7.45–7.37(m,3H),7.34–7.29(m,2H),7.23–7.17(m,1H),7.03–6.96(m,1H),6 .39(d,1H),6.24(d,1H),6.06–5.50(m,1H),4.09–4.02(m,1H),3.63–3.47(m,2H),3.30(s,3H),3.27 –3.20(m,2H),3.09–2.99(m,1H),2.93–2.74(m,5H),2.64–2.58(m,2H),2.40–2.28(m,2H),2.14–2. 06(m,1H),2.05–1.96(m,1H),1.95–1.79(m,2H),1.72–1.54(m,9H),1.42–1.32(m,1H),1.25(t,3H).
[1129] Example 98: Preparation of Compound 98
[1130] Referring to the synthetic method of Example 85, compound 98 (78 mg) was obtained.
[1131] LCMS m / z=475.3[M+H] +
[1132] 1 H NMR (400MHz, CDCl3) δ7.44–7.37(m,1H),6.91–6.83(m,1H),6.39(d,1H),6.25(d ,1H),5.88–5.57(m,1H),4.14–4.07(m,1H),3.70–3.54(m,2H),3.33(s,3H),3.28 –3.20(m,2H),3.19–3.10(m,1H),2.99–2.77(m,6H),2.68–2.57(m,2H),2.25–2. 12(m,5H),2.04–1.98(m,2H),1.95–1.85(m,3H),1.81–1.62(m,6H),1.26(t,3H).
[1133] Example 99: Preparation of Compound 99
[1134] Referring to the synthetic method of Example 87, compound 99 (93 mg) was obtained.
[1135] LCMS m / z=464.3[M+H] +
[1136] 1 H NMR(400MHz, CDCl3)δ7.42–7.31(m,1H),6.40(d,1H),6.20(d,1H),6.08(s,1H),5.1 9–5.10(m,1H),4.07–4.00(m,1H),3.73–3.55(m,2H),3.40–3.32(m,4H),3.32(s,3H ),3.28–3.17(m,3H),3.05–2.86(m,4H),2.85–2.76(m,1H),2.65–2.55(m,2H),2.23 –2.13(m,1H),1.98–1.85(m,1H),1.77–1.61(m,4H),1.62–1.47(m,6H),1.24(t,3H).
[1137] Example 100: Preparation of Compound 100
[1138] Referring to the synthetic method of Example 85, compound 100 (103 mg) was obtained.
[1139] LCMS m / z=493.2[M+H] +
[1140] 1H NMR(400MHz, CDCl3)δ8.12–8.00(m,2H),7.50–7.40(m,1H),7.00–6.92(m,1H),6 .89–6.82(m,1H),6.82–6.48(m,1H),6.41(d,1H),6.30(d,1H),4.45–4.35(m,1H) ,3.67–3.53(m,2H),3.30(s,3H),3.28–3.22(m,2H),3.16–3.05(m,1H),2.92–2. 64(m,7H),2.40–2.30(m,1H),2.15–2.04(m,1H),1.81–1.58(m,4H),1.28(t,3H).
[1141] Example 101: Preparation of Compound 101
[1142] Referring to the synthetic method of Example 34, the target compound 101 (113.0 mg) was obtained.
[1143] LCMS m / z=499.3[M+H] +
[1144] 1 H NMR(400MHz,DMSO-d6)δ7.77(d,1H),7.33–7.27(m,1H),6.76(t,1H),6.42–6.35(m,2H),6.25–5.92( m,1H),4.15–4.08(m,1H),3.72–3.60(m,2H),3.41(t,2H),3.22(s,3H),2.77–2.69(m,1H),2.68–2.6 1(m,2H),2.61–2.56(m,2H),2.55–2.51(m,2H),2.19–2.10(m,1H),1.89–1.78(m,1H),1.73–1.64(m, 5H),1.64–1.55(m,3H),1.50–1.39(m,2H),1.37–1.27(m,2H),1.27–1.21(m,2H),1.21–1.07(m,2H).
[1145] Example 102: Preparation of Compound 102
[1146] Referring to the synthetic method of Example 46, the target compound 102 (12 mg) was obtained.
[1147] LCMS m / z=567.2[M+H] +
[1148] 1 H NMR (400MHz, DMSO-d6) δ8.44(s,1H),8.39(s,1H),8.27–8.20(m,1H),7.81–7.74(m,1H),7.72–7.66(m,1H),7.56–7.49( m,1H),6.20(t,1H),5.91(d,1H),5.69(d,1H),4.97–4.90(m,1H),4.69(s,1H),3.87–3.81(m,2H),3.79(d,1H),3.77–3.6 8(m,3H),3.45–3.38(m,2H),3.20–3.15(m,2H),3.14(s,3H),2.87–2.75(m,2H),2.74–2.61(m,3H),2.36(t,2H),2.23–2 .14(m,1H),2.14–2.05(m,1H),2.05–1.96(m,1H),1.95–1.86(m,1H),1.65–1.51(m,2H),1.50–1.38(m,2H),1.08(t,3H).
[1149] Example 103: Preparation of Compound 103
[1150] Step 1: Preparation of 103A
[1151] 30I (300 mg, 0.62 mmol) was added to a solution of hydrogen chloride in 1,4-dioxane (30 mL, 4 mol / L) and 1,4-dioxane (10 mL). The mixture was reacted at room temperature for 3 hours, concentrated under reduced pressure, and the concentrate was added to dichloromethane (30 mL). 11A (87 mg, 0.68 mmol), DIPEA (400 mg, 3.10 mmol), and HATU (470 mg, 1.24 mmol) were then added, and the mixture was stirred at room temperature for 4 hours. Water (50 mL) was added, and the mixture was extracted with dichloromethane (50 mL x 2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain crude compound 103A (305 mg).
[1152] LCMS m / z=491.5[M+H] +
[1153] Step 2: Preparation of compound 103
[1154] Crude compound 103A (304 mg) and lithium hydroxide monohydrate (78 mg, 1.86 mmol) were added to a mixture of tetrahydrofuran and water (23 mL, V / V = 20 / 3) and stirred at room temperature for 3 h. LCMS confirmed the reaction was complete. The mixture was concentrated under reduced pressure and purified using preparative liquid chromatography (Waters 2767 preparative liquid chromatography; Xbridge Prep C18 5 μm 19*250 mm column); mobile phase composition: acetonitrile / water (containing 5 mmol / L ammonium bicarbonate). The resulting preparative solution was concentrated and lyophilized to yield compound 103 (30 mg).
[1155] LCMS m / z=477.4[M+H] +
[1156] 1 H NMR(400MHz,DMSO-d6)δ7.78(d,1H),7.28–7.19(m,1H),6.35–6.19(m,3H),4.19–4.05(m,1H), 3.41(t,2H),3.22(s,3H),3.19–3.10(m,2H),2.85–2.51(m,6H),2.49–2.36(m,2H),2.2 4–2.07(m,1H),1.98–1.76(m,1H),1.75–1.38(m,12H),1.38–1.05(m,5H),0.90(t,3H).
[1157] Example 104: Preparation of Compound 104
[1158] Referring to the synthesis method of Example 103, Compound 104 (35 mg) was obtained.
[1159] LCMS m / z=507.3[M+H] +
[1160] 1H NMR(400MHz,DMSO-d6)δ8.50–8.36(m,1H),7.85–7.72(m,1H),7.41–7.30(m,1 H),7.27–7.13(m,2H),6.37–6.19(m,3H),4.32–4.22(m,1H),3.47(t,2H),3.2 0(s,3H),3.19–3.06(m,2H),3.00–2.83(m,2H),2.83–2.69(m,3H),2.69–2.57 (m,1H),2.49–2.44(m,2H),2.06–1.81(m,2H),1.67–1.41(m,6H),0.89(t,3H).
[1161] Example 105: Preparation of Compound 105
[1162] The first to third steps were prepared by referring to the fourth to sixth steps of compound 35 to obtain 105C (0.45 g).
[1163] LCMS m / z=479.2[M+H] +
[1164] Steps 4 to 5 were prepared according to the synthetic method of step 1 to step 2 of compound 11. The crude product was purified by preparative liquid chromatography (instrument: Waters 2767 preparative liquid chromatography; chromatographic column: Xbridge Prep C18 5 μm 19*250 mm; mobile phase composition: acetonitrile / water (containing 5 mmol / L ammonium bicarbonate)) to obtain compound 105 (50 mg).
[1165] LCMS m / z=475.3[M+H] +
[1166] 1 H NMR (400MHz, CDCl3) δ7.06–6.93(m,1H),6.18–6.04(m,2H),6.02–5.89(m,1H),4 .12–3.98(m,1H),3.83(s,3H),3.22–3.04(m,1H),3.02–2.89(m,1H),2.88–2.67( m,4H),2.62–2.52(m,2H),2.49–2.41(m,1H),2.26–2.08(m,2H),2.00–1.56(m,1 0H),1.51–1.34(m,2H),1.32–1.13(m,6H),0.81–0.71(m,2H),0.62–0.52(m,2H).
[1167] Example 106: Preparation of Compound 106
[1168] Referring to the synthetic method of Example 34, compound 106 (130 mg) was obtained.
[1169] LCMS m / z=575.4[M+H] +
[1170] 1 H NMR(400MHz,DMSO-d6)δ7.47(d,1H),7.39–7.35(m,2H),7.33–7.25(m,3H),7.21–7.15(m,1H),6 .78(t,1H),6.42–6.35(m,2H),6.25–5.93(m,1H),4.10–4.02(m,1H),3.72–3.60(m,2H),3.37(t, 2H),3.19(s,3H),2.78–2.69(m,1H),2.69–2.55(m,4H),2.54–2.52(m,1H),2.49–2.47(m,1H),2.38–2.2 8(m,2H),1.86–1.77(m,1H),1.77–1.63(m,3H),1.62–1.48(m,7H),1.48–1.33(m,3H),1.32–1.17(m,1H).
[1171] Example 107: Preparation of Compound 107
[1172] Referring to the synthetic method of Example 84, compound 107 (55 mg) was obtained.
[1173] LCMS m / z=500.4[M+H] +
[1174] 1H NMR(400MHz,DMSO-d6)δ7.30(t,1H),6.77(t,1H),6.58(d,1H),6.43–6.34(m,2H),6.25 –5.92(m,1H),4.02–3.95(m,1H),3.72–3.59(m,2H),3.45–3.38(m,2H),3.30–3.23(m,3 H),3.23–3.18(m,4H),2.79–2.72(m,1H),2.72–2.58(m,4H),2.58–2.51(m,2H),1.90–1 .79(m,1H),1.78–1.68(m,1H),1.67–1.56(m,2H),1.56–1.44(m,4H),1.44–1.35(m,4H).
[1175] Example 108: Preparation of Compound 108
[1176] Referring to the synthetic method of Example 34, compound 108 (91 mg) was obtained.
[1177] LCMS m / z=511.3[M+H] +
[1178] 1 H NMR(400MHz,DMSO-d6)δ7.73(d,1H),7.33–7.26(m,1H),6.77(t,1H),6.43–6.35(m,2H),6.25–5.92( m,1H),4.13–4.07(m,1H),3.71–3.60(m,2H),3.41(t,2H),3.21(s,3H),2.92–2.83(m,1H),2.78–2.7 0(m,1H),2.70–2.63(m,2H),2.63–2.56(m,2H),2.56–2.51(m,2H),2.10–2.01(m,4H),2.01–1.94(m, 2H),1.89–1.78(m,3H),1.78–1.70(m,2H),1.70–1.63(m,1H),1.63–1.54(m,2H),1.51–1.38(m,2H).
[1179] Example 109: Preparation of Compound 109
[1180] Referring to the synthetic method of Example 103, compound 109 (30 mg) was obtained.
[1181] LCMS m / z=553.6[M+H]+
[1182] 1 H NMR (400MHz, CDCl3) δ7.54–7.36(m,3H),7.36–7.28(m,2H),7.25–7.15(m,1H),6.99(d,1H),6.3 8(d,1H),6.24(d,1H),5.93(s,1H),4.14–4.01(m,1H),3.65–3.45(m,2H),3.30(s,3H),3.15(t, 2H),3.09–2.94(m,1H),2.94–2.70(m,5H),2.70–2.53(m,2H),2.44–2.26(m,2H),2.16–2.06(m, 1H),2.06–1.96(m,1H),1.96–1.79(m,2H),1.76–1.49(m,11H),1.46–1.28(m,1H),0.99(t,3H).
[1183] Example 110: Preparation of Compound 110
[1184] Referring to the synthetic method of Example 103, compound 110 (25 mg) was obtained.
[1185] LCMS m / z=489.5[M+H] +
[1186] 1 H NMR(400MHz, CDCl3)δ7.45–7.36(m,1H),6.93–6.83(m,1H),6.39(d,1H),6.26 (d,1H),5.88(s,1H),4.18–4.05(m,1H),3.72–3.63(m,1H),3.63–3.54(m,1H) ,3.33(s,3H),3.24–3.09(m,3H),3.03–2.74(m,6H),2.73–2.55(m,2H),2.29– 2.11(m,5H),2.02(t,2H),1.98–1.85(m,3H),1.85–1.58(m,8H),1.00(t,3H).
[1187] Example 111: Preparation of Compound 111
[1188] Step 1: Preparation of 111A
[1189] 30I (300 mg, 0.62 mmol) was added to a solution of hydrogen chloride in 1,4-dioxane (10 mL, 4 mol / L) and 1,4-dioxane (10 mL). The mixture was reacted at room temperature for 3 hours and concentrated under reduced pressure. The concentrate was added to dichloromethane (30 mL), followed by 55A (92 mg, 0.62 mmol) and DIPEA (400 mg, 3.10 mmol). The mixture was stirred at room temperature for 24 hours. Water (50 mL) was added and the mixture was extracted with dichloromethane (50 mL x 2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product 55B (305 mg).
[1190] LCMS m / z=492.4[M+H] +
[1191] Step 2: Preparation of compound 111
[1192] Referring to the second step synthesis method of Example 103, compound 111 (30 mg) was obtained.
[1193] LCMS m / z=478.5[M+H] +
[1194] 1 H NMR (400MHz, CDCl3) δ7.40–7.30(m,1H),6.38(d,1H),6.21(d,1H),6.08(s,1H ),5.37–5.14(m,1H),4.09–3.99(m,1H),3.76–3.64(m,1H),3.64–3.56(m,1H) ,3.43–3.19(m,8H),3.14(t,2H),3.08–2.86(m,4H),2.86–2.74(m,1H),2.60( t,2H),2.25–2.12(m,1H),2.00–1.84(m,1H),1.82–1.44(m,12H),0.98(t,3H).
[1195] Example 112: Preparation of Compound 112
[1196] Referring to the synthetic method of Example 103, compound 112 (30 mg) was obtained.
[1197] LCMS m / z=507.5[M+H] +
[1198] 1H NMR(400MHz, CDCl3)δ7.91(s,1H),6.99–6.83(m,1H),6.07–5.96(m,1H),5. 77–5.67(m,1H),4.28–4.17(m,1H),3.84(s,3H),3.59–3.46(m,2H),3.31(s, 3H),3.20–3.07(m,2H),2.93–2.47(m,8H),2.33–2.06(m,2H),2.06–1.83(m ,3H),1.83–1.57(m,8H),1.57–1.38(m,3H),1.38–1.14(m,3H),1.00(t,3H).
[1199] Example 113: Preparation of Compound 113
[1200] Referring to the synthetic method of Example 103, compound 113 (35 mg) was obtained.
[1201] LCMS m / z=537.5[M+H] +
[1202] 1 H NMR(400MHz, CDCl3)δ8.99(s,1H),8.18–7.97(m,2H),7.05–6.90(m,1H),6.90–6.78(m,1H),6.05–5 .96(m,1H),5.77–5.65(m,1H),4.58–4.44(m,1H),3.86(s,3H),3.53–3.39(m,2H),3.24(s,3H),3.17 –3.07(m,2H),2.88–2.55(m,7H),2.54–2.40(m,1H),2.40–2.29(m,1H),2.26–2.07(m,1H),1.90–1.40(m,6H),1.01(t,3H).
[1203] Example 114: Preparation of Compound 114
[1204] Step 1: Preparation of 114B
[1205] Referring to the first step of the synthesis method of Example 16, 114B (3.4 g) was obtained.
[1206] LCMS m / z=320.9[M+H] +
[1207] Step 2: Preparation of 114C
[1208] 114B (2 g, 6.25 mmol), cyclopropylamine (0.71 g, 12.4 mmol), potassium carbonate (4.32 g, 31.25 mmol), and potassium iodide (0.10 g, 0.60 mmol) were added to DMSO (25 mL) and reacted at 130°C for 96 h. After cooling to room temperature, water (50 mL) was added and the mixture was extracted with ethyl acetate (50 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 0-5%) to afford 114C (1.15 g, 62% yield).
[1209] LCMS m / z=296.1[M+H] +
[1210] Step 3: Preparation of 114D
[1211] Referring to the synthetic method of step 1 of Example 4, 114D (1.25 g) was obtained.
[1212] LCMS m / z=396.1[M+H] +
[1213] Step 4: Preparation of 114E
[1214] Referring to the second step synthesis method of Example 4, 114E (1.5 g) was obtained.
[1215] LCMS m / z=418.3[M+H] +
[1216] Step 5: Preparation of 114F
[1217] Referring to the third step of the synthesis method of Example 4, 114F (700 mg) was obtained.
[1218] LCMS m / z=404.2[M+H] +
[1219] Step 6: Preparation of 114G
[1220] Referring to the fourth step of the synthesis method of Example 4, 114G (950 mg) was obtained.
[1221] LCMS m / z=461.3[M+H] +
[1222] Step 7: Preparation of 114H
[1223] 114G (950 mg, 2.06 mmol) was added to a solution of hydrogen chloride in dioxane (4 mol / L, 30 mL) and 1,4-dioxane (10 mL), stirred at room temperature for 3 h, and concentrated under reduced pressure. Dichloromethane (10 mL) and triethylamine (1 mL) were added to the concentrate, and the mixture was concentrated under reduced pressure. The concentrate was dissolved in dichloromethane (100 mL), washed with saturated sodium bicarbonate solution (50 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was added to 1,4-dioxane (15 mL), and a solution of lithium aluminum hydride in tetrahydrofuran (4 mL, 2.5 M) was slowly added under a nitrogen atmosphere. The mixture was stirred at 100°C for 12 h. The mixture was cooled to room temperature, and water (30 mL) was added, followed by extraction with dichloromethane (50 mL×3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (mobile phase: methanol / dichloromethane (V / V) = 0-20%) to give crude product 114H (730 mg).
[1224] LCMS m / z=333.3[M+1] +
[1225] Step 8: Preparation of 114I
[1226] Referring to the fourth step of the synthesis method in Example 1, 114I (740 mg) was obtained.
[1227] LCMS m / z=548.8[M+1] +
[1228] Step 9: Preparation of 114J
[1229] Referring to the fifth step of the synthesis method of Example 1, 114J (830 mg) was obtained.
[1230] LCMS m / z=576.6[M+1] +
[1231] Step 10: Preparation of compound 114
[1232] Referring to the second step synthesis method of Example 15, compound 114 (45 mg) was obtained.
[1233] LCMS m / z=562.3[M+H] +
[1234] 1H NMR (400MHz, CDCl3) δ9.54(s,1H),8.62(s,1H),7.92(d,1H),7.84–7.71(m,2H),7.70–7.61(m,1H), 7.46–7.36(m,1H),5.76–5.66(m,1H),5.61–5.53(m,1H),4.76–4.67(m,1H),3.47–3.36(m,6H),3.20 (s,3H),2.74–2.54(m,7H),2.48–2.38(m,3H),2.35–2.24(m,1H),2.12–2.04(m,4H),1.99–1.90(m, 1H),1.72–1.63(m,1H),1.59–1.52(m,1H),1.49–1.41(m,1H),0.80–0.72(m,2H),0.71–0.64(m,2H).
[1235] Example 115: Preparation of Compound 115
[1236] Referring to the synthetic method of Example 85, compound 115 (65 mg) was obtained.
[1237] LCMS m / z=457.2[M+H] +
[1238] 1 H NMR (400MHz, CDCl3) δ7.89–7.80(m,2H),7.80–7.73(m,1H),7.50–7.33(m, 4H),6.39–6.31(m,1H),6.34–6.03(m,2H),4.41–4.29(m,1H),3.66–3.52( m,2H),3.26(s,3H),3.25–3.13(m,3H),2.94–2.79(m,5H),2.67–2.56(m,2 H),2.37–2.27(m,1H),2.12–2.01(m,1H),1.77–1.60(m,4H),1.24(t,3H).
[1239] Example 116: Preparation of Compound 116
[1240] Referring to the synthetic method of Example 85, compound 116 (85 mg) was obtained.
[1241] LCMS m / z=481.3[M+H] +
[1242] 1H NMR (400MHz, CDCl3) δ7.80–7.57(m,1H),7.03–6.62(m,1H),7.03–6.62(m,1H ),6.38(d,1H),6.28(d,1H),4.23–4.11(m,1H),3.63–3.49(m,2H),3.30(s,3H ),3.26–3.18(m,2H),3.02–2.92(m,1H),2.89–2.69(m,5H),2.68–2.59(m,2H) ,2.19–2.09(m,1H),2.06–1.79(m,5H),1.75–1.52(m,9H),1.34–1.22(m,4H).
[1243] Example 117: Preparation of Compound 117
[1244] Referring to the synthetic method of Example 103, compound 117 (25 mg) was obtained.
[1245] LCMS m / z=583.4[M+H] +
[1246] 1 H NMR(400MHz, CDCl3)δ8.22(s,1H),7.50–7.40(m,2H),7.38–7.28(m,2H),7.23–7.15(m,1H),6. 97–6.83(m,1H),6.02–5.95(m,1H),5.72–5.64(m,1H),4.24–4.09(m,1H),3.83(s,3H),3.52–3. 33(m,2H),3.27(s,3H),3.16–3.01(m,2H),2.80–2.57(m,5H),2.57–2.40(m,3H),2.40–2.27(m, 2H),2.19–2.05(m,1H),2.05–1.96(m,1H),1.96–1.84(m,2H),1.76–1.29(m,12H),1.00(t,3H).
[1247] Example 118: Preparation of Compound 118
[1248] Referring to the synthetic method of Example 103, compound 118 (30 mg) was obtained.
[1249] LCMS m / z=519.4[M+H] +
[1250] 1H NMR(400MHz, CDCl3)δ8.04(s,1H),6.82(d,1H),6.01(d,1H),5.72(d,1H),4.27–4.19(m,1H),3.85(s,3H),3.58–3.45(m,2H ),3.32(s,3H),3.18–3.07(m,2H),2.97–2.48(m,9H),2.32–2.09(m,5H),2.09–1.86(m,5H),1.85–1.43(m,8H),1.01(t,3H).
[1251] Example 119: Preparation of Compound 119
[1252] Referring to the synthetic method of Example 111, compound 119 (20 mg) was obtained.
[1253] LCMS m / z=508.4[M+H] +
[1254] 1 H NMR(400MHz, CDCl3)δ6.80(s,1H),6.16–5.96(m,2H),5.71(d,1H),4.21–4.08(m,1H),3.83(s,3H),3.69–3.49(m,2H),3.43–3.27(m, 7H),3.20–3.08(m,2H),3.08–2.94(m,1H),2.94–2.49(m,7H),2.31–2.17(m,1H),2.03–1.88(m,1H),1.85–1.45(m,12H),1.00(t,3H).
[1255] Example 120: Preparation of Compound 120
[1256] Referring to the synthetic method of Example 32, compound 120 (14 mg) was obtained.
[1257] LCMS m / z=567.2[M+H] +
[1258] 1H NMR(400MHz,DMSO-d6)δ8.26(d,1H),8.23(s,1H),8.05(d,1H),7.56(t,1H),7.50(d,1H),7.30(d,1H),6.67 (d,1H),5.86(d,1H),5.77(d,1H),4.52(s,1H),3.92–3.84(m,2H),3.46–3.39(m,2H),3.25–3.17(m,2H),3. 10(s,3H),2.93(d,3H),2.70–2.54(m,2H),2.54–2.39(m,3H),2.39–2.28(m,2H),2.25–2.13(m,3H),2.00–1 .88(m,1H),1.88–1.75(m,1H),1.45–1.31(m,2H),1.31–1.15(m,2H),0.52–0.41(m,2H),0.24–0.16(m,2H).
[1259] Example 121: Preparation of Compound 121
[1260] Referring to the synthetic method of Example 18, compound 121 (30 mg) was obtained.
[1261] LCMS m / z=561.2[M+H] +
[1262] 1 H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.43–8.37(m,1H),8.27–8.21(m,1H),7.80–7.74(m,1H),7 .71–7.67(m,1H),7.54–7.48(m,1H),7.19(d,1H),6.62–6.57(m,2H),4.71(t,1H),3.45–3.37(m ,2H),3.13(s,3H),2.90–2.75(m,2H),2.75–2.62(m,3H),2.59–2.51(m,3H),2.17–2.05(m,1H), 2.05–1.94(m,1H),1.66–1.54(m,2H),1.53–1.38(m,2H),0.73–0.66(m,2H),0.45–0.38(m,2H).
[1263] Example 122: Preparation of Compound 122
[1264] Steps 1 to 3 Compound 122D (0.74 g) was obtained by following the synthetic method of Steps 1 to 3 of Example 18.
[1265] LCMS m / z=492.4[M+H] +
[1266] Step 4: Preparation of 122E
[1267] 122D (0.74 g, 1.50 mmol) was added to tetrahydrofuran (10 mL), followed by a solution of tetrabutylammonium fluoride in tetrahydrofuran (2.25 mL, 1.0 mol / L). The mixture was allowed to react at room temperature overnight. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (mobile phase: methanol / dichloromethane (v / v) = 0-8%) to afford 122E (0.53 g, 94% yield).
[1268] LCMS m / z=378.2[M+H] +
[1269] Step 5: Preparation of 122F
[1270] 122E (0.53 g, 1.40 mmol) was added to dichloromethane (10 mL), followed by triethylamine (0.28 g, 2.77 mol) and methanesulfonyl chloride (0.19 g, 1.66 mol). The mixture was allowed to react at room temperature for 2 hours. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (mobile phase: methanol / dichloromethane (v / v) = 0-10%) to afford 122F (0.60 g, 94% yield).
[1271] LCMS m / z=456.3[M+H] +
[1272] Step 6: Preparation of 122G
[1273] 122F (0.60 g, 1.32 mmol) was added to DMF (10 mL), followed by potassium carbonate (0.18 g, 1.30 mol) and 1D (0.40 g, 5.33 mol), and the mixture was reacted at 100°C for 2 hours. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (mobile phase: methanol / dichloromethane (v / v) = 0-10%) to afford 122G (0.21 g, 37% yield).
[1274] LCMS m / z=435.3[M+H] +
[1275] Steps 7 to 9: Compound 122 (5 mg) was obtained by following the synthetic method of Steps 7 to 9 of Example 16.
[1276] LCMS m / z=564.3[M+H] +
[1277] 1 H NMR(400MHz, CDCl3)δ8.58(s,1H),7.97–7.88(m,1H),7.79–7.71(m,2H),7.70–7.63(m,1H) ),7.44–7.33(m,1H),7.12–6.80(m,1H),6.75–6.64(m,2H),4.63–4.54(m,1H),3.87–3.74 (m,2H),3.67–3.46(m,2H),3.31–3.15(m,5H),3.14–3.03(m,1H),2.92–2.71(m,5H),2.69 –2.54(m,4H),2.45–2.36(m,1H),2.21–2.07(m,3H),1.82–1.56(m,4H),1.29–1.23(m,3H).
[1278] Example 123: Preparation of Compound 123
[1279] Referring to the synthetic method of Example 15, compound 123 (50 mg) was obtained.
[1280] LCMS m / z=513.4[M+H] +
[1281] 1 H NMR (400MHz, CDCl3) δ8.78–8.47(m,1H),7.91–7.84(m,2H),7.76–7.70(m,1H),7.50–7.37 (m,3H),6.16–6.11(m,1H),6.08–6.03(m,1H),4.50–4.42(m,1H),4.17–4.07(m,2H),3.56 –3.42(m,2H),3.24(s,3H),2.92–2.66(m,6H),2.62–2.33(m,4H),2.20–2.07(m,1H),1.86 –1.74(m,1H),1.71–1.57(m,2H),1.56–1.40(m,4H),0.85–0.74(m,2H),0.72–0.61(m,2H).
[1282] Example 124: Preparation of Compound 124
[1283] Referring to the synthetic method of Example 55, compound 124 (40 mg) was obtained.
[1284] LCMS m / z=522.4[M+H] +
[1285] 1 H NMR (400MHz, CDCl3) δ7.82–7.44(m,1H),6.15–6.08(m,2H),6.06–6.04(m,1H),4.20–4.07(m, 3H),3.73–3.64(m,4H),3.60–3.49(m,2H),3.45–3.34(m,4H),3.31(s,3H),3.00–2.90(m,1H) ,2.86–2.70(m,4H),2.70–2.52(m,3H),2.49–2.40(m,1H),2.29–2.20(m,1H),2.01–1.91(m,1 H),1.81–1.71(m,1H),1.68–1.49(m,3H),1.44(t,3H),0.82–0.74(m,2H),0.66–0.57(m,2H).
[1286] Example 125: Preparation of Compound 125
[1287] Referring to the synthetic method of Example 15, compound 125 (50 mg) was obtained.
[1288] LCMS m / z=537.5[M+H] +
[1289] 1 H NMR (400MHz, CDCl3) δ9.34–9.13(m,1H),7.74–7.65(m,1H),6.15–6.12(m,1H),6.06– 6.03(m,1H),4.31–4.23(m,1H),4.18–4.07(m,2H),3.53–3.43(m,2H),3.31(s,3H),2 .77–2.55(m,7H),2.50–2.41(m,2H),2.28–2.17(m,1H),2.07–1.79(m,6H),1.74–1.5 3(m,7H),1.49–1.40(m,4H),1.36–1.24(m,1H),0.85–0.76(m,2H),0.71–0.63(m,2H).
[1290] Example 126: Preparation of Compound 126
[1291] Referring to the synthetic method of Example 15, compound 126 (40 mg) was obtained.
[1292] LCMS m / z=521.4[M+H] +
[1293] 1 H NMR (400MHz, CDCl3) δ8.70–8.37(m,1H),7.03–6.93(m,1H),6.16–6.12(m,1H),6.07– 6.03(m,1H),4.27–4.20(m,1H),4.16–4.08(m,2H),4.05–3.97(m,2H),3.56–3.37(m,4 H),3.31(s,3H),2.87–2.34(m,10H),2.29–2.20(m,1H),2.06–1.91(m,1H),1.90–1.7 1(m,5H),1.70–1.55(m,2H),1.53–1.38(m,4H),0.87–0.75(m,2H),0.70–0.58(m,2H).
[1294] Example 127: Preparation of Compound 127
[1295] Referring to the synthetic method of Example 15, compound 127 (40 mg) was obtained.
[1296] LCMS m / z=499.1[M+H] +
[1297] 1 H NMR (400MHz, CDCl3) δ8.56–8.26(m,1H),7.91–7.84(m,2H),7.76–7.69(m,1H),7.51–7.3 8(m,3H),6.18–6.13(m,1H),6.10–6.05(m,1H),4.49–4.40(m,1H),3.88(s,3H),3.59–3. 45(m,2H),3.25(s,3H),2.97–2.88(m,1H),2.86–2.53(m,7H),2.51–2.33(m,2H),2.19–2 .06(m,1H),1.88–1.74(m,1H),1.72–1.46(m,3H),0.86–0.76(m,2H),0.71–0.60(m,2H).
[1298] Example 128: Preparation of Compound 128
[1299] Referring to the synthetic method of Example 55, compound 128 (40 mg) was obtained.
[1300] LCMS m / z=508.1[M+H] +
[1301] 1 H NMR (400MHz, CDCl3) δ7.54–7.29(m,1H),6.16–6.09(m,2H),6.09–6.05(m,1H),4.17 –4.10(m,1H),3.86(s,3H),3.74–3.64(m,4H),3.63–3.50(m,2H),3.46–3.34(m,4H) ,3.31(s,3H),3.04–2.93(m,1H),2.89–2.52(m,7H),2.49–2.42(m,1H),2.29–2.19( m,1H),2.01–1.89(m,1H),1.82–1.52(m,4H),0.83–0.73(m,2H),0.68–0.56(m,2H).
[1302] Example 129: Preparation of Compound 129
[1303] Referring to the synthetic method of Example 15, compound 129 (50 mg) was obtained.
[1304] LCMS m / z=523.2[M+H] +
[1305] 1 H NMR(400MHz, CDCl3)δ9.08–8.90(m,1H),7.73–7.63(m,1H),6.15–6.12(m,1H), 6.07–6.04(m,1H),4.30–4.21(m,1H),3.88(s,3H),3.53–3.45(m,2H),3.30(s, 3H),2.82–2.58(m,7H),2.56–2.42(m,2H),2.23–2.13(m,1H),2.07–1.74(m,6H ),1.72–1.41(m,8H),1.37–1.22(m,1H),0.84–0.76(m,2H),0.70–0.60(m,2H).
[1306] Example 130: Preparation of Compound 130
[1307] Referring to the synthetic method of Example 15, compound 130 (45 mg) was obtained.
[1308] LCMS m / z=507.1[M+H] +
[1309] 1 H NMR (400MHz, CDCl3) δ8.45–8.09(m,1H),7.02–6.96(m,1H),6.16–6.13(m,1H),6.09–6.05(m, 1H),4.26–4.20(m,1H),4.05–3.97(m,2H),3.88(s,3H),3.58–3.48(m,2H),3.46–3.38(m,2H) ,3.32(s,3H),2.91–2.81(m,1H),2.79–2.52(m,7H),2.50–2.35(m,2H),2.29–2.18(m,1H),2. 02–1.89(m,1H),1.89–1.71(m,5H),1.69–1.44(m,3H),0.85–0.76(m,2H),0.70–0.60(m,2H).
[1310] Example 131: Preparation of Compound 131
[1311] Step 1: Preparation of 131A
[1312] 25A (2 g, 10.52 mmol), ethylamine hydrochloride (1.72 g, 21.09 mmol), and potassium carbonate (4.37 g, 31.62 mmol) were added to DMSO (25 mL) and reacted at 90°C for 5 h. The mixture was cooled to room temperature, and water (50 mL) was added. The mixture was extracted with ethyl acetate (50 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 0-33%) to obtain crude product 131A (2.59 g).
[1313] LCMS m / z=215.1[M+H] +
[1314] Step 2: Preparation of 131B
[1315] Referring to the synthesis method of step 1 of Example 4, 131B (3.85 g) was obtained.
[1316] LCMS m / z=315.0[M+H] +
[1317] Step 3: Preparation of 131C
[1318] Referring to the synthesis method of step 2 of Example 4, 131C (1 g) was obtained.
[1319] LCMS m / z=337.2[M+H] +
[1320] Step 4: Preparation of 131D
[1321] Referring to the synthesis method of step 3 of Example 4, 131D (970 mg) was obtained.
[1322] LCMS m / z=323.2[M+H] +
[1323] Step 5: Preparation of 131E
[1324] Referring to the synthesis method of step 4 of Example 4, 131E (1.5 g) was obtained.
[1325] LCMS m / z=380.4[M+H] +
[1326] Step 6: Preparation of 131F
[1327] Referring to the synthesis method of step 5 of Example 6, 131F (0.9 g) was obtained.
[1328] LCMS m / z=266.2[M+H] +
[1329] Step 7: Preparation of 131G
[1330] Referring to the fourth step of the synthesis method in Example 1, 131G (620 mg) was obtained.
[1331] LCMS m / z=481.3[M+H] +
[1332] Step 8: Preparation of 131H
[1333] Referring to the fifth step of the synthesis method of Example 1, 131H (890 mg) was obtained.
[1334] LCMS m / z=509.5[M+H] +
[1335] Step 9: Preparation of Compound 131
[1336] Referring to the second step synthesis method of Example 15, compound 131 (50 mg) was obtained.
[1337] LCMS m / z=495.1[M+H] +
[1338] 1H NMR(400MHz, CDCl3)δ8.61(s,1H),7.93(d,1H),7.84–7.55(m,4H),7.46–7.40(m,1 H),6.25(s,1H),6.15(s,1H),4.66–4.57(m,1H),3.66–3.47(m,2H),3.27(s,3H),3 .25–3.18(m,2H),3.07–2.97(m,1H),2.92–2.79(m,4H),2.74–2.60(m,3H),2.51–2 .42(m,1H),2.28–2.18(m,4H),1.86–1.77(m,1H),1.73–1.53(m,3H),1.29(t,3H).
[1339] Example 132: Preparation of Compound 132
[1340] Referring to the synthetic method of Example 84, compound 132 (61 mg) was obtained.
[1341] LCMS m / z=466.2[M+H] +
[1342] 1 H NMR(400MHz, CDCl3)δ7.36(t,1H),6.38(d,1H),6.22(d,1H),6.16(s,1H),5.6 6–5.14(m,1H),4.16–3.95(m,1H),3.69–3.55(m,6H),3.42–3.33(m,4H),3.31 (s,3H),3.25–3.16(m,3H),3.03–2.86(m,4H),2.83–2.76(m,1H),2.66–2.56( m,2H),2.22–2.12(m,1H),1.96–1.87(m,1H),1.77–1.60(m,4H),1.23(t,3H).
[1343] Example 133: Preparation of Compound 133
[1344] Step 1: Preparation of 133C
[1345] 133A (400 mg, 2.95 mmol), 133B (875 mg, 2.95 mmol), and triethylamine (896 mg, 8.85 mmol) were added to dichloromethane (50 mL) at 0°C and stirred at room temperature for 12 h. The mixture was concentrated under reduced pressure, and ethyl acetate (20 mL) was added to the concentrate. The mixture was stirred at room temperature for 5 min and filtered. The filter cake was washed with ethyl acetate (5 mL x 2). The filtrates were combined and concentrated under reduced pressure to give crude product 133C (650 mg).
[1346] LCMS m / z=162.1[M+H] +
[1347] Step 2: Preparation of 133D
[1348] Referring to the first step of the synthesis method of Example 84, compound 133D (550 mg) was obtained.
[1349] LCMS m / z=492.3[M+H] +
[1350] Step 3: Preparation of compound 133
[1351] Referring to the second step synthesis method of Example 15, compound 133 (70 mg) was obtained.
[1352] LCMS m / z=478.2[M+H] +
[1353] 1 H NMR (400MHz, CDCl3) δ7.37(t,1H),6.38(d,1H),6.22(d,1H),5.89(s,1H),5.62–5.23(m,1H),4.68–4. 49(m,2H),4.15–3.97(m,1H),3.90–3.82(m,1H),3.79–3.71(m,1H),3.69–3.53(m,2H),3.43–3.36(m, 1H),3.35–3.31(m,1H),3.31(s,3H),3.26–3.12(m,3H),3.04–2.83(m,4H),2.84–2.74(m,1H),2.65–2 .56(m,2H),2.25–2.14(m,1H),2.00–1.87(m,1H),1.86–1.77(m,2H),1.76–1.59(m,4H),1.24(t,3H).
[1354] Example 134: Preparation of Compound 134
[1355] Referring to the synthetic method of Example 133, Compound 134 (86 mg) was obtained.
[1356] LCMS m / z=478.1[M+H] +
[1357] 1 H NMR(400MHz, CDCl3)δ7.36(t,1H),6.38(d,1H),6.20(d,1H),5.82(s,1H),5.59–5.2 2(m,1H),4.64–4.54(m,2H),4.13–4.02(m,1H),3.92–3.83(m,1H),3.80–3.73(m,1H ),3.71–3.56(m,2H),3.40–3.29(m,5H),3.25–3.13(m,3H),3.00–2.76(m,5H),2.64 –2.56(m,2H),2.25–2.11(m,1H),2.02–1.89(m,1H),1.84–1.63(m,6H),1.23(t,3H).
[1358] Example 135: Preparation of Compound 135
[1359] Referring to the synthetic method of Example 120, Compound 135 (20 mg) was obtained.
[1360] LCMS m / z=555.4[M+H] +
[1361] 1 H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.39(s,1H),8.24(d,1H),7.81–7.73(m,1H),7.69(d,1H),7.56–7.48 (m,1H),6.36–6.20(m,1H),5.94(d,1H),5.73(d,1H),4.75–4.65(m,1H),4.05–3.98(m,2H),3.64–3.58(m,2 H),3.46–3.38(m,2H),3.28(s,3H),3.21–3.11(m,5H),2.89–2.75(m,2H),2.75–2.61(m,3H),2.59–2.53(m, 1H),2.37(t,2H),2.16–2.05(m,1H),2.05–1.95(m,1H),1.63–1.51(m,2H),1.51–1.37(m,2H),1.08(t,3H).
[1362] Example 136: Preparation of Compound 136
[1363] Step 1: Preparation of compound 136B
[1364] 7A (3 g, 11.24 mmol), 136A (2.06 g, 11.24 mmol), cesium carbonate (7.32 g, 22.48 mmol), palladium acetate (0.25 g, 1.12 mmol), and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (1.30 g, 2.25 mmol) were placed in a three-necked flask under nitrogen. Dry 1,4-dioxane (60 mL) was added. The mixture was heated to 95°C for 1 h, cooled to room temperature, filtered through celite, and the filtrate was concentrated. The mixture was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 1:1) and further slurried with ethyl acetate / petroleum ether (v / v) = 10:1, 50 mL) to afford compound 136B (3 g, 72% yield).
[1365] LCMS m / z=367.2[MH] -
[1366] Steps 2 to 9 were prepared by following the synthetic method of steps 3 to 10 of Example 74 to obtain compound 136 (25 mg).
[1367] LCMS m / z=549.1[M+H] +
[1368] 1 H NMR(400MHz, CDCl3)δ9.31(s,1H),8.58(s,1H),7.93(d,1H),7.82–7.62(m, 3H),7.49–7.35(m,2H),6.66(s,1H),6.17(d,1H),6.02(d,1H),4.62–4.51(m ,1H),3.78(s,3H),3.72–3.55(m,2H),3.35–3.17(m,4H),3.06–2.81(m,5H), 2.74–2.60(m,2H),2.49–2.36(m,1H),2.22–2.06(m,1H),1.89–1.62(m,4H).
[1369] Example 137: Preparation of Compound 137
[1370] Referring to the synthetic method of compound 39, compound 137 (42 mg) was obtained.
[1371] LCMS m / z=547.4[M+H] +
[1372] 1 H NMR(400MHz, CDCl3)δ8.59(s,1H),8.02–7.97(m,1H),7.96–7.89(m,1H),7.82–7.76(m,1H),7.74–7.66(m,2 H),7.64–7.56(m,1H),7.48–7.39(m,1H),6.80–6.74(m,1H),6.65–6.53(m,1H),6.51–6.43(m,1H),5.83–5. 55(m,1H),4.57–4.42(m,1H),3.81–3.70(m,1H),3.68–3.60(m,1H),3.40–3.25(m,6H),3.12–2.96(m,4H),2 .95–2.82(m,1H),2.79–2.61(m,2H),2.54–2.39(m,1H),2.16–1.99(m,1H),1.93–1.68(m,4H),1.28(t,3H).
[1373] Example 138: Preparation of Compound 138
[1374] Referring to the synthesis method of compound 39, compound 138 (120 mg) was obtained.
[1375] LCMS m / z=559.1[M+H] +
[1376] 1H NMR(400MHz, CDCl3)δ8.60(s,1H),8.06–8.00(m,1H),7.97–7.91(m,1H),7.82–7.77(m,1H),7.75 –7.67(m,2H),7.64–7.56(m,1H),7.48–7.41(m,1H),7.02–6.95(m,1H),6.89–6.81(m,1H),6.53– 6.44(m,1H),6.12–5.91(m,1H),4.56–4.43(m,1H),3.81–3.71(m,1H) ,3.70–3.59(m,1H),3.44–3.28(m,4H),3.13–2.96(m,4H),2.96–2.86( m,1H),2.78–2.63(m,2H),2.59–2.51(m,1H),2.50–2.42(m,1H),2.15– 1.97(m,1H),1.90–1.68(m,4H),0.91–0.76(m,2H),0.67–0.54(m,2H).
[1377] Example 139: Preparation of Compound 139
[1378] The first step was carried out according to the fourth step of compound 7 to obtain 139A (1.5 g).
[1379] LCMS m / z=290.2[M+H] +
[1380] Step 2: Preparation of 139B
[1381] 139A (1.5 g, 5.18 mmol) was added to dioxane (30 mL), followed by a solution of lithium aluminum hydride in tetrahydrofuran (3.3 mL, 2.5 mol / L). The mixture was allowed to react at room temperature for 5 h. 5 mL of water was slowly added, and the mixture was stirred for 5 min. Silica gel was then added and the sample was mixed. The sample was purified by column chromatography (mobile phase: methanol / dichloromethane (v / v) = 0-12%) to afford 139B (0.38 g, 27% yield).
[1382] LCMS m / z=276.2[M+H] +
[1383] Step 3 to Step 5: Referring to the synthesis method of step 3 to step 5 of compound 105, compound 139 (320 mg) was obtained.
[1384] LCMS m / z=487.2[M+H] +
[1385] 1 H NMR(400MHz, CDCl3)δ8.92(s,1H),6.85–6.63(m,1H),6.22–6.12(m,1H),6.10–6.02(m,1 H),4.28–4.15(m,1H),3.89(s,3H),2.97–2.84(m,1H),2.83–2.64(m,3H),2.62–2.53(m, 1H),2.52–2.38(m,2H),2.33–2.21(m,1H),2.20–2.00(m,2H),1.97–1.85(m,2H),1.84–1 .38(m,10H),1.36–1.15(m,3H),0.87–0.77(m,2H),0.74–0.60(m,2H),0.58–0.41(m,4H).
[1386] Example 140: Preparation of Compound 140
[1387] Step 1: Preparation of compound 140B
[1388] Compound 140A (8 g, 29.97 mmol), ethylamine hydrochloride (7.33 g, 89.89 mmol), and N,N-diisopropylethylamine (19.37 g, 149.86 mmol) were added to DMSO (100 mL) and heated to 110°C for 36 h. After cooling to room temperature, water (200 mL) was added, and the mixture was extracted with ethyl acetate (150 mL × 3). The mixture was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 1:1) to obtain compound 140B (2.6 g, 38% yield).
[1389] LCMS m / z=231.3[M+H] +
[1390] Step 2: Preparation of compound 140C
[1391] Compound 140B (2 g, 8.65 mmol) and triethylamine (2.63 g, 25.99 mmol) were added to DCM (50 mL), and tert-butyldimethylsilyl trifluoromethanesulfonate (2.97 g, 11.24 mmol) was added at 0°C. The mixture was reacted at 0°C for two hours, and water (50 mL) was added. The mixture was extracted with dichloromethane (50 mL×3), dried over anhydrous sodium sulfate, filtered, concentrated, and separated and purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (V / V) = 1:5) to give compound 140C (2.9 g, yield: 97%).
[1392] LCMS m / z=345.1[M+H] +
[1393] Step 3: Preparation of Compound 140D
[1394] Compound 140C (2.9 g, 8.40 mmol) was added to tetrahydrofuran (50 mL), followed by 4-dimethylaminopyridine (1.23 g, 10.07 mmol) and di-tert-butyl dicarbonate (5.50 g, 25.20 mmol), and the mixture was allowed to react overnight at 50°C. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 1:10) to afford compound 140D (3.5 g, 94% yield).
[1395] LCMS m / z=445.1[M+H] +
[1396] Step 4: Preparation of Compound 140E
[1397] Referring to the second step synthesis method of Example 4, 140E (2.8 g) was obtained.
[1398] LCMS m / z=481.4[M+H] +
[1399] Step 5: Preparation of Compound 140F
[1400] Compound 140E (3.2 g, 6.66 mmol) was added to hydrochloric acid (50 mL, 6 mol / L) and reacted at 60°C for 2 h. After the reaction, the mixture was concentrated and the crude product was directly used for the next step.
[1401] LCMS m / z=239.2[M+H] +
[1402] Step 6: Preparation of Compound 140G
[1403] The crude hydrochloride of compound 140G obtained in the previous step was added to dichloromethane (100 mL), followed by N,N-diisopropylethylamine (4.30 g, 33.3 mmol), compound 1D (0.65 g, 8.67 mmol), and HATU (5.07 g, 13.34 mmol). The mixture was allowed to react at room temperature overnight. Saturated sodium bicarbonate solution (100 mL) was added, and the mixture was extracted with dichloromethane (50 mL × 3). The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (mobile phase: dichloromethane / methanol (v / v) = 10:1) to obtain crude compound 140G (5 g).
[1404] LCMS m / z=296.2[M+H]+
[1405] Steps 7 to 10: Compound 140 (60 mg) was obtained by following the synthetic method of Steps 7 to 10 of Example 74.
[1406] LCMS m / z=511.4[M+H] +
[1407] 1 H NMR(400MHz, CDCl3)δ8.50(s,1H),7.92(d,1H),7.82(s,1H),7.78–7.70(m,1H),7.7 1–7.64(m,1H),7.42–7.34(m,1H),6.87(s,1H),6.38(s,1H),6.29(s,1H),4.65–4.49 (m,3H),3.67–3.49(m,2H),3.25(s,3H),3.22–3.04(m,3H),2.96–2.66(m,5H),2.64 –2.49(m,2H),2.43–2.25(m,1H),2.21–2.08(m,1H),1.78–1.51(m,4H),1.21(t,3H).
[1408] Example 141: Preparation of Compound 141
[1409] Referring to the synthetic method of Example 55, compound 141 (60 mg) was obtained.
[1410] LCMS m / z=534.5[M+H] +
[1411] 1H NMR (400MHz, CDCl3) δ8.01–7.58(m,1H),6.16–6.10(m,1H),6.07–6.03(m,1H),5.84–5.76(m,1H),4.67–4.59 (m,2H),4.20–4.14(m,1H),4.14–4.06(m,2H),3.93–3.87(m,1H),3.81–3.75(m,1H),3.60–3.48(m,2H),3.45 –3.40(m,1H),3.37–3.29(m,4H),2.98–2.87(m,1H),2.83–2.71(m,4H),2.69–2.53(m,3H),2.49–2.41(m,1H) ,2.30–2.20(m,1H),2.03–1.89(m,1H),1.88–1.50(m,6H),1.44(t,3H),0.83–0.74(m,2H),0.69–0.55(m,2H).
[1412] Example 142: Preparation of Compound 142
[1413] Referring to the synthetic method of Example 55, compound 142 (60 mg) was obtained.
[1414] LCMS m / z=534.5[M+H] +
[1415] 1 H NMR (400MHz, CDCl3) δ7.91–7.48(m,1H),6.14–6.09(m,1H),6.07–6.02(m,1H),5.80–5.69(m,1H),4 .65–4.58(m,2H),4.20–4.05(m,3H),3.96–3.89(m,1H),3.82–3.75(m,1H),3.62–3.51(m,2H),3.44 –3.28(m,5H),2.99–2.91(m,1H),2.88–2.72(m,4H),2.71–2.54(m,3H),2.47–2.39(m,1H),2.29–2. 18(m,1H),2.03–1.91(m,1H),1.86–1.49(m,6H),1.43(t,3H),0.83–0.73(m,2H),0.67–0.55(m,2H).
[1416] Example 143: Preparation of Compound 143
[1417] Referring to the synthetic method of Example 55, compound 143 (30 mg) was obtained.
[1418] LCMS m / z=556.5[M+H] +
[1419] 1 H NMR (400MHz, CDCl3) δ8.14–7.84(m,1H),6.24–6.17(m,1H),6.15–6.11(m,1H),6.07 –6.03(m,1H),4.20–4.06(m,3H),3.61–3.46(m,6H),3.31(s,3H),2.99–2.88(m,1H) ,2.86–2.56(m,7H),2.49–2.40(m,1H),2.28–2.18(m,1H),2.03–1.89(m,5H),1.84– 1.73(m,1H),1.69–1.50(m,3H),1.44(m,3H),0.85–0.75(m,2H),0.67–0.56(m,2H).
[1420] Example 144: Preparation of Compound 144
[1421] Step 1: Preparation of 144B
[1422] Compound 144A (5000 mg, 26.73 mmol) was added to tetrahydrofuran (100 mL), followed by 4-dimethylaminopyridine (653 mg, 5.35 mmol) and di-tert-butyl dicarbonate (29.17 g, 133.65 mmol). The mixture was allowed to react overnight at 50°C. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 0-10%) to afford compound 144B (9.8 g, 95% yield).
[1423] LCMS m / z=233.1[M-155] +
[1424] Step 2: Preparation of 144C
[1425] Referring to the synthesis method of step 2 of Example 4, the crude product of 144C (13.96 g) was obtained.
[1426] LCMS m / z=409.2[M+H] +
[1427] Step 3: Preparation of 144E
[1428] The crude product of 144C (13.96 g) was added to a solution of hydrogen chloride in dioxane (4 mol / L, 30 mL) and 1,4-dioxane (10 mL), stirred at room temperature for 3 h, and concentrated under reduced pressure. Dichloromethane (10 mL), methanol (10 ml), and triethylamine (2 mL) were added to the concentrate, and the mixture was concentrated under reduced pressure. The concentrate was added to dichloromethane (500 mL), followed by the addition of 144D (12.62 g, 170.79 mmol), anhydrous sodium carbonate (10.87 g, 102.56 mmol), 2,2'-bipyridine (8.01 g, 51.28 mmol), and anhydrous copper acetate (12.41 g, 68.33 mmol), and stirred at 30°C overnight. After cooling to room temperature, the reaction solution was filtered through celite, the filtrate was concentrated under reduced pressure, and the residue was separated and purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 0-10%) to give 144E (2.2 g).
[1429] LCMS m / z=237.2[M+H] +
[1430] Step 4: Preparation of 144F
[1431] Referring to the synthesis method of step 3 of Example 4, 144F (2 g) was obtained.
[1432] LCMS m / z=223.1[M+H] +
[1433] Step 5: Preparation of 144G
[1434] Referring to the synthesis method of step 4 of Example 4, 144G (2.9 g) was obtained.
[1435] LCMS m / z=280.2[M+H] +
[1436] Step 6: Preparation of 144H
[1437] 144G (2.9 g) was added to 1,4-dioxane (50 mL), and a solution of lithium aluminum hydride in tetrahydrofuran (11 mL, 2.5 M) was slowly added under a nitrogen atmosphere. The mixture was stirred at 100°C for 12 hours. After cooling to room temperature, water (30 mL) was added, and the mixture was extracted with dichloromethane (50 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (mobile phase: methanol / dichloromethane (v / v) = 0-20%) to give crude product 144H (450 mg).
[1438] LCMS m / z=266.2[M+1] +
[1439] Step 7: Preparation of 144I
[1440] Referring to the fourth step of the synthesis method in Example 1, 144I (850 mg) was obtained.
[1441] LCMS m / z=481.4[M+H] +
[1442] Step 8: Preparation of 144J
[1443] Referring to the fifth step of the synthesis method of Example 1, 144J (1.3 g) was obtained.
[1444] LCMS m / z=509.3[M+H] +
[1445] Step 9: Preparation of Compound 144
[1446] Referring to the second step synthesis method of Example 15, compound 144 (35 mg) was obtained.
[1447] LCMS m / z=495.3[M+H] +
[1448] 1 H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.43–8.35(m,1H),8.24(d,1H),7.81–7.75(m,1H),7.73–7.67 (m,1H),7.58–7.44(m,1H),7.01(d,1H),6.17(d,1H),5.64–5.52(m,1H),4.73–4.65(m,1H),3.43–3 .39(m,2H),3.35–3.30(m,2H),3.14(s,3H),2.86–2.75(m,2H),2.72–2.61(m,3H),2.57–2.51(m,1H ),2.41(t,2H),2.15–1.97(m,2H),1.95(s,3H),1.63–1.52(m,2H),1.51–1.37(m,2H),1.11(t,3H).
[1449] Example 145: Preparation of Compound 145
[1450] Referring to the synthetic method of Example 140, Compound 145 (100 mg) was obtained.
[1451] LCMS m / z=523.5[M+H] +
[1452] 1 H NMR (400MHz, DMSO) δ8.55(s,1H),7.94(d,1H),7.79(d,1H),7.75–7.68(m,1H),7.66(s ,1H),7.48–7.41(m,1H),6.83–6.44(m,3H),4.65(s,2H),4.53–4.40(m,1H),3.77–3.67 (m,1H),3.67–3.57(m,1H),3.37–3.23(m,4H),3.09–2.78(m,5H),2.64(t,2H),2.49–2. 33(m,2H),2.17–2.02(m,1H),1.84–1.60(m,4H),0.82–0.67(m,2H),0.60–0.50(m,2H).
[1453] Example 146: Preparation of Compound 146
[1454] Step 1: Preparation of compound 146B
[1455] Compound 146A (5 g, 13.78 mmol), cyclopropylamine (2.36 g, 41.34 mmol), and potassium carbonate (5.71 g, 41.34 mmol) were added to DMSO (50 mL), reacted at 100°C for 3 h, cooled to room temperature, added with water (50 mL), and extracted with ethyl acetate (50 mL×3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The product was separated and purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (V / V) = 1:10) to give compound 146B (2.6 g, yield: 56%).
[1456] LCMS m / z=338.9[M+H] +
[1457] Step 2: Preparation of Compound 146C
[1458] Under nitrogen, compound 146B (3.35 g, 9.88 mmol), phenylboronic acid (1.20 g, 9.88 mmol), tetrakistriphenylphosphine palladium (0.57 g, 0.49 mmol), and potassium carbonate (4.10 g, 29.64 mmol) were added to a mixture of toluene (50 mL) and water (25 mL) and refluxed overnight. The mixture was cooled to room temperature, water (30 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 1:10) to afford compound 146C (0.9 g, 31% yield).
[1459] LCMS m / z=289.1[M+H] +
[1460] Steps 3 to 10: Compound 146 (50 mg) was obtained by following the synthetic method of Steps 3 to 10 of Example 140.
[1461] LCMS m / z=569.7[M+H] +
[1462] 1 H NMR(400MHz, CDCl3)δ8.61(s,1H),7.95(d,1H),7.80(d,1H),7.78–7.66(m,1H),7.66–7.53(m, 3H),7.51–7.38(m,4H),7.02–6.56(m,3H),4.60–4.50(m,1H),3.79–3.68(m,1H),3.68–3.59(m, 1H),3.32(s,3H),3.30–3.20(m,1H),3.07–2.84(m,5H),2.84–2.66(m,2H),2.62–2.52(m,1H), 2.52–2.42(m,1H),2.21–2.05(m,1H),1.96–1.66(m,4H),0.92–0.76(m,2H),0.71–0.57(m,2H).
[1463] Example 147: Preparation of Compound 147
[1464] Step 1: Preparation of compound 147B
[1465] Compound 146A (5 g, 13.78 mmol), ethylamine hydrochloride (2.25 g, 27.56 mmol), and potassium carbonate (9.52 g, 68.90 mmol) were added to DMSO (50 mL), reacted at 100°C for 8 h, cooled to room temperature, added with water (50 mL), extracted with ethyl acetate (50 mL×3), dried over anhydrous sodium sulfate, filtered, concentrated, and separated and purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (V / V) = 1:10) to give compound 147B (2.4 g, yield: 53%).
[1466] LCMS m / z=326.9[M+H] +
[1467] Step 2: Preparation of Compound 147C
[1468] Referring to the third step synthesis method of Example 140, compound 147C (3 g) was obtained.
[1469] LCMS m / z=370.8[M-55] +
[1470] Step 3: Preparation of Compound 147D
[1471] Under nitrogen, compound 147C (3 g, 7.02 mmol), phenylboronic acid (0.86 g, 7.02 mmol), tetrakistriphenylphosphine palladium (0.81 g, 0.70 mmol), and potassium carbonate (2.91 g, 21.06 mmol) were added to a mixture of toluene (100 mL) and water (50 mL) and refluxed overnight. The mixture was cooled to room temperature, water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (mobile phase: ethyl acetate / petroleum ether (v / v) = 1:10) to afford compound 147D (1.5 g, 57% yield).
[1472] LCMS m / z=321.0[M-55] +
[1473] Steps 4 to 10: Compound 147 (20 mg) was obtained by following the synthetic method of Steps 4 to 10 of Example 140.
[1474] LCMS m / z=557.3[M+H] +
[1475] 1 H NMR(400MHz, CDCl3)δ8.60(s,1H),7.94(d,1H),7.80(d,1H),7.75–7.67(m,1H), 7.67–7.54(m,3H),7.51–7.37(m,4H),6.93–6.30(m,3H),4.61–4.50(m,1H),3.81 –3.67(m,1H),3.67–3.56(m,1H),3.45–3.14(m,6H),3.10–2.84(m,5H),2.84–2. 67(m,2H),2.55–2.42(m,1H),2.26–2.04(m,1H),1.99–1.61(m,4H),1.31(t,3H).
[1476] Example 148: Preparation of Compound 148
[1477] Step 1: Preparation of 148B
[1478] 148A (1.5 g, 9.31 mmol) was added to ultra-dry THF (20 mL), cooled to 0°C, and 60% NaH (0.45 g, 11.25 mmol) was slowly added. The reaction was allowed to proceed for 0.5 h. Deuterated iodomethane (1.48 g, 10.21 mmol) was then added via syringe and allowed to react at room temperature for 2 h. The reaction was quenched by the slow addition of water (15 mL), and the mixture was extracted with ethyl acetate (20 mL x 2). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to afford crude 148B (1.4 g), which was directly used in the next step.
[1479] LCMS m / z=79.1[M-99] +
[1480] 1 H NMR (400MHz, Chloroform-d) δ4.86(s,1H),3.43(t,2H),3.34–3.24(m,2H),1.44(s,9H).
[1481] Step 2: Preparation of 148C hydrochloride
[1482] Crude 148B (1.4 g) was added to 4 M dioxane hydrochloride (20 mL) and reacted at room temperature for 2 h. The reaction solution was concentrated under reduced pressure to give the hydrochloride salt of crude 148C (1 g), which was directly used for the next reaction.
[1483] 1 H NMR(400MHz,Chloroform-d)δ8.23(s,3H),3.72(t,2H),3.32–3.18(m,2H).
[1484] Steps 3 to 7 were carried out with reference to the synthesis method of compound 105 to obtain compound 148 (140 mg).
[1485] LCMS m / z=508.4[M+H] +
[1486] 1H NMR(400MHz,Chloroform-d)δ8.23–7.84(m,1H),6.96–6.82(m,1H),6.18–6.12(m,1H), 6.10–6.04(m,1H),4.29–4.13(m,1H),3.87(s,3H),3.63–3.46(m,2H),2.99–2.86(m,1H ),2.85–2.70(m,4H),2.69–2.53(m,3H),2.51–2.42(m,1H),2.29–2.08(m,2H),2.05–1. 84(m,3H),1.82–1.37(m,9H),1.34–1.12(m,3H),0.86–0.75(m,2H),0.70–0.59(m,2H).
[1487] Biological test cases
[1488] Test Example 1: Integrin αvβ6 ELISA Detection Test
[1489] LAP was diluted to a final concentration of 0.25 μg / ml in TBS buffer, and 50 μl of the solution was transferred to a 96-well plate for coating overnight at 4°C. The plate was washed three times with TBS buffer, followed by the addition of 150 μl of blocking buffer (TBS buffer containing 1% BSA) and blocking at 37°C for 1 hour. The plate was washed three times with TBS buffer, and 0.1 μg / ml of αvβ6 integrin protein was prepared in TBS buffer containing 0.1% BSA. 50 μl of the integrin protein was transferred to a 96-well plate, followed by the addition of 1 μl of various compound concentrations or DMSO, and incubation at room temperature for 2 hours. Biotinylated anti-αv antibody was diluted to 0.5 μg / ml in TBS buffer containing 0.1% BSA. The plate was washed three times with TBS buffer, and 50 μl of the antibody was added and incubated at room temperature for 1 hour. The plate was washed three times with TBS buffer, and 50 μl of Streptavidin-HRP was added and incubated at room temperature for 20 minutes. Add 50 μl of TMB substrate and incubate at room temperature for 20 min. Finally, add 25 μl of stop buffer (2 M H2SO4) and read the OD value of the plate at 450 nm on a microplate reader. Calculate the IC using GraphPad Prism 6 software. 50 value.
[1490] Table 1 Inhibitory activity of test compounds against αvβ6 Note: In Table 1, A<5nM, 5nM≤B<50nM, 50nM≤C<0.5μM, 0.5μM≤D
[1491] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good inhibitory activity against αvβ6.
[1492] Test Example 2: Integrin αvβ1 ELISA test
[1493] Fibronectin was diluted to a final concentration of 3 μg / ml in TBS buffer, and 50 μl of the solution was transferred to a 96-well plate for coating overnight at 4°C. The plate was washed three times with TBS buffer, followed by the addition of 150 μl of blocking buffer (TBS buffer containing 1% BSA) and blocking at 37°C for 1 hour. The plate was washed three times with TBS buffer, and αvβ1 integrin protein was diluted to 1 μg / ml in TBS buffer containing 0.1% BSA. 50 μl of the integrin protein was transferred to a 96-well plate, followed by the addition of 1 μl of various compound concentrations or DMSO, and incubation at room temperature for 2 hours. Biotinylated anti-αv antibody was diluted to 0.5 μg / ml in TBS buffer containing 0.1% BSA. The plate was washed three times with TBS buffer, and 50 μl of the antibody was added and incubated at room temperature for 1 hour. The plate was washed three times with TBS buffer, and 50 μl of Streptavidin-HRP was added and incubated at room temperature for 20 minutes. Add 50 μl of TMB substrate and incubate at room temperature for 20 min. Finally, add 25 μl of stop buffer (2 M H2SO4) and read the OD value of the plate at 450 nm on a microplate reader. Calculate the IC using GraphPad Prism 6 software. 50 value.
[1494] Table 2 Inhibitory activity of test compounds against αvβ1 Note: In Table 2, A<5nM, 5nM≤B<50nM, 50nM≤C<0.5μM, 0.5μM≤D
[1495] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good inhibitory activity against αvβ1.
[1496] Test Example 3: αvβ1-fibronectin cell adhesion assay IC 50 Determination of
[1497] 2.5μg / mL rhFibronectin (#4305-FNB, R&D systems) was coated on E-plate 96PET and incubated overnight at 4°C. On the day of the assay, the plate was washed twice with 150μL / well PBS, blocked with 100μL / well blocking buffer at room temperature, and washed again with 150μL / well PBS. 50μL / well HBSS assay buffer containing the test compound was added to the E-Plate 96PET. xCELLigence RTCA MP recorded cell parameters, and 50μL / well a5 knockout / avb1 overexpressing CHO cell suspension in the logarithmic growth phase was added to the E-Plate96PET to a final concentration of 100,000 cells / well. Cell adhesion kinetics parameters were then recorded every 5 minutes using xCELLigence RTCA MP.
[1498] Inhibition rate calculation: %Inhibition = 100% - (Signalcmpd - SignalAve_PC) / (SignalAve_VC - SignalAve_PC) × 100%.
[1499] Table 3 Inhibitory activity of test compounds on avβ1 adhesion Note: In Table 3, A<5nM, 5nM≤B<50nM, 50nM≤C<0.5μM, 0.5μM≤D
[1500] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good inhibitory activity against the adhesion of αvβ1 in CHO a5ko cells.
[1501] Test Example 4: αvβ6-LAP cell adhesion assay IC 50 Determination of
[1502] 50 μl / well of Recombinant Human LAP solution was coated in a 96-well plate, sealed, and incubated overnight at 4°C. On the day of the assay, the plate was washed four times with 180 μl of buffer using a Multidrop, then blocked with 150 μl of assay buffer (containing 1% BSA) at 37°C for 1 hour, and then washed three times with 150 μl of TBS buffer. A suspension of SW480 cells overexpressing avb6 was collected in a 15 ml centrifuge tube, centrifuged at 1000 rpm for 5 minutes at room temperature to pellet the cells, and washed twice with DPBS. Cells were counted using Vi-Cell and resuspended in assay buffer to a cell density of 4 million cells / mL. 50 μl of the cell solution was transferred to the coated plate to a cell density of 200,000 cells / well. 1 μl of compound solution was added using a Janus assay, and the plate was incubated at 37°C for 120 minutes. The coated plate was washed twice with assay buffer, and non-adherent cells were removed using BlueWash. 50 μL / well of substrate solution was transferred to each well and incubated at 37°C for 2 hours. Finally, 90 μL / well of stop solution was added on the SpectraMax 340PC, and the absorbance was measured at 405 nm.
[1503] Table 4 Inhibitory activity of test compounds on avβ6 adhesion Note: In Table 4, A<5nM, 5nM≤B<50nM, 50nM≤C<0.5μM, 0.5μM≤D
[1504] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good inhibitory activity against the adhesion of αvβ6 in SW480 cells.
[1505] Test Example 5: αvβ5PC-3 cell adhesion experiment IC 50 Determination of
[1506] PC3 cells in the logarithmic growth phase and overexpressing αvβ5 were prepared. 50 μL / well of recombinant human vitronection solution was transferred to a 96-well plate, sealed and incubated overnight at 4°C. The next day, the plate was washed four times with buffer, and then 150 μL of detection buffer containing 1% BSA was added to seal the plate at 37°C for 1 hour, and then washed three times with 150 μL of TBS buffer. 50 μL of cell suspension was transferred to the coated plate to a cell density of 2x10^5 cells / well, 1 μL of compound was added using Janus, and incubated at 37°C for 120 minutes. The coated plate was washed twice with assay buffer and non-adherent cells were removed by BlueWash. 50 μL / well of substrate solution was transferred to the wells and incubated at 37°C for 2 hours. After adding 90 μL / well stop solution on the SpectraMax 340PC, the absorbance was measured at 405 nm.
[1507] Table 5 Inhibitory activity of test compounds on avβ5 adhesion
[1508] Conclusion: The compounds of the present invention, such as the example compounds, have weaker off-target inhibition on αvβ5 adhesion in PC-3 cells. Specifically, compounds 10, 11, and 14 have weaker off-target inhibition on αvβ5 adhesion in PC-3 cells compared to the control compound 1.
[1509] The structure of control compound 1 is as follows, and its synthesis refers to patent WO2019173653A1.
[1510] Test Example 6: Pharmacokinetic Test in Mice
[1511] Experimental animals: Male C57 mice, 25-30 g, purchased from Beijing Huafukang Biotechnology Co., Ltd.
[1512] Experimental Design: On the day of the experiment, ICR mice were randomly divided into groups according to body weight. They were fasted but not watered for 14-18 hours before administration and fed 4 hours after administration.
[1513] Table 6 Dosage information
[1514] Intravenous administration solvent: 5% DMA + 5% Solutol + 90% Saline
[1515] Oral administration solvent: 5% DMSO + 95% 0.5% MC
[1516] (DMA: N,N-dimethylacetamide; Solutol: polyethylene glycol-15-hydroxystearate; Saline: normal saline; DMSO: dimethyl sulfoxide; MC: methylcellulose)
[1517] Before and after drug administration, 0.06 mL of blood was collected via the orbital cavity under isoflurane anesthesia. The blood was placed in an EDTAK2 centrifuge tube and centrifuged at 5000 rpm at 4°C for 10 minutes to collect plasma. Blood was collected at 5, 15, 30 minutes, and 1, 2, 4, 7, and 24 hours. All samples were stored at -80°C prior to analysis and quantitative analysis was performed using LC-MS / MS.
[1518] Table 7 Pharmacokinetic parameters of test compounds in mouse plasma
[1519] Conclusion: The compounds of the present invention, such as the example compounds, have good oral absorption. Specifically, compounds 11 and 14 have better pharmacokinetic properties in mice than the control compound 1.
[1520] Test Example 7: Pharmacokinetic Test in Rat
[1521] Experimental animals: Male SD rats, 200-220 g, purchased from Chengdu Dashuo Experimental Animal Co., Ltd.
[1522] Experimental design: On the day of the experiment, SD rats were randomly divided into groups according to body weight. They were fasted but not watered for 14-18 hours before administration and fed 4 hours after administration.
[1523] Table 8 Dosage information
[1524] Intravenous administration solvent: 5% DMA + 5% Solutol + 90% Saline
[1525] Oral administration solvent: 5% DMSO + 95% 0.5% MC
[1526] (DMA: N,N-dimethylacetamide; Solutol: polyethylene glycol-15-hydroxystearate; Saline: normal saline; DMSO: dimethyl sulfoxide; MC: methylcellulose)
[1527] Before and after drug administration, 0.15 mL of blood was collected intraorbitally under isoflurane anesthesia. The blood was placed in an EDTAK2 centrifuge tube and centrifuged at 5000 rpm at 4°C for 10 minutes to collect plasma. Blood was collected at 0, 5, 15, 30 minutes, and 1, 2, 4, 7, and 24 hours. All samples were stored at -80°C prior to analysis and quantitative analysis was performed using LC-MS / MS.
[1528] Conclusion: The compounds of the present invention, such as the example compounds, have good pharmacokinetic properties.
[1529] Test Example 8: Beagle Dog Pharmacokinetic Test
[1530] Experimental animals: Male beagle dogs, weighing approximately 8-10 kg, were purchased from Beijing Mas Biotechnology Co., Ltd.
[1531] Experimental Design: On the day of the experiment, beagle dogs were randomly divided into groups according to body weight. They were fasted but not watered for 14-18 hours before administration and fed 4 hours after administration.
[1532] Table 9 Dosage information
[1533] Intravenous administration solvent: 5% DMA + 5% Solutol + 90% Saline
[1534] Oral administration solvent: 5% DMSO + 95% (0.5% MC)
[1535] (DMA: N,N-dimethylacetamide; Solutol: polyethylene glycol-15-hydroxystearate; Saline: normal saline; DMSO: dimethyl sulfoxide; MC: methylcellulose)
[1536] Before and after dosing, 1 mL of blood was collected from the jugular vein or limb vein. The blood was placed in an EDTAK2 centrifuge tube and centrifuged at 5000 rpm at 4°C for 10 minutes to collect plasma. Blood was collected at 0, 5, 15, 30 minutes, and 1, 2, 4, 6, 8, 10, 12, and 24 hours. All samples were stored at -80°C prior to analysis and quantitative analysis was performed using LC-MS / MS.
[1537] Table 10 Pharmacokinetic parameters of test compounds in dog plasma
[1538] Conclusion: The compounds of the present invention, such as the example compounds, have good pharmacokinetic properties in dogs. Specifically, compounds 11 and 14 have better pharmacokinetic properties in dogs than the control compound 1.
Claims
1. A compound represented by the general formula (I) or a stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, in, A is selected from 3 to 15-membered carbocyclic groups or 4 to 15-membered heterocyclic groups, wherein the carbocyclic groups or heterocyclic groups are optionally substituted by 1 to 20 R a replace; Or A is selected from C 1-6 Alkyl, the alkyl group is optionally substituted by 1 to 4 R a replace; B is selected from 3 to 15-membered carbocyclic groups or 4 to 15-membered heterocyclic groups, wherein the carbocyclic groups or heterocyclic groups are optionally substituted by 1 to 4 R b replace; or B is selected from H or C 1-6 Alkyl, the alkyl group is optionally substituted by 1 to 4 R b replace; Y is selected from C=O, C=S or a bond; X 1 Selected from -(CR x1a R x1b ) n1 - or -NH-; X 2 Selected from -(CR x2a R x2b ) n2 -; X 3 Selected from -(CR x3a R x3b ) n3 -; X 4 Selected from -(CR x4a R x4b ) n4 -; X 5 Selected from a bond, -NH-, -O-, -S-, -S(=O) 2 -, -C(=O), -C(=S), -C(=NH), -NHC(=S)NH-, -NHC(=O)NH-, -NHC(=NH)NH-, -NHS(=O) 2 NH-, -NHC(=S)-, -NHC(=O)-, -NHC(=NH)-, -NHS(=O) 2 -, -C(=S)NH-, -C(=O)NH-, -C(=NH)NH- or -S(=O) 2 NH-; n1, n2, n3, n4 are each independently selected from 0, 1, 2, 3, 4 or 5; R 1 Selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -C 0-4 Alkylene-C 3-6 Carbon ring, -C 0-4 Alkylene-3 to 7 membered heterocyclic ring, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 R 1A replaced by; R 1A Each independently selected from H, deuterium, halogen, OH, =O, CN, NH 2 、NO 2 , COOH, CONH 2 , C 1-6 Alkyl, OC 1-6 Alkyl, SC 1-6 Alkyl, -SO 2 C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -CONHC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 alkyl) 2 、-OC 3-6 Carbocyclic ring, -O-3 to 7 membered heterocyclic ring, -NH-C 3-6 Carbocyclic ring, -NH-3 to 7-membered heterocyclic ring, -SC 3-6 Carbocyclic ring, -S-3 to 7 membered heterocyclic ring, -C 0-4 Alkylene-C 3-6 Carbon ring, -C 0-4 Alkylene-3 to 7 membered heterocyclic ring, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 R k replaced by; R a , R b , R x1a , R x1b , R x2a , R x2b , R 3a , R 3b , R x3a , R x3b , R x4a , R x4b Each independently selected from H, deuterium, halogen, OH, =O, CN, NH 2 、NO 2 , COOH, CONH 2 、C(=O)NHCH 3 、S(=O) 2 CH 3 , C 1-6 Alkyl, OC 1-6 Alkyl, SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 alkyl) 2 、-OC 3-6 Carbocyclic ring, -O-3 to 7 membered heterocyclic ring, -NH-C 3-6 Carbocyclic ring, -NH-3 to 7-membered heterocyclic ring, -SC 3-6 Carbocyclic ring, -S-3 to 7 membered heterocyclic ring, -C 0-4 Alkylene-C 3-6 Carbon ring, -C 0-4 Alkylene-3 to 7 membered heterocyclic ring, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 R k replaced by; Alternatively, two R b , R x1a With R x1b , R x2a With R x2b , R 3a With R 3b , R x3a With R x3b , R x4a With R x4b The atoms to which they are respectively attached together form a 3- to 8-membered carbocyclic ring or a 4- to 8-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 R k replace; R k Each independently selected from deuterium, halogen, OH, =O, CN, NH 2 、NO 2 , COOH, CONH 2 , C 1-6 Alkyl, OC 1-6 Alkyl, SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 alkyl) 2 、-OC 3-6 Carbocyclic ring, -O-3 to 7 membered heterocyclic ring, -NH-C 3-6 Carbocyclic ring, -NH-3 to 7-membered heterocyclic ring, -SC 3-6 Carbocyclic ring, -S-3 to 7 membered heterocyclic ring, -C 0-4 Alkylene-C 3-6 Carbon ring, -C 0-4 Alkylene-3 to 7 membered heterocycle, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic or heterocyclic ring is optionally substituted by 1 to 4 deuterium, halogen, =O, CN, OH, NH 2 , C 1-6 Alkyl, C 1-6 Alkoxy is substituted with a substituent; provided that B is not selected from 2. The compound according to claim 1 or its stereoisomer, tautomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, in, A is selected from a 3- to 12-membered carbocyclic ring or a 4- to 12-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 20 R a replace; Or A is selected from C 1-4 Alkyl, the alkyl group is optionally substituted by 1 to 4 R a replace; B is selected from a 3- to 12-membered carbocyclic ring or a 4- to 12-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 R b replace; or B is selected from H or C 1-4 Alkyl, the alkyl group is optionally substituted by 1 to 4 R b replace; n1, n2, n4 are each independently selected from 0, 1, 2, 3; n3 is selected from 1, 2, 3, 4 or 5; R 1 Selected from C 1-5 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 carbocyclic ring, 3 to 6 membered heterocyclic ring, the alkyl, alkenyl, alkynyl, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 R 1A replaced by; R 1A Each independently selected from H, deuterium, halogen, OH, =O, CN, NH 2 、NO 2 , COOH, CONH 2 , C 1-4 Alkyl, OC 1-4 Alkyl, SC 1-4 Alkyl, -SO 2 C 1-4 Alkyl, -NHCOC 1-4 Alkyl, -CONHC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 alkyl) 2 、-OC 3-6 Carbocyclic ring, -O-3 to 6-membered heterocyclic ring, -NH-C 3-6 Carbocyclic ring, -NH-3 to 6-membered heterocyclic ring, -SC 3-6 Carbocyclic ring, -S-3 to 6-membered heterocyclic ring, -C 0-3 Alkylene-C 3-6 Carbon ring, -C 0-3 Alkylene-3 to 7 membered heterocyclic ring, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 R k replaced by; R a , R b , R x1a , R x1b , R x2a , R x2b , R 3a , R 3b , R x3a , R x3b , R x4a , R x4b Each independently selected from H, deuterium, halogen, OH, =O, CN, NH 2 、NO 2 , COOH, CONH 2 、C(=O)NHCH 3 、S(=O) 2 CH 3 , C 1-4 Alkyl, OC 1-4 Alkyl, SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 alkyl) 2 、-OC 3-6 Carbocyclic ring, -O-3 to 7 membered heterocyclic ring, -NH-C 3-6 Carbocyclic ring, -NH-3 to 6-membered heterocyclic ring, -SC 3-6 Carbocyclic ring, -S-3 to 6-membered heterocyclic ring, -C 0-3 Alkylene-C 3-6 Carbon ring, -C 0-3 Alkylene-3 to 7 membered heterocyclic ring, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 R k replaced by; Alternatively, two R b , R x1a With R x1b , R x2a With R x2b , R 3a With R 3b , R x3a With R x3b , R x4a With R x4b The atoms to which they are respectively attached together form a 3- to 6-membered carbocyclic ring or a 4- to 6-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally substituted by 1 to 4 R k replace; R k Each independently selected from deuterium, halogen, OH, =O, CN, NO 2 NH 2 , COOH, CONH 2 , C 1-4 Alkyl, OC 1-4 Alkyl, SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 alkyl) 2 、-OC 3-6 Carbocyclic ring, -O-3 to 7 membered heterocyclic ring, -NH-C 3-6 Carbocyclic ring, -NH-3 to 7-membered heterocyclic ring, -SC 3-6 Carbocyclic ring, -S-3 to 7 membered heterocyclic ring, -C 0-2 Alkylene-C 3-6 Carbon ring, -C 0-2 Alkylene-3 to 7 membered heterocycle, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic or heterocyclic ring is optionally substituted by 1 to 4 deuterium, halogen, =O, CN, OH, NH 2 , C 1-4 Alkyl, C 1-4 The alkoxy group is substituted with an alkoxy substituent.
3. The compound according to claim 2, or a stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, in, A or B is selected from phenyl, naphthyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, thiazolyl, thienyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, oxetanyl, tetrahydrofuranyl, oxahexyl, benzocyclobutenyl, benzocyclopentenyl, benzocyclohexenyl, benzopyrrolyl, benzopyrazolyl, benzimidazolyl, benzopyridine yl, benzopyrimidinyl, benzopyrazinyl, benzopyridazinyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, benzisoxazolyl, benzisothiazolyl, benzofuranyl, pyridopyrrolyl, pyridopyrazolyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyridopyrazinyl, pyridopyridazinyl, pyridothiazolyl, pyridothiphenyl, pyridoxazolyl, pyridisoxazolyl, pyridisothiazolyl, pyridofuranyl, pyrazolopyrimidinyl, pyrrolopyrimidinyl, thienopyrimidinyl, imidazopyrimidinyl, thiazolopyrimidinyl, furanopyrimidinyl, benzodihydrofuranyl, pyridonyl, The A is optionally replaced by 1 to 4 R a substituted, said B is optionally substituted with 1 to 4 R b replace; or A is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, wherein the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl is optionally substituted by 1 to 4 R a replace; Or B is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, wherein the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl is optionally substituted by 1 to 4 R b replace; R 1 is selected from methyl, ethyl, propyl, butyl, vinyl, propenyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, thiazolyl, thienyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, wherein the methyl alkyl, ethyl, propyl, butyl, vinyl, propenyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, thiazolyl, thienyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, optionally substituted with 1 to 4 R 1A replaced by; R 1A Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH 2 、NO 2 , COOH, CONH 2 NHCH 3 、N(CH 3 ) 2 NHCOCH 3 、CONHCH 3 , methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, -O-phenyl, -O-cyclopropyl, -O-pyridyl, methylthio, -SO 2 -CH 3 、-SO 2 -CH 2 CH 3 , vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, azetidinyl, azetyl, oxetanyl, oxolyl, 1,4-dioxane, 1,3-dioxane, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl, pyridinyl, the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, azetidinyl, azetyl, oxetanyl, oxolyl, 1,4-dioxane, 1,3-dioxane, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl, pyridinyl, the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, azetidinyl, azetyl, oxetanyl, oxolyl, 1,4-dioxane, 1,3-dioxane, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl, pyridinyl are optionally substituted by 1 to 4 selected from R k substituted by a substituent; R a , R b , R x1a , R x1b , R x2a , R x2b , R 3a , R 3b , R x3a , R x3b , R x4a , R x4b Each independently selected from H, deuterium, halogen, OH, =O, CN, NH 2 、NO 2 , COOH, CONH 2 、C(=O)NHCH 3 、S(=O) 2 CH 3 , O-cyclopropyl, O-cyclobutyl, O-cyclopentyl, O-cyclohexyl, O-phenyl, NHCH 3 NHCH 2 CH 3 , NH-propyl, NH-isopropyl, NH-tert-butyl, NH-cyclobutyl, NH-cyclopentyl, NH-cyclohexyl, NH-cyclopropyl, NH-pyrazolyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, pyridinyl, phenyl, imidazolyl, The CH 2 , CH 3 , methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, imidazolyl, pyridinyl, phenyl, optionally with 1 to 4 R k replaced by; Alternatively, two R b , R x1a With R x1b , R x2a With R x2b , R 3a With R 3b , R x3a With R x3b , R x4a With R x4b The atoms connected thereto together form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl, or morpholinyl group, wherein the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl, or morpholinyl group is optionally substituted by 1 to 4 R k replace; R k Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH 2 、NO 2 , COOH, CONH 2 NHCH 3 、N(CH 3 ) 2 , methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl, pyridinyl, imidazolyl, the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, pyrazolyl, phenyl, pyridinyl, imidazolyl, the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, pyrazolyl, phenyl, pyridinyl, imidazolyl are optionally substituted by 1 to 4 radicals selected from deuterium, F, Cl, Br, I, =O, CN, OH, NH 2 , C 1-4 Alkyl, C 1-4 The alkoxy group is substituted with an alkoxy substituent.
4. The compound according to claim 3 or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, in, A is selected from phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, azetidinyl, pyrrolidinyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, piperidinyl, piperazinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, thienyl, oxazolyl, furanyl, oxetanyl, tetrahydrofuranyl, oxacyclohexyl, benzocyclopentenyl, benzopyrrolyl , benzopyrazolyl, benzopyridinyl, benzopyrimidinyl, benzopyridazinyl, benzopyrazinyl, benzothiophenyl, benzofuranyl, pyridopyrrolyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrazinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, pyridopyrimidinyl, pyrazolopyrimidinyl, pyrrolopyrimidinyl, thienopyrimidinyl, benzodihydrofuranyl, pyridonyl, The A is optionally replaced by 1 to 4 R a replace; or A is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl; B is selected from phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, piperidinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, thienyl, oxazolyl, furanyl, benzocyclopentenyl, benzopyrrolyl, benzopyrazolyl, benzopyridinyl, benzopyrimidinyl, benzopyridazinyl, benzothienyl, benzofuranyl, pyridopyrrolyl, pyridoimidazolyl, pyridopyridinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, pyridopyrimidinyl, pyrazolopyrimidinyl, pyrrolopyrimidinyl, thienopyrimidinyl, benzodihydrofuranyl, pyridonyl, and said B is optionally substituted by 1 to 4 R b replace; or B is selected from H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl; R 1 is selected from methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, wherein the methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl is optionally substituted by 1 to 4 R 1A replaced by; R 1A Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NHCOCH 3 、CONHCH 3 , methyl, ethyl, methoxy, ethoxy, -O-phenyl, -O-cyclopropyl, -O-pyridyl, -SO 2 -CH 3 、-SO 2 -CH 2 CH 3 , cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, azopentyl, tetrahydrofuranyl, 1,4-dioxane, pyrrolidinyl, piperidinyl, pyrazolyl, the methyl, ethyl, methoxy, ethoxy, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, azopentyl, tetrahydrofuranyl, 1,4-dioxane, pyrrolidinyl, piperidinyl, pyrazolyl, phenyl, pyridinyl are optionally substituted by 1 to 4 selected from R k substituted by a substituent; R x1a , R x1b , R x2a , R x2b , R 3a , R 3b , R x3a , R x3b , R x4a , R x4b Each independently selected from H, deuterium, F, Cl, Br, I, OH, =O, CN, NH 2 , methyl, ethyl, methoxy, ethoxy, cyclopropyl, wherein the methyl, ethyl, methoxy, ethoxy, cyclopropyl is optionally substituted by 1 to 4 R k replaced by; R a Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH 2 , CH 2 F. CHF 2 CF 3 , CH 2 OH、OCF 3 , OCHF 2 、OCH 2 OH, C(=O)NHCH 3 、S(=O) 2 CH 3 , O-phenyl, NH-cyclopropyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, propynyl, propargyl, methylthio, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrazolyl, phenyl, pyridyl, R b Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH 2 , CH 2 F. CHF 2 CF 3 , CH 2 OH、OCF 3 , OCHF 2 、OCH 2 OH, C(=O)NHCH 3 、S(=O) 2 CH 3 NHCH 3 NHCH 2 CH 3 , O-cyclopropyl, O-cyclobutyl, O-cyclopentyl, O-cyclohexyl, O-phenyl, NH-propyl, NH-isopropyl, NH-tert-butyl, NH-cyclopropyl, NH-cyclobutyl, NH-cyclopentyl, NH-cyclohexyl, NH-phenyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, propynyl, propargyl, methylthio, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrazolyl, phenyl, pyridinyl, pyrrolidinyl, piperidinyl, imidazolyl, Alternatively, two R b , R x1a With R x1b , R x2a With R x2b , R 3a With R 3b , R x3a With R x3b , R x4a With R x4b The atoms to which they are respectively attached together form a cyclopropyl group; R k Deuterium, F, Cl, Br, I, OH, =O, CN, NH 2 、NO 2 NHCH 3 、N(CH 3 ) 2 , COOH, CONH 2 , CH 2 F. CHF 2 CF 3 , CH 2 OH、OCF 3 , OCHF 2 、OCH 2 OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, propynyl, propargyl, methylthio, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrazolyl, phenyl, imidazolyl, cyclopentyl, cyclohexyl.
5. The compound according to claim 4 or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, in, A is selected from the following substituted or unsubstituted groups: When substituted, it is optionally substituted with 1 to 4 R a replace; or A is selected from isopropyl and tert-butyl; B is selected from the following substituted or unsubstituted groups: When substituted, it is optionally substituted with 1 to 4 R b replace; or B is selected from H, methyl; R a Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH 2 , CH 2 F. CHF 2 CF 3 , CH 2 OH、OCF 3 , OCHF 2 、OCH 2 OH, C(=O)NHCH 3 、S(=O) 2 CH 3 , NH-cyclopropyl, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclobutyl, pyrazolyl, O-phenyl, phenyl, pyridyl, R b Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH 2 , CH 2 F. CHF 2 CF 3 , CH 2 OH、OCF 3 , OCHF 2 、OCH 2 OH, C(=O)NHCH 3 、S(=O) 2 CH 3 NHCH 3 NHCH 2 CH 3 , NH-propyl, NH-isopropyl, NH-tert-butyl, NH-cyclopropyl, NH-cyclobutyl, NH-cyclopentyl, NH-cyclohexyl, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclobutyl, pyrazolyl, O-cyclopropyl, O-cyclobutyl, O-cyclopentyl, O-cyclohexyl, O-phenyl, phenyl, pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, imidazolyl, R 1 Selected from Y is selected from C=O or a bond; X 1 Selected from a bond, -NH-, -CH 2 -、-CHF-、-CF 2 -、-CH(CH 3 )-、-C(CH 3 ) 2 -、 X 2 Selected from -CH 2 CH 2 -、-CF 2 CH 2 -、-CHFCH 2 -、-CH 2 CH 2 CH 2 -、-CH 2 C(CH 3 ) 2 -、-C(CH 3 ) 2 CH 2 -、 X 3 Selected from -CH 2 CH 2 CH 2 -, -CH 2 CH 2 CH 2 CH 2 -, -CH 2 C(CH 3 ) 2 CH 2 -, -CH 2 CF 2 CH 2 -, -CH 2 CH 2 C(CH 3 ) 2 -, -CH 2 CH 2 CF 2 -, X 4 Select from bonds, -CH 2 -、-CH 2 CH 2 -、-CH(CH 3 )-、-C(CH 3 ) 2 -、 -CF 2 -; X 5 is selected from a bond, -NH-, -NHC(=S)NH-, -NHC(=O)NH-, -NHC(=NH)NH- or -NHS(=O) 2 NH-.
6. The compound according to claim 1 or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, in, The compound represented by general formula (I) is selected from the compounds represented by general formula (III-1) or (III-2), A is selected from the following substituted or unsubstituted groups: When substituted, it is optionally substituted with 1 to 4 R a replace; R a Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH 2 , CH 2 F. CHF 2 CF 3 , CH 2 OH、OCF 3 , OCHF 2 、OCH 2 OH, NH-cyclopropyl, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl; R 1 Selected from R b Each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH 2 , CH 2 F. CHF 2 CF 3 , CH 2 OH、OCF 3 , OCHF 2 、OCH 2 OH, C(=O)NHCH 3 、S(=O) 2 CH 3 NHCH 3 NHCH 2 CH 3 , NH-propyl, NH-isopropyl, NH-tert-butyl, NH-cyclopropyl, NH-cyclobutyl, NH-cyclopentyl, NH-cyclohexyl, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclobutyl, pyrazolyl, O-cyclopropyl, O-cyclobutyl, O-cyclopentyl, O-cyclohexyl, O-phenyl, phenyl, pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, imidazolyl, 7. The compound according to claim 1 or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, in, The compound is selected from the structures shown in Table S.
8. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 or a stereoisomer, tautomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, and a pharmaceutically acceptable carrier. Preferably, the pharmaceutical composition contains 1 to 1500 mg of a compound according to any one of claims 1 to 7 or a stereoisomer, tautomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof.
9. Use of the compound according to any one of claims 1 to 7 or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal or the pharmaceutical composition according to claim 8 in the preparation of a drug for idiopathic pulmonary fibrosis.
10. A method for treating a disease in a mammal, the method comprising administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 7 or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, or a pharmaceutical composition according to claim 8, the therapeutically effective amount preferably being 1-1500 mg, and the disease preferably being idiopathic pulmonary fibrosis.
Citation Information
Patent Citations
Amino acid compounds and methods of use
CN112135612A
Methods of treating respiratory diseases using amino acid compounds
CN115989235A
Propanoic acid derivatives that inhibit binding of integrins to their receptors
CN1370143A
Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
CN1735601A
Nonanoic and decanoic acid derivatives and uses thereof
WO2017189828A1
Cited By
Substituted pyridine and phenyl compounds
WO2025238514A1
